{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 110,
   "metadata": {},
   "outputs": [],
   "source": [
    "import openai\n",
    "import os\n",
    "from openai import OpenAI\n",
    "from dotenv import load_dotenv, find_dotenv\n",
    "_ = load_dotenv(find_dotenv()) # read local .env file\n",
    "openai.api_key = os.environ['OPENAI_API_KEY']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 111,
   "metadata": {},
   "outputs": [],
   "source": [
    "# account for deprecation of LLM model\n",
    "import datetime\n",
    "# Get the current date\n",
    "current_date = datetime.datetime.now().date()\n",
    "\n",
    "# # Define the date after which the model should be set to \"gpt-3.5-turbo\"\n",
    "# target_date = datetime.date(2024, 6, 12)\n",
    "\n",
    "# # Set the model variable based on the current date\n",
    "# if current_date > target_date:\n",
    "#     llm_model = \"gpt-3.5-turbo\"\n",
    "# else:\n",
    "#     llm_model = \"gpt-3.5-turbo-0301\"\n",
    "llm_model = \"gpt-4\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 81,
   "metadata": {},
   "outputs": [],
   "source": [
    "def get_completion(prompt, model=llm_model):\n",
    "    client = OpenAI(api_key='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')\n",
    "    messages = [{\"role\": \"user\", \"content\": prompt}]\n",
    "    response = client.chat.completions.create(\n",
    "        model=model,\n",
    "        messages=messages,\n",
    "        temperature=0, \n",
    "    )\n",
    "    return response.choices[0].message[\"content\"]\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 82,
   "metadata": {},
   "outputs": [],
   "source": [
    "customer_email = \"\"\"\n",
    "Arrr, I be fuming that me blender lid \\\n",
    "flew off and splattered me kitchen walls \\\n",
    "with smoothie! And to make matters worse,\\\n",
    "the warranty don't cover the cost of \\\n",
    "cleaning up me kitchen. I need yer help \\\n",
    "right now, matey!\n",
    "\"\"\"\n",
    "\n",
    "style = \"\"\"American English \\\n",
    "in a calm and respectful tone\n",
    "\"\"\"\n",
    "\n",
    "prompt = f\"\"\"Translate the text \\\n",
    "that is delimited by triple backticks \n",
    "into a style that is {style}.\n",
    "text: ```{customer_email}```\n",
    "\"\"\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "get_completion(prompt)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "metadata": {},
   "outputs": [],
   "source": [
    "from langchain_openai import ChatOpenAI"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "ChatOpenAI(client=<openai.resources.chat.completions.Completions object at 0x10f47adf0>, async_client=<openai.resources.chat.completions.AsyncCompletions object at 0x10f484340>, model_name='gpt-4', temperature=0.0, openai_api_key=SecretStr('**********'), openai_proxy='')"
      ]
     },
     "execution_count": 21,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# To control the randomness and creativity of the generated\n",
    "# text by an LLM, use temperature = 0.0\n",
    "chat = ChatOpenAI(temperature=0.0, model=llm_model)\n",
    "chat"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 84,
   "metadata": {},
   "outputs": [],
   "source": [
    "template_string = \"\"\"Translate the text \\\n",
    "that is delimited by triple backticks \\\n",
    "into a style that is {style}. \\\n",
    "text: ```{text}```\n",
    "\"\"\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 97,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "HumanMessagePromptTemplate(prompt=PromptTemplate(input_variables=['style', 'text'], template='Translate the text that is delimited by triple backticks into a style that is {style}. text: ```{text}```\\n'))"
      ]
     },
     "execution_count": 97,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "from langchain.prompts import ChatPromptTemplate\n",
    "\n",
    "prompt_template = ChatPromptTemplate.from_template(template_string)\n",
    "prompt_template[0]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 86,
   "metadata": {},
   "outputs": [],
   "source": [
    "customer_style = \"\"\"American English \\\n",
    "in a calm and respectful tone\n",
    "\"\"\"\n",
    "customer_email = \"\"\"\n",
    "Arrr, I be fuming that me blender lid \\\n",
    "flew off and splattered me kitchen walls \\\n",
    "with smoothie! And to make matters worse, \\\n",
    "the warranty don't cover the cost of \\\n",
    "cleaning up me kitchen. I need yer help \\\n",
    "right now, matey!\n",
    "\"\"\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 87,
   "metadata": {},
   "outputs": [],
   "source": [
    "customer_messages = prompt_template.format_messages(\n",
    "                    style=customer_style,\n",
    "                    text=customer_email)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 88,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "<class 'list'>\n",
      "<class 'langchain_core.messages.human.HumanMessage'>\n"
     ]
    }
   ],
   "source": [
    "print(type(customer_messages))\n",
    "print(type(customer_messages[0]))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 92,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "HumanMessage(content=\"Translate the text that is delimited by triple backticks into a style that is American English in a calm and respectful tone\\n. text: ```\\nArrr, I be fuming that me blender lid flew off and splattered me kitchen walls with smoothie! And to make matters worse, the warranty don't cover the cost of cleaning up me kitchen. I need yer help right now, matey!\\n```\\n\")"
      ]
     },
     "execution_count": 92,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "customer_messages[0]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 93,
   "metadata": {},
   "outputs": [],
   "source": [
    "customer_response = chat(customer_messages)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 96,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "\"I am really frustrated that my blender lid flew off and splattered my kitchen walls with smoothie! And to make matters worse, the warranty doesn't cover the cost of cleaning up my kitchen. I need your help right now, friend!\""
      ]
     },
     "execution_count": 96,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "customer_response.content"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 39,
   "metadata": {},
   "outputs": [],
   "source": [
    "service_reply = \"\"\"Hey there customer, \\\n",
    "the warranty does not cover \\\n",
    "cleaning expenses for your kitchen \\\n",
    "because it's your fault that \\\n",
    "you misused your blender \\\n",
    "by forgetting to put the lid on before \\\n",
    "starting the blender. \\\n",
    "Tough luck! See ya!\n",
    "\"\"\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 40,
   "metadata": {},
   "outputs": [],
   "source": [
    "service_style_pirate = \"\"\"\\\n",
    "a polite tone \\\n",
    "that speaks in English Pirate\\\n",
    "\"\"\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 41,
   "metadata": {},
   "outputs": [],
   "source": [
    "service_reply_message = prompt_template.format_messages(\n",
    "                    style=service_style_pirate,\n",
    "                    text=service_reply)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 42,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[HumanMessage(content=\"Translate the text that is delimited by triple backticks into a style that is a polite tone that speaks in English Pirate. text: ```Hey there customer, the warranty does not cover cleaning expenses for your kitchen because it's your fault that you misused your blender by forgetting to put the lid on before starting the blender. Tough luck! See ya!\\n```\\n\")]"
      ]
     },
     "execution_count": 42,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "service_reply_message"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 43,
   "metadata": {},
   "outputs": [],
   "source": [
    "service_response = chat(service_reply_message)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 45,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "\"```Ahoy there, me hearty, the warranty be not extendin' to cover cleanin' costs for yer galley, on account of it bein' yer own blunder that ye misused yer mixin' device by forgettin' to secure the top afore settin' it in motion. Hard cheese, matey! Until we cross paths again!```\""
      ]
     },
     "execution_count": 45,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "service_response.content"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 46,
   "metadata": {},
   "outputs": [],
   "source": [
    "from langchain.prompts import ChatPromptTemplate\n",
    "\n",
    "# Define the template for extracting clinical variables\n",
    "clinical_template = \"\"\"\\\n",
    "Please review the following patient information and answer the questions below:\n",
    "\n",
    "Patient Information:\n",
    "{text}\n",
    "\n",
    "Questions:\n",
    "1. What is the cancer stage of the patient?\n",
    "2. Is the HR status positive or negative?\n",
    "3. Is the HER2 status positive or negative?\n",
    "\n",
    "Format your answers as a JSON object with the keys: cancer_stage, hr_status, her2_status.\n",
    "\"\"\"\n",
    "\n",
    "# Create a prompt template object\n",
    "prompt_template = ChatPromptTemplate.from_template(clinical_template)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 47,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Example clinical notes\n",
    "clinical_notes = \"\"\"\n",
    "The patient has been diagnosed with breast cancer. The pathology report shows a Grade II tumor with positive hormone receptors. HER2 testing returned negative results.\n",
    "\"\"\"\n",
    "\n",
    "# Format the messages using the template\n",
    "messages = prompt_template.format_messages(text=clinical_notes)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 48,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{\n",
      "  \"cancer_stage\": \"Stage II\",\n",
      "  \"hr_status\": \"Positive\",\n",
      "  \"her2_status\": \"Negative\"\n",
      "}\n"
     ]
    }
   ],
   "source": [
    "from langchain.chat_models import ChatOpenAI\n",
    "\n",
    "# Initialize the chat model (make sure to configure API keys and model settings properly)\n",
    "chat = ChatOpenAI(temperature=0.0, model=\"gpt-3.5-turbo\")  # Example model\n",
    "\n",
    "# Send the request and get the response\n",
    "response = chat(messages)\n",
    "print(response.content)  # Output for inspection\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 49,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'cancer_stage': 'Stage II', 'hr_status': 'Positive', 'her2_status': 'Negative'}\n"
     ]
    }
   ],
   "source": [
    "from langchain.output_parsers import ResponseSchema, StructuredOutputParser\n",
    "\n",
    "# Define response schemas for each clinical variable\n",
    "cancer_stage_schema = ResponseSchema(name=\"cancer_stage\", description=\"Cancer stage\")\n",
    "hr_status_schema = ResponseSchema(name=\"hr_status\", description=\"HR status\")\n",
    "her2_status_schema = ResponseSchema(name=\"her2_status\", description=\"HER2 status\")\n",
    "\n",
    "# Create an output parser with these schemas\n",
    "response_schemas = [cancer_stage_schema, hr_status_schema, her2_status_schema]\n",
    "output_parser = StructuredOutputParser.from_response_schemas(response_schemas)\n",
    "\n",
    "# Parse the output\n",
    "output_dict = output_parser.parse(response.content)\n",
    "print(output_dict)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 50,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'Stage II'"
      ]
     },
     "execution_count": 50,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "output_dict['cancer_stage']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 51,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Total Characters: 8795\n"
     ]
    }
   ],
   "source": [
    "import PyPDF2\n",
    "\n",
    "def count_characters_in_pdf(file_path):\n",
    "    with open(file_path, \"rb\") as file:\n",
    "        reader = PyPDF2.PdfReader(file)\n",
    "        total_chars = sum(len(page.extract_text() or \"\") for page in reader.pages)\n",
    "    return total_chars\n",
    "\n",
    "file_path = \"/Users/ahmed-elbakri/Downloads/Python/Ops Analytics/Clinical Trials/IHC-addendum-example-with-FISH.pdf\"\n",
    "total_characters = count_characters_in_pdf(file_path)\n",
    "print(f\"Total Characters: {total_characters}\")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 55,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "  \n",
      "ANATOMIC  PATHOLOGY \n",
      "REPORT \n",
      " \n",
      " Laboratory Medical Director:  Ly Ma, M.D.   \n",
      "3301 C Street, Ste 200E \n",
      "Sacramento,CA 95816 \n",
      "(916) 446-0424 \n",
      "Fax: (916) 446-9330 \n",
      "www.dpmginc.com  \n",
      " \n",
      " **********ADDENDUM REPORT **********  \n",
      "Patient: TEST, TEST   Age: 68   (01/01/55)  Pathology #:  DPS-23-99999 \n",
      " \n",
      "Acct#:  Sex: FEMALE Epic:   \n",
      "    \n",
      "Doctor: dpmg  test      \n",
      "3301 C Street #200E \n",
      "SACRAMENTO, CA  95816 Date Obtained:  10/31/2023 \n",
      " Date Received:  11/01/2023 \n",
      "   \n",
      "    \n",
      " \n",
      "Page 1 of 3 \n",
      " \n",
      "MICHAEL ASTUDILLO, M.D. GRANT HAYASHI, M.D. N. KEIT H McMURRY, M.D. RON ROWBERRY, M.D ALAE YASEEN, M.D.  \n",
      "MARIAN BUTCHER, M.D. MARY KEOHANE, M.D. AMANDA MULL INS, M.D. SASAN SETOODEH, M.D. ZHEN YAN, M.D. \n",
      "DARIO V. CACCAMO, M.D. IVAN KLEMENT, M.D. JONATHAN MUSICANT, M.D. KIM WANG, M.D. FRED ZHANG, M.D. \n",
      "NICHOLAS COLEY, M.D. LONG Li, M.D. KAI NI, M.D. ANN A WONG, M.D.  \n",
      "JOYCE CHEN, M.D., Ph.D. LY MA, M.D. ANDREA L. ONG, M.D. HANNAH WONG, M.D.  \n",
      "SOHEIL DADRAS, M.D. DEREK K. MARSEE, M.D. JUAN RONG , M.D. JIANMIN XU, M.D.  \n",
      " CLINICAL DATA:  HX \n",
      " \n",
      "SPECIMEN:  A. RIGHT BREAST MRI BIOPSY - ANTERIOR \n",
      "B. RIGHT BREAST MRI BIOPSY - POSTERIOR \n",
      " \n",
      "DIAGNOSIS: \n",
      " \n",
      "A. BREAST, RIGHT ANTERIOR, MRI-GUIDED NEEDLE BIOPSY : SMALL INTRADUCTAL \n",
      "PAPILLOMA (APPROXIMATELY 2 MM FOCUS).  \n",
      " \n",
      "B. BREAST, RIGHT POSTERIOR, MRI-GUIDED NEEDLE BIOPS Y:  \n",
      "1. ATYPICAL DUCTAL HYPERPLASIA (ADH). \n",
      "2. CLUSTER OF APOCRINE METAPLASIA.  \n",
      "3. COLUMNAR CELL CHANGE, SCLEROSING ADENOSIS, AND B ENIGN EPITHELIUM \n",
      "ASSOCIATED MICROCALCIFICATIONS. \n",
      " \n",
      "NOTE:  Immunohistochemical stains for p63 and SMMH are pe rformed, and show absence of myoepithelial \n",
      "cells in the invasive carcinoma. \n",
      " \n",
      "ER, PR, Her2/neu studies will be performed, and the  results will be reported separately. Dr. Sasan Set oodeh \n",
      "has reviewed H&E slides and concurs. The report is faxed to the office of Dr. Test on 11/01/2023. \n",
      " \n",
      "GROSS DESCRIPTION:  SBL:gcg \n",
      " \n",
      "A. Placed in formalin at 9:50 a.m. in a container l abeled with the patient's  name and \"RT breast A anterior\" is a 2.3 \n",
      "x 2.0 x 0.45 cm aggregate of yellow to dark red-bro wn cores of  fibrofatty tissue admixed with a dark red-brown app arent \n",
      "blood clot. The specimen is filtered and entirely s ubmitted between sponges in cassettes A1 and A2.  \n",
      " \n",
      "B. Placed in formalin at 9:50 a.m. in a container l abeled with the patient's  name and \"RT breast B posterior\" is a \n",
      "2.7 x 2.5 x 0.5 cm aggregate of light grey to yello w cores of  fibrofatty tissue. The specimen is filtered and ent irely \n",
      "submitted between sponges in cassettes B1 and B2.  \n",
      " \n",
      " \n",
      " \n",
      " \n",
      "This report may include a photomicrograph of the sl ide under examination.  For a variety of reasons, i ncluding the limitations of some electronic interfa ces, the photomicrograph may not appear on the \n",
      "version of this report that you view.  The photomic rograph is not of diagnostic quality and should not  be relied upon by any professional.  Health care p rofessionals should rely only upon the \n",
      "pathologist's written interpretation.  \n",
      " \n",
      "Final Diagnosis on 11/01/2023 by Long Li, M.D.  \n",
      "Electronically signed at Diagnostic Pathology Medic al Group, Inc  \n",
      "3301 C Street, Suite 200E  SACRAMENTO, CA  95816   \n",
      "   \n",
      "ANATOMIC  PATHOLOGY \n",
      "REPORT \n",
      " \n",
      " Laboratory Medical Director:  Ly Ma, M.D.   \n",
      "3301 C Street, Ste 200E \n",
      "Sacramento,CA 95816 \n",
      "(916) 446-0424 \n",
      "Fax: (916) 446-9330 \n",
      "www.dpmginc.com  \n",
      " \n",
      " **********ADDENDUM REPORT **********  \n",
      "Patient: TEST, TEST   Age: 68   (01/01/55)  Pathology #:  DPS-23-99999 \n",
      " \n",
      "Acct#:  Sex: FEMALE Epic:   \n",
      "    \n",
      "Doctor: dpmg  test      \n",
      "3301 C Street #200E \n",
      "SACRAMENTO, CA  95816 Date Obtained:  10/31/2023 \n",
      " Date Received:  11/01/2023 \n",
      "   \n",
      "    \n",
      " \n",
      "Page 2 of 3 \n",
      " \n",
      "MICHAEL ASTUDILLO, M.D. GRANT HAYASHI, M.D. N. KEIT H McMURRY, M.D. RON ROWBERRY, M.D ALAE YASEEN, M.D.  \n",
      "MARIAN BUTCHER, M.D. MARY KEOHANE, M.D. AMANDA MULL INS, M.D. SASAN SETOODEH, M.D. ZHEN YAN, M.D. \n",
      "DARIO V. CACCAMO, M.D. IVAN KLEMENT, M.D. JONATHAN MUSICANT, M.D. KIM WANG, M.D. FRED ZHANG, M.D. \n",
      "NICHOLAS COLEY, M.D. LONG Li, M.D. KAI NI, M.D. ANN A WONG, M.D.  \n",
      "JOYCE CHEN, M.D., Ph.D. LY MA, M.D. ANDREA L. ONG, M.D. HANNAH WONG, M.D.  \n",
      "SOHEIL DADRAS, M.D. DEREK K. MARSEE, M.D. JUAN RONG , M.D. JIANMIN XU, M.D.  \n",
      " ADDENDUM:  \n",
      " \n",
      "Immunohistochemistry Evaluation \n",
      " \n",
      "Specimen: RIGHT BREAST - ANTERIOR \n",
      "Estrogen Receptor: POSITIVE  (<5% Tumor Staining, Intensity 0) \n",
      "Progesterone Receptor: POSITIVE  (<5% Tumor Staining, Intensity 0) \n",
      "HER-2/: EQUIVOCAL  (Score 2+) \n",
      " \n",
      "Specimen: RIGHT BREAST - POSTERIOR \n",
      "Estrogen Receptor: POSITIVE  (<5% Tumor Staining, Intensity 0) \n",
      "Progesterone Receptor: POSITIVE  (<5% Tumor Staining, Intensity 0) \n",
      "HER-2/: EQUIVOCAL  (Score 2+) \n",
      " \n",
      "* Note: The specimen will be reflexed to Her-2/neu testing by fluorescence in situ hybridization (FISH ). Results may be obtained from Neogenomics Laborat ories, 31 \n",
      "Columbia, Aliso Viejo CA 92656. 1-866-776-5907.  An  addendum to add the FISH results to this report wi ll follow. \n",
      " \n",
      "INTERPRETIVE INFORMATION  \n",
      "All tests performed on formalin-fixed, paraffin-emb edded tissue using ultraview DAB detection system a nd utilizing the following antibodies: SP1 (ER), \n",
      "1E2 (PgR), 4B5 (HER2). Fixation conditions meet req uirements specified in the ASCO / CAP Guidelines (c old ischemia times <1 hour, fixation times \n",
      "between 6-72 hours) unless otherwise specified. Int ernal and external controls are evaluated for each assay, and show appropriate results unless \n",
      "otherwise specified. The ER and PR immunoperoxidase  tests were developed and their performance charact eristics determined by DPMG.  These \n",
      "tests have not been cleared or approved by the U.S.  Food and Drug Administration.  The FDA has determi ned that such clearance or approval is not \n",
      "necessary. ultraView DAB Pathway is FDA approved fo r diagnostic evaluation of HER-2/neu overexpression  as an aid in the assessment of patients \n",
      "for when Herceptin (Trastuzumab) treatment is being  considered.  \n",
      "Scoring Criteria for ER/PR are as follow: POSITIVE:  ≥1% immunoreactive tumor cells present. LOW POSITIVE : 1-10% of tumor cells immunoreactive \n",
      "(for ER in invasive carcinoma only). NEGATIVE: <1% tumor cells immunoreactive.  Scoring Criteria for H ER2 IHC are as follow: POSITIVE (Score 3+): \n",
      "Complete membrane staining that is intense and >10%  of tumor cells. EQUIVOCAL (Score 2+): Weak to mode rate complete membrane staining in \n",
      ">10% of tumor cells or Complete membrane staining t hat is intense but within ≤10% of tumor cells. NEGATIVE (Score 1+):  Incomplet e membrane \n",
      "staining that is faint/barely perceptible and withi n >10% of tumor cells. NEGATIVE (Score 0): No stain ing observed or Membrane stating that is \n",
      "incomplete and is faint/barely perceptible and with in ≤10% of tumor cells.  \n",
      "References:  \n",
      "Wolff AC, Hammond MEH, Allison KH, et al. HER2 test ing in breast cancer: American Society of Clinical Oncology/College of American Pathologists \n",
      "clinical practice guideline focused update. Arch Pa thol Lab Med. 2018;142(11):1364-1382.  \n",
      "Allison KH, Hammond MEH, et al. Estrogen and Proges terone Receptor Testing in Breast Cancer: American Society of Clinical Oncology/College of \n",
      "American Pathologists Guideline Update. Arch Pathol  Lab Med. 2020 May;144(5):545-563.  \n",
      " \n",
      "Addendum #1 on 11/01/2023 by Grant Petty  \n",
      "Electronically signed at Diagnostic Pathology Medic al Group, Inc  \n",
      "3301 C Street, Suite 200E  SACRAMENTO, CA  95816    \n",
      "ANATOMIC  PATHOLOGY \n",
      "REPORT \n",
      " \n",
      " Laboratory Medical Director:  Ly Ma, M.D.   \n",
      "3301 C Street, Ste 200E \n",
      "Sacramento,CA 95816 \n",
      "(916) 446-0424 \n",
      "Fax: (916) 446-9330 \n",
      "www.dpmginc.com  \n",
      " \n",
      " **********ADDENDUM REPORT **********  \n",
      "Patient: TEST, TEST   Age: 68   (01/01/55)  Pathology #:  DPS-23-99999 \n",
      " \n",
      "Acct#:  Sex: FEMALE Epic:   \n",
      "    \n",
      "Doctor: dpmg  test      \n",
      "3301 C Street #200E \n",
      "SACRAMENTO, CA  95816 Date Obtained:  10/31/2023 \n",
      " Date Received:  11/01/2023 \n",
      "   \n",
      "    \n",
      " \n",
      "Page 3 of 3 \n",
      " \n",
      "MICHAEL ASTUDILLO, M.D. GRANT HAYASHI, M.D. N. KEIT H McMURRY, M.D. RON ROWBERRY, M.D ALAE YASEEN, M.D.  \n",
      "MARIAN BUTCHER, M.D. MARY KEOHANE, M.D. AMANDA MULL INS, M.D. SASAN SETOODEH, M.D. ZHEN YAN, M.D. \n",
      "DARIO V. CACCAMO, M.D. IVAN KLEMENT, M.D. JONATHAN MUSICANT, M.D. KIM WANG, M.D. FRED ZHANG, M.D. \n",
      "NICHOLAS COLEY, M.D. LONG Li, M.D. KAI NI, M.D. ANN A WONG, M.D.  \n",
      "JOYCE CHEN, M.D., Ph.D. LY MA, M.D. ANDREA L. ONG, M.D. HANNAH WONG, M.D.  \n",
      "SOHEIL DADRAS, M.D. DEREK K. MARSEE, M.D. JUAN RONG , M.D. JIANMIN XU, M.D.  \n",
      "  \n",
      " \n",
      "ADDENDUM:  \n",
      " \n",
      "Addended Results: \n",
      " \n",
      "HER2 FISH testing was performed and interpreted by NeoGenomics Laboratories.  \n",
      " \n",
      "HER2 FISH Results: Positive \n",
      " \n",
      "Interpretation: \n",
      "Average HER2 signals/nucleus: 4.2 \n",
      "Average CEN 17 signals/nucleus: 1.1 \n",
      "HER2/CEN 17 signal ratio: 3.8 \n",
      "Number of Observers: 1 \n",
      "Group: 1 No IHC needed \n",
      " \n",
      "SS:snc   \n",
      " \n",
      "Addendum #2 on 11/03/2023 by Sasan Setoodeh, M.D.  \n",
      "Electronically signed at Sutter Roseville Hospital  \n",
      "One Medical Plaza Ctr  ROSEVILLE, CA  95661   \n",
      " \n"
     ]
    }
   ],
   "source": [
    "import streamlit as st\n",
    "from PyPDF2 import PdfReader\n",
    "from langchain.text_splitter import CharacterTextSplitter\n",
    "from langchain.embeddings.openai import OpenAIEmbeddings\n",
    "from langchain.vectorstores import FAISS\n",
    "from langchain.chains.question_answering import load_qa_chain\n",
    "from langchain.llms import OpenAI\n",
    "from langchain.callbacks import get_openai_callback\n",
    "import os\n",
    "from langchain_community.vectorstores import FAISS\n",
    "from langchain_community.llms import OpenAI\n",
    "from langchain_community.callbacks import get_openai_callback\n",
    "\n",
    "\n",
    "# Specify the path to the PDF file\n",
    "pdf_path = \"/Users/ahmed-elbakri/Downloads/Python/Ops Analytics/Clinical Trials/IHC-addendum-example-with-FISH.pdf\"\n",
    "\n",
    "# Create a PDF reader object\n",
    "pdf_reader = PdfReader(pdf_path)\n",
    "\n",
    "# Initialize an empty string to accumulate the text from each page\n",
    "text1 = \"\"\n",
    "\n",
    "# Loop through each page in the PDF\n",
    "for page in pdf_reader.pages:\n",
    "    # Extract text from the current page and append it to the `text` string\n",
    "    page_text = page.extract_text()\n",
    "    if page_text:  # Check if page_text is not None\n",
    "        text1 += page_text\n",
    "\n",
    "# Now `text` contains all the text extracted from the PDF file\n",
    "print(text1)\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 69,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Total tokens used: 13\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "'Total tokens used: 13'"
      ]
     },
     "execution_count": 69,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "import openai\n",
    "\n",
    "def get_token_count(text, model=\"gpt-4\"):\n",
    "    client = openai.OpenAI(api_key='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')\n",
    "    \n",
    "    # Creating a completion request to the OpenAI API\n",
    "\n",
    "    response = client.chat.completions.create(\n",
    "        model=model,\n",
    "        messages=[{\"role\": \"system\", \"content\": text}],\n",
    "        max_tokens=1  # Setting to minimal valid number to initiate response\n",
    "    )\n",
    "    # Extracting the token count from the response based on your confirmed working method\n",
    "    # This assumes the response object has a `choices` list with structured content.\n",
    "    token_count = response.usage.total_tokens  # Adjusted to match your working example structure\n",
    "    return f\"Total tokens used: {token_count}\"\n",
    "\n",
    "\n",
    "# Example usage\n",
    "text1 = \"Your extracted text goes here\"\n",
    "print(get_token_count(text1))\n",
    "\n",
    "\n",
    "get_token_count(text1)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 72,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Columns in DataFrame: Index(['SPACE', 'TYPE', 'STATUS', 'HR', 'HER2', 'LINE', 'ID', 'NAME', 'ALIAS',\n",
      "       'ELIGIBILITY', 'PI', 'CRC', 'GROUP', 'QC'],\n",
      "      dtype='object')\n"
     ]
    }
   ],
   "source": [
    "import pandas as pd\n",
    "\n",
    "def load_and_clean_data(filepath):\n",
    "    df = pd.read_csv(filepath)\n",
    "    # Print the actual column names to verify them\n",
    "    print(\"Columns in DataFrame:\", df.columns)\n",
    "    return df\n",
    "\n",
    "# Example usage\n",
    "filepath = \"/Users/ahmed-elbakri/Downloads/Python/Ops Analytics/Clinical Trials/bcm.trial.data - Sheet1.csv\"\n",
    "df = load_and_clean_data(filepath)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "import pandas as pd\n",
    "\n",
    "def load_and_clean_data(filepath):\n",
    "    # Load the CSV file\n",
    "    df = pd.read_csv(filepath)\n",
    "    \n",
    "    # Print the original shape of the dataframe for debugging\n",
    "    print(\"Original DataFrame shape:\", df.shape)\n",
    "\n",
    "    # Remove duplicates: adjust the subset list as needed to include columns that should be unique\n",
    "    # If all columns should match to consider a row a duplicate, you can omit the `subset` argument\n",
    "    df = df.drop_duplicates(subset=['ELIGIBILITY'], keep='first')\n",
    "\n",
    "    # Print the shape after removing duplicates to see how many duplicates were removed\n",
    "    print(\"DataFrame shape after removing duplicates:\", df.shape)\n",
    "    print(df)\n",
    "\n",
    "    return df\n",
    "\n",
    "# Example usage\n",
    "filepath = \"/Users/ahmed-elbakri/Downloads/Python/Ops Analytics/Clinical Trials/bcm.trial.data - Sheet1.csv\"\n",
    "trials_df = load_and_clean_data(filepath)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 180,
   "metadata": {},
   "outputs": [],
   "source": [
    "from langchain.output_parsers import ResponseSchema\n",
    "from langchain.output_parsers import StructuredOutputParser"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 181,
   "metadata": {},
   "outputs": [],
   "source": [
    "t_schema = ResponseSchema(name=\"T Staging\", description=\"Extract the T staging: (T) Staging:\")\n",
    "n_schema = ResponseSchema(name=\"N Staging\", description=\"Extract the N staging: (N) Staging:\")\n",
    "m_schema = ResponseSchema(name=\"M Staging\", description=\"Extract the M staging: (M) Staging:\")\n",
    "er_schema = ResponseSchema(name=\"ER Status\", description=\"Extract the ER status: (ER) Status:\")\n",
    "her2_schema = ResponseSchema(name=\"HER2 Presence\", description=\"Extract the HER2 presence: HER2 Presence:\")\n",
    "ilc_schema = ResponseSchema(name=\"ILC Receptor Status\", description=\"Extract the ILC receptor status: Infiltrating Lobular Carcinoma (ILC) Receptor Status:\")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 182,
   "metadata": {},
   "outputs": [],
   "source": [
    "response_schemas = [t_schema, n_schema, m_schema, er_schema, her2_schema, ilc_schema]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 183,
   "metadata": {},
   "outputs": [],
   "source": [
    "outputParser = StructuredOutputParser.from_response_schemas(response_schemas)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 184,
   "metadata": {},
   "outputs": [],
   "source": [
    "format_instructions = outputParser.get_format_instructions()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 185,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "The output should be a markdown code snippet formatted in the following schema, including the leading and trailing \"```json\" and \"```\":\n",
      "\n",
      "```json\n",
      "{\n",
      "\t\"T Staging\": string  // Extract the T staging: (T) Staging:\n",
      "\t\"N Staging\": string  // Extract the N staging: (N) Staging:\n",
      "\t\"M Staging\": string  // Extract the M staging: (M) Staging:\n",
      "\t\"ER Status\": string  // Extract the ER status: (ER) Status:\n",
      "\t\"HER2 Presence\": string  // Extract the HER2 presence: HER2 Presence:\n",
      "\t\"ILC Receptor Status\": string  // Extract the ILC receptor status: Infiltrating Lobular Carcinoma (ILC) Receptor Status:\n",
      "}\n",
      "```\n"
     ]
    }
   ],
   "source": [
    "print(format_instructions)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 186,
   "metadata": {},
   "outputs": [],
   "source": [
    "template = \"\"\"\n",
    "    Review the following text to determin TNM staging((Tis) T1a T1b T1c T2 T3 T4 AND N0 N1 N2 N3)According to the American Joint Committee on Cancer (AJCC), T1a breast cancer tumors are 0.5 cm or smaller, while T1b tumors are larger than 0.5 cm but not more than 1 cm. T1 tumors are further subdivided into T1a, T1b, and T1c based on their greatest diameter:\n",
    "            T1a: 0.1 to 0.5 cm\n",
    "            T1b: 0.6 to1 cm\n",
    "            T1c: 1 to 2 cm, \n",
    "            ER status, HER2 presence, patient cancer histology (IDC, ILC),\n",
    "            and receptor status. sometimes the information does not directly mention TNM staging but provide tumor size that could lead to determining the staging, use that when availalble.\n",
    "            \n",
    "            If the information is insufficient,\n",
    "            please indicate that not enough information is present. \n",
    "            Format your response as follows (print each result in a seperate line):\n",
    "            (T) Staging: [Your Response Here], \\n\n",
    "            (N) Staging: [Your Response Here], \\n\n",
    "            (M) Staging: [Your Response Here], \\n\n",
    "            (ER) Status: [Your Response Here], \\n\n",
    "            HER2 Presence: [Your Response Here], \\n\n",
    "            nfiltrating Lobular Carcinoma (ILC) Receptor Status: [Your Response Here]\n",
    "            \n",
    "            text: {text}\n",
    "            {format_instructions}\n",
    "    \"\"\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 187,
   "metadata": {},
   "outputs": [],
   "source": [
    "text1 = \"\"\" \n",
    "\n",
    "SAMPLE CASE\n",
    "\n",
    "MMG Screen\n",
    "Comparison is made to exams dated: 2/28/2022 mammogram, 2/25/2021 \n",
    "mammogram, 2/10/2020 mammogram, 1/3/2019 mammogram, 1/2/2018 mammogram, and \n",
    " 12/23/2016 mammogram - Baylor St. Luke's Medical Center- McNair.  There \n",
    "are scattered fibroglandular elements in both breasts that could obscure a \n",
    "lesion on mammography.   \n",
    "Tomosynthesis was used. Current study was also evaluated with a Computer \n",
    "Aided Detection (CAD) system.   \n",
    "There are benign calcifications in both breasts.  There also are biopsy \n",
    "clips in the right breast.  Additionally, there are benign post operative \n",
    "findings and a biopsy clip in the left breast.   \n",
    "There is a 0.9 cm asymmetry in the right breast anterior depth superior \n",
    "region seen on the mediolateral oblique view only.   \n",
    "No other significant masses, calcifications, or other findings are seen in \n",
    "either breast.   \n",
    "IMPRESSION: INCOMPLETE:NEED ADDITIONAL IMAGING EVALUATION \n",
    "The 0.9 cm asymmetry in the right breast is indeterminate.  An ultrasound \n",
    "is recommended and will be performed today.   \n",
    "\n",
    "\n",
    "\n",
    "\n",
    "\n",
    "MMG DX\n",
    "BILATERAL DIAGNOSTIC MAMMOGRAM FINDINGS:\n",
    "Tomosynthesis 3D imaging of the both breasts was performed. \n",
    "The current study was also evaluated with a Computer Aided Detection (CAD) sytem.\n",
    "The breasts have scattered areas of fibroglaUSndular density.  \n",
    "There are benign calcifications in both breasts.  There are postoperative findings in the left breast.  A scar marker overlies the right breast.\n",
    "There are biopsy clips in the right breast.\n",
    "There is a 1.3 cm focal asymmetry in the right breast at 12 o'clock anterior depth.\n",
    " \n",
    "IMPRESSION: \n",
    "The 1.3 cm focal asymmetry in the right breast at 12 o'clock is indeterminate. A right diagnostic mammogram (true lateral, rolled views, anterior compression) and ultrasound are recommended for further evaluation. \n",
    "\n",
    "Breast US\n",
    "DIAGNOSTIC ULTRASOUND FINDINGS:\n",
    "Color and grayscale sonography were performed of the area of interest in the right breast.  Real-time imaging was also performed.  A female technologist was present in the room for the entire procedure.\n",
    "There is a 0.7 x 0.6 x 0.7 cm mixed echogenic area in the right breast at 12:00 located 2 cm from the nipple.  This likely correlates to the mammographic finding. Examination of RIGHT axilla with no detected abnormalities. \n",
    " \n",
    "IMPRESSION:\n",
    "The mixed echogenic area in the right breast at 12:00 located 2 cm from the nipple is suspicious for malignancy.  An ultrasound-guided biopsy is recommended\n",
    "\n",
    "\n",
    "PATH from Bx\n",
    "A. BREAST, RIGHT 12:00, 2CM FN, ULTRASOUND GUIDED CORE BIOPSY\n",
    "          - INFILTRATING LOBULAR CARCINOMA, PARTIALLY VARIANT SUBTYPE\n",
    "                    - HISTOLOGIC GRADE : 2/3 BY ESBR CRITERIA\n",
    "                    - NO DEFINITE LYMPHOVASCULAR INVASION SEEN\n",
    "                    - PERINEURAL INFILTRATION IS SEEN\n",
    "                    - NO SIGNIFICANT TUMOR INFILTRATING LYMPHOCYTES\n",
    "          - BENIGN BREAST TISSUE\n",
    " \n",
    "COMMENT\n",
    "BIOMARKERS PERFORMED ON SECTION A1 \n",
    "ESTROGEN RECEPTOR: POSITIVE\n",
    "Proportion score: 5/5\n",
    "Intensity score: 3/3\n",
    "SUMMARY: 100% POSITIVE, STRONG INTENSITY   \n",
    " \n",
    "PROGESTERONE RECEPTOR: POSITIVE\n",
    "Proportion score: 5/5\n",
    "Intensity score: 3/3\n",
    "SUMMARY: 99% POSITIVE, STRONG INTENSITY\n",
    " \n",
    "HER 2 OVER-EXPRESSION: NEGATIVE (SCORE: 0) \n",
    " \n",
    "Ki67 (Proliferation marker): AVERAGE 18% (cut off-20%)\n",
    " \"\"\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 188,
   "metadata": {},
   "outputs": [],
   "source": [
    "prompt_template = ChatPromptTemplate.from_template(template)\n",
    "message = prompt_template.format_messages(text=text1,format_instructions=format_instructions)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 189,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "    Review the following text to determin TNM staging((Tis) T1a T1b T1c T2 T3 T4 AND N0 N1 N2 N3)According to the American Joint Committee on Cancer (AJCC), T1a breast cancer tumors are 0.5 cm or smaller, while T1b tumors are larger than 0.5 cm but not more than 1 cm. T1 tumors are further subdivided into T1a, T1b, and T1c based on their greatest diameter:\n",
      "            T1a: 0.1 to 0.5 cm\n",
      "            T1b: 0.6 to1 cm\n",
      "            T1c: 1 to 2 cm, \n",
      "            ER status, HER2 presence, patient cancer histology (IDC, ILC),\n",
      "            and receptor status. sometimes the information does not directly mention TNM staging but provide tumor size that could lead to determining the staging, use that when availalble.\n",
      "            \n",
      "            If the information is insufficient,\n",
      "            please indicate that not enough information is present. \n",
      "            Format your response as follows (print each result in a seperate line):\n",
      "            (T) Staging: [Your Response Here], \n",
      "\n",
      "            (N) Staging: [Your Response Here], \n",
      "\n",
      "            (M) Staging: [Your Response Here], \n",
      "\n",
      "            (ER) Status: [Your Response Here], \n",
      "\n",
      "            HER2 Presence: [Your Response Here], \n",
      "\n",
      "            nfiltrating Lobular Carcinoma (ILC) Receptor Status: [Your Response Here]\n",
      "            \n",
      "            text:  \n",
      "\n",
      "SAMPLE CASE\n",
      "\n",
      "MMG Screen\n",
      "Comparison is made to exams dated: 2/28/2022 mammogram, 2/25/2021 \n",
      "mammogram, 2/10/2020 mammogram, 1/3/2019 mammogram, 1/2/2018 mammogram, and \n",
      " 12/23/2016 mammogram - Baylor St. Luke's Medical Center- McNair.  There \n",
      "are scattered fibroglandular elements in both breasts that could obscure a \n",
      "lesion on mammography.   \n",
      "Tomosynthesis was used. Current study was also evaluated with a Computer \n",
      "Aided Detection (CAD) system.   \n",
      "There are benign calcifications in both breasts.  There also are biopsy \n",
      "clips in the right breast.  Additionally, there are benign post operative \n",
      "findings and a biopsy clip in the left breast.   \n",
      "There is a 0.9 cm asymmetry in the right breast anterior depth superior \n",
      "region seen on the mediolateral oblique view only.   \n",
      "No other significant masses, calcifications, or other findings are seen in \n",
      "either breast.   \n",
      "IMPRESSION: INCOMPLETE:NEED ADDITIONAL IMAGING EVALUATION \n",
      "The 0.9 cm asymmetry in the right breast is indeterminate.  An ultrasound \n",
      "is recommended and will be performed today.   \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "MMG DX\n",
      "BILATERAL DIAGNOSTIC MAMMOGRAM FINDINGS:\n",
      "Tomosynthesis 3D imaging of the both breasts was performed. \n",
      "The current study was also evaluated with a Computer Aided Detection (CAD) sytem.\n",
      "The breasts have scattered areas of fibroglaUSndular density.  \n",
      "There are benign calcifications in both breasts.  There are postoperative findings in the left breast.  A scar marker overlies the right breast.\n",
      "There are biopsy clips in the right breast.\n",
      "There is a 1.3 cm focal asymmetry in the right breast at 12 o'clock anterior depth.\n",
      " \n",
      "IMPRESSION: \n",
      "The 1.3 cm focal asymmetry in the right breast at 12 o'clock is indeterminate. A right diagnostic mammogram (true lateral, rolled views, anterior compression) and ultrasound are recommended for further evaluation. \n",
      "\n",
      "Breast US\n",
      "DIAGNOSTIC ULTRASOUND FINDINGS:\n",
      "Color and grayscale sonography were performed of the area of interest in the right breast.  Real-time imaging was also performed.  A female technologist was present in the room for the entire procedure.\n",
      "There is a 0.7 x 0.6 x 0.7 cm mixed echogenic area in the right breast at 12:00 located 2 cm from the nipple.  This likely correlates to the mammographic finding. Examination of RIGHT axilla with no detected abnormalities. \n",
      " \n",
      "IMPRESSION:\n",
      "The mixed echogenic area in the right breast at 12:00 located 2 cm from the nipple is suspicious for malignancy.  An ultrasound-guided biopsy is recommended\n",
      "\n",
      "\n",
      "PATH from Bx\n",
      "A. BREAST, RIGHT 12:00, 2CM FN, ULTRASOUND GUIDED CORE BIOPSY\n",
      "          - INFILTRATING LOBULAR CARCINOMA, PARTIALLY VARIANT SUBTYPE\n",
      "                    - HISTOLOGIC GRADE : 2/3 BY ESBR CRITERIA\n",
      "                    - NO DEFINITE LYMPHOVASCULAR INVASION SEEN\n",
      "                    - PERINEURAL INFILTRATION IS SEEN\n",
      "                    - NO SIGNIFICANT TUMOR INFILTRATING LYMPHOCYTES\n",
      "          - BENIGN BREAST TISSUE\n",
      " \n",
      "COMMENT\n",
      "BIOMARKERS PERFORMED ON SECTION A1 \n",
      "ESTROGEN RECEPTOR: POSITIVE\n",
      "Proportion score: 5/5\n",
      "Intensity score: 3/3\n",
      "SUMMARY: 100% POSITIVE, STRONG INTENSITY   \n",
      " \n",
      "PROGESTERONE RECEPTOR: POSITIVE\n",
      "Proportion score: 5/5\n",
      "Intensity score: 3/3\n",
      "SUMMARY: 99% POSITIVE, STRONG INTENSITY\n",
      " \n",
      "HER 2 OVER-EXPRESSION: NEGATIVE (SCORE: 0) \n",
      " \n",
      "Ki67 (Proliferation marker): AVERAGE 18% (cut off-20%)\n",
      " \n",
      "            The output should be a markdown code snippet formatted in the following schema, including the leading and trailing \"```json\" and \"```\":\n",
      "\n",
      "```json\n",
      "{\n",
      "\t\"T Staging\": string  // Extract the T staging: (T) Staging:\n",
      "\t\"N Staging\": string  // Extract the N staging: (N) Staging:\n",
      "\t\"M Staging\": string  // Extract the M staging: (M) Staging:\n",
      "\t\"ER Status\": string  // Extract the ER status: (ER) Status:\n",
      "\t\"HER2 Presence\": string  // Extract the HER2 presence: HER2 Presence:\n",
      "\t\"ILC Receptor Status\": string  // Extract the ILC receptor status: Infiltrating Lobular Carcinoma (ILC) Receptor Status:\n",
      "}\n",
      "```\n",
      "    \n"
     ]
    }
   ],
   "source": [
    "print(message[0].content)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 190,
   "metadata": {},
   "outputs": [],
   "source": [
    "load_dotenv()\n",
    "api_key = os.getenv('OPENAI_API_KEY')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 191,
   "metadata": {},
   "outputs": [],
   "source": [
    "model=\"gpt-4\"\n",
    "temperature=0.0\n",
    "initialize_chat_client = ChatOpenAI(api_key=api_key, temperature=temperature, model=model)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 192,
   "metadata": {},
   "outputs": [],
   "source": [
    "response = initialize_chat_client(message)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 193,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "```json\n",
      "{\n",
      "\t\"T Staging\": \"T1b\",  \n",
      "\t\"N Staging\": \"N0\",  \n",
      "\t\"M Staging\": \"Not enough information\",  \n",
      "\t\"ER Status\": \"Positive\",  \n",
      "\t\"HER2 Presence\": \"Negative\",  \n",
      "\t\"ILC Receptor Status\": \"Positive\"\n",
      "}\n",
      "```\n"
     ]
    }
   ],
   "source": [
    "print(response.content)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 194,
   "metadata": {},
   "outputs": [],
   "source": [
    "output_dict = outputParser.parse(response.content)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 196,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "dict"
      ]
     },
     "execution_count": 196,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "output_dict"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 200,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'T Staging': 'T1b', 'N Staging': 'N0', 'M Staging': 'Not mentioned', 'ER Status': 'Positive', 'HER2 Presence': 'Negative', 'ILC Receptor Status': 'Positive'}\n"
     ]
    }
   ],
   "source": [
    "import os\n",
    "from dotenv import load_dotenv\n",
    "from PyPDF2 import PdfReader\n",
    "from langchain.prompts import ChatPromptTemplate\n",
    "from langchain_openai import ChatOpenAI\n",
    "from langchain.output_parsers import ResponseSchema, StructuredOutputParser\n",
    "\n",
    "def setup_response_parsers():\n",
    "    \"\"\"Create and return structured output parsers and format instructions.\"\"\"\n",
    "    response_schemas = [\n",
    "        ResponseSchema(name=\"T Staging\", description=\"Extract the T staging: (T) Staging:\"),\n",
    "        ResponseSchema(name=\"N Staging\", description=\"Extract the N staging: (N) Staging:\"),\n",
    "        ResponseSchema(name=\"M Staging\", description=\"Extract the M staging: (M) Staging:\"),\n",
    "        ResponseSchema(name=\"ER Status\", description=\"Extract the ER status: (ER) Status:\"),\n",
    "        ResponseSchema(name=\"HER2 Presence\", description=\"Extract the HER2 presence: HER2 Presence:\"),\n",
    "        ResponseSchema(name=\"ILC Receptor Status\", description=\"Extract the ILC receptor status: Infiltrating Lobular Carcinoma (ILC) Receptor Status:\")\n",
    "    ]\n",
    "    output_parser = StructuredOutputParser.from_response_schemas(response_schemas)\n",
    "    format_instructions = output_parser.get_format_instructions()\n",
    "    return output_parser, format_instructions\n",
    "\n",
    "def create_chat_prompt(text, format_instructions):\n",
    "    \"\"\"Generate a chat prompt template based on provided text and format instructions.\"\"\"\n",
    "    template = \"\"\"\n",
    " Review the following text to determin TNM staging((Tis) T1a T1b T1c T2 T3 T4 AND N0 N1 N2 N3)According to the American Joint Committee on Cancer (AJCC), T1a breast cancer tumors are 0.5 cm or smaller, while T1b tumors are larger than 0.5 cm but not more than 1 cm. T1 tumors are further subdivided into T1a, T1b, and T1c based on their greatest diameter:\n",
    "            T1a: 0.1 to 0.5 cm\n",
    "            T1b: 0.6 to1 cm\n",
    "            T1c: 1 to 2 cm, \n",
    "            ER status, HER2 presence, patient cancer histology (IDC, ILC),\n",
    "            and receptor status. sometimes the information does not directly mention TNM staging but provide tumor size that could lead to determining the staging, use that when availalble.\n",
    "            \n",
    "            If the information is insufficient,\n",
    "            please indicate that not enough information is present. \n",
    "            Format your response as follows (print each result in a seperate line):\n",
    "            (T) Staging: [Your Response Here], \\n\n",
    "            (N) Staging: [Your Response Here], \\n\n",
    "            (M) Staging: [Your Response Here], \\n\n",
    "            (ER) Status: [Your Response Here], \\n\n",
    "            HER2 Presence: [Your Response Here], \\n\n",
    "            nfiltrating Lobular Carcinoma (ILC) Receptor Status: [Your Response Here]\n",
    "            \n",
    "            text: {text}\n",
    "            {format_instructions}\n",
    "    \"\"\"\n",
    "    prompt_template = ChatPromptTemplate.from_template(template)\n",
    "    return prompt_template.format_messages(text=text, format_instructions=format_instructions)\n",
    "\n",
    "def initialize_chat_client(api_key, model=\"gpt-4\", temperature=0.0):\n",
    "    \"\"\"Initialize and return a chat client.\"\"\"\n",
    "    return ChatOpenAI(api_key=api_key, temperature=temperature, model=model)\n",
    "\n",
    "def main():\n",
    "    load_dotenv()\n",
    "    api_key = os.getenv('OPENAI_API_KEY')\n",
    "\n",
    "    # Set up response parsers and format instructions\n",
    "    output_parser, format_instructions = setup_response_parsers()\n",
    "\n",
    "    # Create chat prompt\n",
    "    text1 = \"\"\" MMG Screen\n",
    "Comparison is made to exams dated: 2/28/2022 mammogram, 2/25/2021 \n",
    "mammogram, 2/10/2020 mammogram, 1/3/2019 mammogram, 1/2/2018 mammogram, and \n",
    " 12/23/2016 mammogram - Baylor St. Luke's Medical Center- McNair.  There \n",
    "are scattered fibroglandular elements in both breasts that could obscure a \n",
    "lesion on mammography.   \n",
    "Tomosynthesis was used. Current study was also evaluated with a Computer \n",
    "Aided Detection (CAD) system.   \n",
    "There are benign calcifications in both breasts.  There also are biopsy \n",
    "clips in the right breast.  Additionally, there are benign post operative \n",
    "findings and a biopsy clip in the left breast.   \n",
    "There is a 0.9 cm asymmetry in the right breast anterior depth superior \n",
    "region seen on the mediolateral oblique view only.   \n",
    "No other significant masses, calcifications, or other findings are seen in \n",
    "either breast.   \n",
    "IMPRESSION: INCOMPLETE:NEED ADDITIONAL IMAGING EVALUATION \n",
    "The 0.9 cm asymmetry in the right breast is indeterminate.  An ultrasound \n",
    "is recommended and will be performed today.   \n",
    "\n",
    "\n",
    "\n",
    "\n",
    "\n",
    "MMG DX\n",
    "BILATERAL DIAGNOSTIC MAMMOGRAM FINDINGS:\n",
    "Tomosynthesis 3D imaging of the both breasts was performed. \n",
    "The current study was also evaluated with a Computer Aided Detection (CAD) sytem.\n",
    "The breasts have scattered areas of fibroglaUSndular density.  \n",
    "There are benign calcifications in both breasts.  There are postoperative findings in the left breast.  A scar marker overlies the right breast.\n",
    "There are biopsy clips in the right breast.\n",
    "There is a 1.3 cm focal asymmetry in the right breast at 12 o'clock anterior depth.\n",
    " \n",
    "IMPRESSION: \n",
    "The 1.3 cm focal asymmetry in the right breast at 12 o'clock is indeterminate. A right diagnostic mammogram (true lateral, rolled views, anterior compression) and ultrasound are recommended for further evaluation. \n",
    "\n",
    "Breast US\n",
    "DIAGNOSTIC ULTRASOUND FINDINGS:\n",
    "Color and grayscale sonography were performed of the area of interest in the right breast.  Real-time imaging was also performed.  A female technologist was present in the room for the entire procedure.\n",
    "There is a 0.7 x 0.6 x 0.7 cm mixed echogenic area in the right breast at 12:00 located 2 cm from the nipple.  This likely correlates to the mammographic finding. Examination of RIGHT axilla with no detected abnormalities. \n",
    " \n",
    "IMPRESSION:\n",
    "The mixed echogenic area in the right breast at 12:00 located 2 cm from the nipple is suspicious for malignancy.  An ultrasound-guided biopsy is recommended\n",
    "\n",
    "\n",
    "PATH from Bx\n",
    "A. BREAST, RIGHT 12:00, 2CM FN, ULTRASOUND GUIDED CORE BIOPSY\n",
    "          - INFILTRATING LOBULAR CARCINOMA, PARTIALLY VARIANT SUBTYPE\n",
    "                    - HISTOLOGIC GRADE : 2/3 BY ESBR CRITERIA\n",
    "                    - NO DEFINITE LYMPHOVASCULAR INVASION SEEN\n",
    "                    - PERINEURAL INFILTRATION IS SEEN\n",
    "                    - NO SIGNIFICANT TUMOR INFILTRATING LYMPHOCYTES\n",
    "          - BENIGN BREAST TISSUE\n",
    " \n",
    "COMMENT\n",
    "BIOMARKERS PERFORMED ON SECTION A1 \n",
    "ESTROGEN RECEPTOR: POSITIVE\n",
    "Proportion score: 5/5\n",
    "Intensity score: 3/3\n",
    "SUMMARY: 100% POSITIVE, STRONG INTENSITY   \n",
    " \n",
    "PROGESTERONE RECEPTOR: POSITIVE\n",
    "Proportion score: 5/5\n",
    "Intensity score: 3/3\n",
    "SUMMARY: 99% POSITIVE, STRONG INTENSITY\n",
    " \n",
    "HER 2 OVER-EXPRESSION: NEGATIVE (SCORE: 0) \n",
    " \n",
    "Ki67 (Proliferation marker): AVERAGE 18% (cut off-20%)\n",
    "\"\"\"  # Add your sample case text here\n",
    "    message = create_chat_prompt(text1, format_instructions)\n",
    "\n",
    "    # Initialize chat client and get response\n",
    "    chat_client = initialize_chat_client(api_key)\n",
    "    response = chat_client(message)\n",
    "\n",
    "    # Parse and print output\n",
    "    output_dict = output_parser.parse(response.content)\n",
    "    print(output_dict)\n",
    "\n",
    "if __name__ == '__main__':\n",
    "    main()\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results https://finance.yahoo.com/news/soleno-therapeutics-provides-corporate-reports-200500052.html\n",
      "While institutions invested in Soleno Therapeutics, Inc. (NASDAQ:SLNO) benefited from last week's 4.8% gain, private equity firms stood to gain the most https://finance.yahoo.com/news/while-institutions-invested-soleno-therapeutics-115009705.html\n",
      "Soleno Therapeutics Announces Pricing of Approximately $138 Million Public Offering Of Common Stock https://finance.yahoo.com/news/soleno-therapeutics-announces-pricing-approximately-023200234.html\n",
      "Soleno Therapeutics Announces Proposed Public Offering of Common Stock https://finance.yahoo.com/news/soleno-therapeutics-announces-proposed-public-200100632.html\n",
      "Soleno Therapeutics Announces Peer-Reviewed Publication of Data Comparing DCCR Treatment to the Natural History of Prader-Willi Syndrome https://finance.yahoo.com/news/soleno-therapeutics-announces-peer-reviewed-120000042.html\n",
      "Why Soleno Therapeutics Stock Is Skyrocketing Today https://finance.yahoo.com/news/why-soleno-therapeutics-stock-skyrocketing-151100273.html\n",
      "Soleno Therapeutics Receives Breakthrough Therapy Designation from U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome (PWS) https://finance.yahoo.com/news/soleno-therapeutics-receives-breakthrough-therapy-120000455.html\n",
      "Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://finance.yahoo.com/news/soleno-therapeutics-announces-inducement-grants-200500916.html\n",
      "CEO Bhatnagar Anish Sells 18,980 Shares of Soleno Therapeutics Inc (SLNO) https://finance.yahoo.com/news/ceo-bhatnagar-anish-sells-18-055421217.html\n",
      "Insider Sell: CFO James Mackaness Sells 5,175 Shares of Soleno Therapeutics Inc (SLNO) https://finance.yahoo.com/news/insider-sell-cfo-james-mackaness-055416560.html\n",
      "We're Not Worried About Soleno Therapeutics' (NASDAQ:SLNO) Cash Burn https://finance.yahoo.com/news/were-not-worried-soleno-therapeutics-104442306.html\n",
      "Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results https://finance.yahoo.com/news/soleno-therapeutics-provides-corporate-reports-210500675.html\n",
      "Soleno Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference https://finance.yahoo.com/news/soleno-therapeutics-present-td-cowen-130000296.html\n",
      "Soleno Therapeutics, Inc. (SLNO) Is a Great Choice for 'Trend' Investors, Here's Why https://finance.yahoo.com/news/soleno-therapeutics-inc-slno-great-135005593.html\n",
      "Charter downgraded, Cigna upgraded: Wall Street's top analyst calls https://finance.yahoo.com/news/charter-downgraded-cigna-upgraded-wall-151041068.html\n",
      "Soleno Therapeutics to Present at Upcoming February Investor Conferences https://finance.yahoo.com/news/soleno-therapeutics-present-upcoming-february-130000533.html\n",
      "Analysts Expect Breakeven For Soleno Therapeutics, Inc. (NASDAQ:SLNO) Before Long https://finance.yahoo.com/news/analysts-expect-breakeven-soleno-therapeutics-124611551.html\n",
      "Here's Why Momentum in Soleno Therapeutics, Inc. (SLNO) Should Keep going https://finance.yahoo.com/news/heres-why-momentum-soleno-therapeutics-135006784.html\n",
      "Soleno Therapeutics Strengthens Leadership Team with Key Appointments https://finance.yahoo.com/news/soleno-therapeutics-strengthens-leadership-team-130000359.html\n",
      "Here's What Could Help Soleno Therapeutics, Inc. (SLNO) Maintain Its Recent Price Strength https://finance.yahoo.com/news/heres-could-help-soleno-therapeutics-135006865.html\n"
     ]
    }
   ],
   "source": [
    "import requests\n",
    "from lxml import html\n",
    "\n",
    "def get_yahoo_finance_news(stock_symbol):\n",
    "    url = f\"https://finance.yahoo.com/quote/{stock_symbol}/news\"\n",
    "    headers = {\n",
    "        'User-Agent': 'Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/90.0.4430.212 Safari/537.36'\n",
    "    }\n",
    "    response = requests.get(url, headers=headers)\n",
    "    tree = html.fromstring(response.content)\n",
    "\n",
    "    # Use the full XPath to extract news\n",
    "    news_list = []\n",
    "    for i in range(1, 61):  # Assuming there are up to 60 news items, adjust the range as needed\n",
    "        try:\n",
    "            title_xpath = f'/html/body/div[1]/main/section/section/section/article/section[2]/div[2]/div/div/ul/li[{i}]/section/div/a/h3'\n",
    "            title_element = tree.xpath(title_xpath)\n",
    "            if title_element:\n",
    "                title = title_element[0].text_content()\n",
    "                link = title_element[0].getparent().get('href')\n",
    "                if not link.startswith('http'):\n",
    "                    link = \"https://finance.yahoo.com\" + link\n",
    "                news_list.append({'title': title, 'url': link})\n",
    "        except IndexError:\n",
    "            break  # Break if the number of items is less than expected\n",
    "\n",
    "    return news_list\n",
    "\n",
    "# Example usage:\n",
    "stock_symbol = 'SLNO'\n",
    "news = get_yahoo_finance_news(stock_symbol)\n",
    "for item in news:\n",
    "    print(item['title'], item['url'])\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Why Iovance Stock Is Down 18% Today https://finance.yahoo.com/news/why-iovance-stock-down-18-180328025.html\n",
      "Who normally has the cheapest car insurance? https://a.beap.gemini.yahoo.com/mbclk?bv=3.0.0&es=AQAAAHYM5bi0c-zPxmq6Fdzvb_vsyvFXJqacFq22Y3GEa4-cQFtSJ85elH0TxMg6NTF6kyZ2c9s8_VPmdGgFwjX1axG3sIaKZBJIO4CQ6wJW30a5oR7-Y7XStbureYzQ4p4CSiuv5qBmAjMGzyR8pAu35LzkTja1U_ImAeZ54DyiYAKf6XiBLXnQ8fS3OH86IYL73A6U_AXkBKL3vJUpN7LvPlOaKj13AvGtwfqnO61j2ZVg3sJAm8oEqNM_5tmrt8xmot07qHbXaSoD3iO9BwIkEW1f-VlszWDs2zraR9BuO_HCqArXZQLtC15zkmZ9kD9JrcoPJVRU9HoivvIhVExUk86li_ZixcoHp5PwEhUjM8BSiqlgY9NiKg7rGi0yQjwviRF81IDOvb2gN7DuTTJZsBeotKCDJ6BtFXieTGPAJokZ5jO3iGhYy1E29FbRUVxI5odb0dnJkI8KMMUEg7aS-hSlrWSilbCpZj7_X4VId1E82uRssUrFx0llOhM_m2GQxyDfRgjFwFKGXNcb5tecI_x4GXmRTIfBxt6LGH688AGGh204ZF5oBvjtuTHstFnAJtmR3Va5LTwFrz-ncJTkLOYRTI_bKF5AVyFELWrhLk2mgJ-jShKKzqSLSCOZDy2Cewsqkkxd6XMok1AJNFedyPnGKSm_wRO9dJcoK9AN-8OG2OClySm-8r7oE5qzIXmDulDCbgNxQX_ne6VXyJqvyV4K1MZftdXnhMV4V2nZB6lggO6mozjnyBX-SZFthFQ0vzbL4cX-sVy_MIJ9OJFlQeyV25RXE5SaijfWC38HZTnwEx8vjS6teFPLcmNAtFh-DAj5kMAh11QUAcXgO9y_-XuzYV-zmjh-5cpOh8w25-7GvPMJwkgXaDvtAC9PSBRXobFHBexXvoSBii4d0ltJuLmoTbdRwUcsQNW6sHH_JHMrsP2_n-YsBEqoaVYwZESo7mW7mivrpfHD47ZFuifW1L235FvU9hXCYjCAPuWUL3rTl3dOwl-cuQZ8gB-oCeHhczm0SJLK2yxtMdKQri4Mkkz-QYRzFjvA_BPZspAuUYz9cNOZsExP5oj_3-ARR0fmfjd4sdwbfm8_P1llfPQuOKKoZL905oT1np_U2Q50--y6fJd3p-G1wS_5C2ysC7z81mZG3A43zyzVMG-SEePsBSpIkwGp0y6qJeSXhJuvRlGl9RI0cIzmeVg1MQgWsj1_3u_Dis2bGwtESIhZyLxJ1OhYYg146_p4PVm4u0tKQPMBO_f71TnOYnFneznvCKiyC8jbFr_2mIrtNx-cYG7muMt4OpEZj66fMtwPqKI6LZ1oAnmd4FgvSfIarKoMH9CrFB9TP3GhX34mODQq1f9qWf4Rk4iANofnBtA-WwwC6Psd4Ec27P2MzS37Ms2afVWplmOPau_Or6I0A5jRCKDSImcADQT-EUuEyDOLhnk-XPf893NwCrb4JFIt7iQDjI_2Y2VOn2kiwWbbrY6HFhtPzOYlhOFYh-d3ObbKK0TFhMRIzsrsKE7b9EhzSQ6w9cFWmGqdqPIz5iqwA4K7g7HqhLQlGUUft2lqvqjsyCwCvVll2n7mzvSr7f0fgnMZdWfOM6fgHigiIOv2fJgJT9i6Kvkw8yIMOl-Z9lvCVQBMjqQ2DSGytW1IiEfrlEO-puqMCgysMUFwKbGU7uaVIGPLkJrfhf0AzWpF3tHwLRK7wmCHYCDJHnLxhDT_Lyk73GYx9Oq_i5lETUnaWSS91dFG_1gZxqSNKNCH7sEs2VYDTTDJoIyWKc1i5rM5aFCjZxbTpX7cbIGcngR_Ftj-_EbKn5cXs1Q_mpAHvu__Uhx7QdRlhz_ftcTWug1G-_i6Gij3kRpT4i7i-FJ4lDAHvz3Yb3s1HbBvCUVQvnW_wV_kjfgaEU837PFiW6K7EOTSRqqL2EM2-osoDlUMWdprH-mdxSlYtPo0VRO92RsgZiy6CAcspkr9iT5-pgwql0uQKBbhHrQrPUGiglhRqM6iNPe03G_texpItdIytQCPCFhtZf-MR3YPEEr3JzcX4D7mcJyHsIy-hWDKKfbDF7zXFMDbRnXUMbnRzmuXNa74eru-TMLK7pG17Q0K1n7UM0xjZoz8ey9-oW3nW_2EBPwtE27fiTA8aFOFzq4gamSOwMTUBuOzihhXK75Lx3pkWmnyPmVAjshoe2kJ4USZYjb8_2GJPVYR90K2sLmYwgU1VgA01IemVtLl9yO30mDH21QfK2E7WqJhhuCBrhhrq-Ha2XSNSuR6d-rSYdWYbB_21lCHOgutoGaljerBYgoeQ3ulJCIPwKapqbPwIhutqxKuDxse_rtntEL0ev47ZS_GsklC996QWc9hu2g_yb6iKYmUBtd9uB0PFzPjY8k8UISTvVGRB_vQqEaHztLCwqCHXXVMju4vQ7mrfKy6k_m42x4fa38N5Z2BN6jE3XJPdLeX9OVCwTmerUEJEACOW-ZGj1KRfuM_moFi3UpaDeqyXrqkh2lO2-CYAxd3C3F99VN48au6nJbQDFaxJeh1us04y1BamDj9_FECX34XY2qkm2yAErCo_54nw1jrgAo1u6oOZRBuhOk2tSOgynOktFK4EQp-sLqfdfODGjHAMuCc3agVehxbXOD_H_Slb-YZMNooaGifjIql0OwOgIl1UhnLcVK8DlZXKCUT40Naa1pRT_plotSyegJBVm_H-MJjvG9aFA3wZHkWhPLVsF12hoJVYKi9NLdAvSV41RYuO4dwpKV3RFbCeSdtI2FKzDGj-pi77vX8b3clNCs5hj-b0Zo5fRSIyXkTQzLfn_Lt9M7jsPH_IHO3g1YdR7K-SYJ5Q74Tn8CGF6xVJN3czxHjvwWFpjNCjzFC4EZp7UzYuo_UaaRzik9aClNJzVKY48fLzSy6GYLl5khUFWtiBTZj7Q1O5pdRROJnDe1dm1w5z_mV6HxjMpw_2asA2qbuVs4MdWd7sPOnyHw6d7MMKrH9J91ws_-_UHnc-TGe2e3QTlxuimiYWdefVprLJieKjU9EEKwpw7n68AMKs9bW3rb8pFFoQ6MFk0kkRcxbC7UrMLJeSr1EsFWYK-K_5ybrsz-rL_33q6VyQqXavddL-ZMuHxAhqQJQ_cBwbyUsZzVt0MheSIvLHyRYxYJBGLUAd7SJQAQH0aaucyifbjDnQktuSSs6A0UpbUXi6aAJmCGEsEZCzK-bvvWV9j9pfiJ967Hm-j8hdhX3ZoGYfLzPj3Ev5z0Cvn29h97WYpFOMKLh3-jNYxl8z3byYUAf_fcpwHe_ufR18YERIdRi0wDxl2uAuNBE2MmQCey0wlhL86DXXcHljDqw9W4BRs-3X1rdQR--93KwU5q6n4svvweoAT_-iMcV3J1rvduXzkSFSEschoNRKfZCJjQBdLOsbUseQLyYwCfnE8m_3oGLFM8y9Dyr2R41SxMh857ldc005pTBdtuP5nHbE9srI10ZWFsxuM5MZ5HoN1U7arpXNHBj6G4Q7ffnlKruv_8tI7TBAbKiopRhFKs3k5QseQLmNbQ5gWb2_47_2I3OLocqt8CkEVMIasNPcR_ejFrcCcaVQ_mZxR66tgAETtcDoW_ioiD4Fwb15Ug5mW-4FAM1tFsbzkh945jBtFCqyzd4YwyvT1rqr_-Yz79yx-5DOQ\n",
      "Iovance Biotherapeutics' Patient Selection for Amtagvi Launch Minimizing Attrition, Truist Securities Says https://finance.yahoo.com/news/iovance-biotherapeutics-apos-patient-selection-173544625.html\n",
      "Iovance Biotherapeutics Inc (IOVA) Q1 2024 Earnings: Aligns with EPS Projections Amidst Strong ... https://finance.yahoo.com/news/iovance-biotherapeutics-inc-iova-q1-165532752.html\n",
      "Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q1 2024 Earnings Call Transcript https://finance.yahoo.com/news/iovance-biotherapeutics-inc-nasdaq-iova-163350605.html\n",
      "Iovance (IOVA) Q1 Earnings Surpass, Sales Lag Estimates https://finance.yahoo.com/news/iovance-iova-q1-earnings-surpass-145800904.html\n",
      "Step into Spring With a Guided Adventure in Oregon https://a.beap.gemini.yahoo.com/mbclk?bv=3.0.0&es=AQAAAKJ9hYd3gg4izZsqH0KrI0sLo2uGqc3Tb054HJYDuLJlMhi7AK7mDIhh7E5jsdW80TRxibhI1K6ziW6Xa-R0MhevrQHpOOGYLZInmGESDSbW6wW2fZ15Vb9O4EHN5uHiQBtMUQEYafk6blPFEJwHSlWCH2RktgfxE9gvJVFo99zdYqiL41Isfiuu4Ar9M3_roK1jgMpIy0Hgs0QXonpOusaWGAGFFjwpSpUsk1Rn-TJU7zasTNxfYjMKvJJfwtM2iXcA4AUjcgVAhppejclVoyN2vRBSb6TmyTmwrqS5O1_j_Mpn857zXHqiBce7czWOyCNRLCwVuYLyASy6OcCXlLrDMRWhvVLSjJLJdvstwL5Rsaf-CAuhoibxuoN9MbBxZk9o91FEO65fUZdA7T6xcLn9HRYDQ3BA0RCcq4P3-x5ysxHQhVUMindsNB6X4PBKjj2cXtmI6vcbCsf_ctXRhKTkVLlgJ0cYyW-5P2M53ae16l4kUJYup78b-99mZJhrnNqIjzm7Oyu1XBtx9aYZMKZPnuAAYQ0rkHOvOur_UvpTihl_Wz7Nxk4KXU7nWqO8LAAT9kzv5-0YwyN3TYXTg3viYtnBORduWBNGrbofkXh8BEwGBS_IhUGeN6rLwHRJa4w1iwZkQxlD7QMhLKwSSWJnXe8nmdJYSWcphlPt29M5kiUTZX_NeougijtY9Ylc4rAJLV3cYhrKvrfvlkKV0_dABLm9hCM7qLeNGqXyQcrm5rO1H7AKU2EVRTxpjjRHbeOTJuqJJRPBpctGKcFZSNCSO4i9HizLObuKfTTVAcBWd0LFsqzM_thy0YdVAe07FpzRWYvlbyRcrkVwffe3Kz_mo1QqkGHS6_Pu07csgfcgvqEygLLi2hkQ-iMhwo12A7x3E8Skgbwx8aYsQqSKqdQtjNEMuI2_UAY2SEzKj3q52MjJ3Uzb5hjq9M9LO0vc7TXqarqRJdZyjzRQ5t4jQvKKaBlH_GPtiZTYU8VDiUESH8nkWjiKIjVqOD5jmMbfv4xxgmMvsXPlFob6U10woYsqEHXX1cLwLJXXFje7C9zce1sI_GWkN0Yvlo0c3XuQgHWDL68fLhO5Ox0Z5FeylkTrUe4DpGoZgrH6tl1GNatH9KJb7_xMVlTuByBh3jlv1aH3jqDxMNLUiJ8jb2ORcXUeEx4uT9QFu0nMb16b36bSQXN_CMnN7aEEG6mQCUITXP9Ob6-gInzR5n_cBzUWvIqPWgR_wnr4V46rUUSEwdiEKi1T6yZiJAOcEmiaABP0CYrz_4R7802IBrNqZRVPGqpKRGrj7CWKAOw-WRw9pu4zfWecCdM9lUv3LhNBxPGZ4MQkpydfoNiPVmDoe8y3v3z6ybi_05V8UXnkh8CjWeevdtgh5-8hEcdkK95T7KD4MmxCa11URRjvnAoaH3Ydc_xtR1ukQzcHVXzTnnyCobTHtCWQjEhbD80CCJWu9EeWP62v5CMh6aKGHecW_lLzHfrsTFSAGVAs6AnttSATbZYs86Cr8lwNegcrMDuW3kbzX_StCEse11amLijEK7zM31WM9MvO2DIuAbsr0exNcc1jEqhLCl74IP4BJD7XsqsGYQLDvMJLZJK_ZNJPT9IcRxHjgvhI4sH81pT-Kx68lhpEbOdtmVMl3ovi_RsoF04_gdZJbYmQlkQ7rW_y1uO91rsRgVlaGZD1XgiDVJTSFmCZkMZ-V3AdKdV3hIiR6PIf_bzRIGCNSckD65PO0nh6c_UtfWyK0U5qxYdm9jQnQA0xoA7Z_4Z-cOco_loF-2VVdjZZf63P00v4jzlIeuzf9JdEqLP4EpYay0PGLF_plUhi5Dv-xAPVICv91hVNrJC7ENJuAwL6WriCpCJUD5BzQvrlPd7maJHYKmv7XXslKxExac4AG0n3gmJ0mSjX-47qx0SOKbSENE2PpP38-Yqo1PHTUIPIb9LRVeOgX1uJvK7P3ij85AgqWxBPuFFNVB2i1RksxkahrHx8LEeYEE6_NL23B-q3RkNhyvbkFYkj60MrPGMJUI4AyZdGSAUs0vZOtk_kpgJP5hjh4Lm8_9_nQ30ggZ9K3Hm8VZ1A1RPbxmetnXWCDccIWoDqAV_BXZhWELZZhNbzciy6C2H58-RtsmvyiPLB8RZN7e89Qq4yoXPCXtpT6wxzd5UcciMfRJ94AWdAmFwGPKTdgfFNNdHgAlV5Rsq-iEWm4gwV36QC2hT5V9gdkj3m3r6XGl-uKBh2ibIr-0G8yP_tA7E7unf4nDQwss6EEb7Bi_hFWf17OiglWvV-zNzrUk8Yh0-97Gq961cmNLaRQw3Y7fwj2Cr0fDx_6htmlGN7M43e_hoIVRZvEnsyv1VFSb2HqQiJNbU1i98NPMwzJYksD9npdved-bL2uVI6icH46gmxGGxoTYe8_fNnnrR3IlXmXPElM4eJ6qhLnx_-qI5C2t0tkTG_FRERhbzwwP-t1xeA4CR0nNcxgiSQubWje_X4lWoASJ0ODHzscfGTljYU52CIFjyyOb83GzhTe8pBeGjkuQPSc3kVRYi4CVKvV_0yFF4KMAbgN_xbmfow7O52f2WxW2oT1UWuoHFt82hZRQt3fNupmABsMAX3xiayaDYLKok1qRZCjJ5X0h0-Txei1gwiDsOJQ-qgpQYsfe41GI-3LUBk5mhM2EkjlQMqftPXTAqCT-sz63LRpzV3mp02-0UhR80RB0cvTnqNVRo-GTNEbiJRJxNaH4cz-r1gPeunZLcIK4cDY677K5llbaR0llehsfuQpN2hUM75jldYTb1bQSm2cTFHvMBCPg81A1TzEpk7W6Q2i0oueLVlUtakVWjlJqXLV8Ls6jrHqW4jJlYTTFfObNCRpRzv8pcEyJVbi8YaYfme8s-wdkWL-yuL0RKwImnVIWykc8qu4foWu2UdMtTmE310QlPIgxkBY_bC5HvbWaCdshgI48DHb_7a48K8CHpl8d15gK-X7w9jlvP4waJ1FuFz6BfXaEhbZrCOecGJ0Z2RPkS8zniMrNjjTm3Yzl88Wu-NspIT4u7bmmcmJc_r41en10NwdWzfbGdMpX81UkZchp_bG3digjl5_pjwRc8u0QsBBFHHJ6mQzm0foL6LodV5GituGyiz5Tq7U-AlllfhIGjvNhI3w2nyB28hsckfndA4P4HMMJ5KEwOwE94xmA8A4kIEoOh4Ev3u-UBKyZJYTtQ9w924\n",
      "Iovance Biotherapeutics Reports First Quarter 2024 Financial Results and Corporate Updates https://finance.yahoo.com/news/iovance-biotherapeutics-reports-first-quarter-200100343.html\n",
      "Watch These 5 Drug Stocks for Q1 Earnings: Beat or Miss? https://finance.yahoo.com/news/watch-5-drug-stocks-q1-144000100.html\n",
      "Iovance (IOVA) Gears Up for Q1 Earnings: Here's What to Expect https://finance.yahoo.com/news/iovance-iova-gears-q1-earnings-135600812.html\n",
      "Iovance Biotherapeutics to Host First Quarter 2024 Financial Results Conference Call and Webcast on Thursday, May 9, 2024 https://finance.yahoo.com/news/iovance-biotherapeutics-host-first-quarter-100100601.html\n",
      "Who Normally Has the Cheapest Car Insurance? https://a.beap.gemini.yahoo.com/mbclk?bv=3.0.0&es=AQAAANDEwBWYEqIXgSqK-lWfOrv8_CuMEXVWcoztgLqJDsoMYkFaUrTaAZ6vKOK1RRtlY7Zle94R75HlbMpqt31EKV4S1Hz8ffI6K3TL7KidBax9-qz3sXBF3LzSUFwSA8M6-Lxn_MiqusUYfC5eN67ljW79PPrQe0cqTs-1yKfZ0Jx-v89STnDKhZjM_fNG4bXi0vi3PxI8LRD75osPfeqQ_NsZdowJGwirkbPEqBrQw4tPTXcR-q8qjH5g5Pr2mOLth21zx58MPrufizM1oAaGRyGrcnH5TZYR40EeBnbprxnrMQE954TFJu3h8vxxIz8i3N3dxWVVAtpfFxbjAKrK_EzTTOCHUwQugum3NFyoIadmPlvIBKC5xKQR_ozzAlT9nKlNjoO82UxNxWxvaRWi0BYDcSySqDW6EORSty_2tFDquQW62NP_ZTqe2lBlsp_NAPchyz8QDcxIjrwWvx44Je5DNVicF-A3Cb7kp5_h26QAVg5ghTmIBHVuKVPtCU-bg23P8ZrZPhiQCV7zq3mAHPDaeoewKpv8L9i-micjP4vu8tsS5lnZ7KuhPWPG8fu_dXPx7dg655gcdbZB1w9rTgPuvmhEoBDTrMQsK5KtHmu0fdVQ9zssLnrG9LMb3Wp4RxNF8bGHsIz8ud9kMPKDLdMqfiCia3kUgu-ZWASaOI_UP8L0-an68naoK5EVzKdgmQzkXCeeUVC_RGvibxPhgyTKojoH_gn56soAIRjf-Wf_0EqeY7dSW2Yp5EWtsTlsjcojLM2p627vBCpAhO-x5oRapZC-NkmRGgPoSE7dCEAM9PsAGyx8A2QtkHmfoybjt0b2RMkCzMhbUj80BtOaprPCiE3lu9jxFUxs77_0Vl4sjty1JSnRS_rV1scTH4e3w4DwAWwDKuZxLsOHjk28x9QGFGQ_sMQdFEagArn_pPPt5PHct0IxBW_BS6qV7dVPyzIZmOUri4Qb2ur-lt3t_vF4uv1QTVAtzFr0kd7_-wEQe37olhEUkuTTHRBCHnt_R66rGePYPROpEg4H_uQXjETDS8XTZ4Xq4zV4vZFXdtBydbzcBvqsLh6BRqCJ37DoHp3Tp-Xyem31CASj0j8yZ-C2HyNSe4kcN5c6XYhk-BrYmcALvv1uKR-Iyb3diRwDBwBxUG2tkTRxT2RAyyK3TazRiWl78gv1HWiemRrEda0coFC-lO6NFUc5xqVlQav7SfEKvkVFzwZ5DKz8g65HY7KiVFv59s80cWUNVgS1cneozqQvdDpHK9NKtkgkNdDjju_zLFeJIXESEr7pSMOi1IMZrGuMwxXW_Lu5BfprwASad_HihRhM1sKS_8-EpUrVJLQn_gBDwv4zSmrv1ka_SBNgea1DCkr7BKTIEe_T998beKBkK94NlhGXbhMB7fp091F4iTns70CkosjzHOB-iND5QL-oQwdAId8-xPorK3lnSOnIIEvaDhbppHAYTiJlmO6qSpNF8DIjyh4bwF0eEeXft6SXd792MbSl8UyFzj5r3zID5SPNL0zvYQgtEOE9DARu80oQWnUXvrKaUEIhbnbgPsoBbu2cjoquEUBHMtyvBk-7JUDRT16WFhgsctCIKv16bExMgtY9Ahh720MCZrqMcZJbYVEskUkCznoOOjutMyA2sdgDFAzt_2GQQNd6ikGqIInCU897gZXUQYYN7H4KXAKA_R-vfkYmTy5Pcqwb0F-R29iLBHj83Y9VQFRyCItHai3mUC2S6YR6uKyL2W5lIGQj8tsWzZLt0AfKkcxo13vN2ZHzNsW73S5AULbnBN4hiR9p_iPua0_M4NAaJK0hlvBSxLXDOLE3kV6Qy_28HqVJIQUOdPwVa7SE_TemEvjo3rF_Adq433Ylp0M4m3NDeeCiTcYuFe37uOslyEuWjbYFVAEcNc4eL3rnAUWvULgagy-V5nTdjtj79S0hLZ7DIVrvTgAxCdWZoLOJ7Tp7jUkZxRg6WFi9AmpOy-Y7AZMCHKhAjXNY1fD9L7Ji-K50FAXvNjAB7rbxuVfvgj-dLjSbdlF4GEuq8jsGlWzf-bwMzldHkOGGQsUw4ST2rwC8o0UAwG3TTVgdXwTiLdQR6oUCqLdhtJycNGySJWrIY3IavbETPKNWi2FUzKn1O32KwX7SCbWpI93I_R2UDYHit_MaBMDCwKCDvnt3praCGTESz1k4K9hBFtBJJ12YJGf6W2RZUyQ4hxxXb9EGAZWP2PIV4MpB_5Ju3gGHV6XdufR1POl6vQZvnaRdVSA7hPLZtkGLuf9IHRABhyhhuA-e4546K6QOgCXRAawRLR7yWlYH1H4KS1lwM-Ek5FMvYK3DuFAsYuXvLzBFbHgyCSmH37RE9sRjLIQak05ADMP86WqstQzy4mZr9hjuHxXbIVTl-4NEG9noiINsHE4eCdpleev_1lQ-WcHLvcaIR4-75cdoyq9dczY7wuQpcP9cOBiy4cqWYJvV-0Z1UHtCL4YZeJ9GB5z9VooS0aser6ZB3OOJN5pAteRYd-eh8kH65kMxnpmX8vxkOP72AYgEBuly4ceqYna4YDQvy2LEYrPOm7HQYv1vvYuCOLELbiX3t2u0x1jw1FAuT8ypAo-xUoXr4TLUIWE_4SCoBBb3aziRz3JhWaf1vbjgWwLKHvMaTF0YtW_dzedenFJ_Go7_LlCVpqU9clJfGtP7h8PpBGBI6My-TiObpxfmfMx5_U2xGMlw7JoL-TJtI40xeAIho_jhBt4aZlZNHaBatmRGAl70tDYHca0r5D1t7XThXyvQhdYCNBNX3_KtQYNQ8tA2SGT8KUgl2sSksTDmKALkZMpKGpWwMCxxzMd6hFJobPOloT7wUvHpxAjHjPdHXULFWK7CoIUoNhTfj4t0c2xwaAhjkdNNCYHtStVXIn9UvkmtTHz5eFYJnRJjNqrXwojaFmRGIEd89eg2VK1mqCUfA_SmvatpLZwB2hvuTvEGu_13IZn9tHc-xYnYZXBQoBpHHEJ1aYx5ohl0RAff9M5WjtFSnHBDwk_Jrc4wxnxByVj7yl2lR6dgtdR7umCehuH8KfH1fy2xISrAWPO7ztO2_NJ7DktHNUXK37iTYyfWgL4xfVc-PTf5_uWdKntucqPLhzDD-xbOuGI96KUcyaL0Q2wYo3njlfS5A6qBVQjSQ-SR4w9wwk33hfs-mXT8LWh2i4PCYTzf5OpIaN7QSC3X5R7IMXRM9fyCK3UpqCBn29V1g9iOpm076-oad8ZPMaJLKCZ5bQ095JJnkFwJ8mVikOdyKJHWYY9NDELNKxWG7imIxfRiC3PexodsKDB5-dg_XMsHfKtU3LW-dRYLEVzr0TyAdN5FXKERQoZTf-fsUCx2f6WE73XZ7hCGlk9G8FmAcAy3mDYy_YePYR08zu5SNJaDsxvJmhhO8355o_eJ3xaQ3C88fczNQZeo6NvTUzvKVw-5k_lNbQTniJ0U4AAab9vaUlD4yCIWNMNA0r1-A3Q6TtOB2SA8YnGB7Eh3z0gP1TNmwZmJAb59Ag2Kkc0kf41wk1EUQchGrWFzWw1B7KaMTw-9EFCADj-nEO7VeKtTOuA-5MFiAEuTi7syVzcVibI6_AFdGcPMzsI701S3KEM5FIInq9nQgcF_6tkAXtVaVdHgVI78Yf-zR9RHFycAkpjVBoGEH06igBGKIa9P8xD6QzlVjq7d_-yS41rj4gU5g8YFt3s\n",
      "Iovance Biotherapeutics to Present at Upcoming Conferences https://finance.yahoo.com/news/iovance-biotherapeutics-present-upcoming-conferences-100100873.html\n",
      "With 63% ownership of the shares, Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is heavily dominated by institutional owners https://finance.yahoo.com/news/63-ownership-shares-iovance-biotherapeutics-181522845.html\n",
      "Where Will Iovance Biotherapeutics Stock Be in 5 Years? https://finance.yahoo.com/news/where-iovance-biotherapeutics-stock-5-184400116.html\n",
      "The Top 3 Biotech Stocks to Buy in April 2024 https://finance.yahoo.com/news/top-3-biotech-stocks-buy-110000357.html\n",
      "Pay 0% Interest for Up to 21 Months https://a.beap.gemini.yahoo.com/mbclk?bv=3.0.0&es=AQAAAIpw6sn3JHPtcfidyMSZ5ELrtVmzaI0kdaf9wyB3bEoxKTOkYPS5wtsyhkAAlgG5fs3WShsjChcJ50wsITNFnU_8NxOcu9J8EkV8JMuu7YSwACZs2b5YLL6tUHyKQSOo9YTYkFYOmJqhVSrLA7ybrQJMnA_VanSVZtXJlLT4iNPs4eRJiPTb9W_5408OczZcXW8S-fHbMycLODrozq4z5TlKhVc9_ZGdEGoN5ll_6nwJ1_vNbdRmOWC-SvXP4BjLlBqHVUaJazaOjIMQaB8ratEJEeSMK-ZkgZIQkSuG6PVa7N00APYvLiXlnUvKsFXMF5LIJa1e6UOhbLLS5WeHgUb9AcBv0vGmhB6x3CCOXz95Jdfgdcg6pTDRm6rGwB23IPAvJgeBMue9HcVYjMMe_zmNGc6EmDj48EX3nHq8QYsvmsdJz7m3hWzk2Vi7hfULq68W9N4NuMPAUTNkDBsacJd3OEibQ4BXpa1x8RN6bofLSf7tdUgmVcuzTpRIkyEJK7nlT9_y4dJbP2RA9elJkCR6T9qhm8UmFoSjov8PjChIv6u6-36BzCMEMdrPgEMIyeZBIGESRW1tZfZEsrqTXGiGwGmTKmKFp48aQBWG7_8tBMLi5qneIsVNOkASYarkFuOwYY1TZ8QV_gVZa1KL7QZnSaX2jURLcWBxNw7M15tbDOudBM7-XnbKn8qguYbgn21nBw4lCYNFMrNfJlKweP-1BqhokoV6A8VllZAZSxHCAMmgImMRCNqIwvV234YTf1x-l-KGWf27ksdt802HeOtqiJGR2LyKlWri6eNYl-2vFP1YLY5E9vxF43z-WE38_126URibH0MCRrgRaQ-ppkbwXoBSkLNBP2Nkvs9Riq3BOdiU-4jN2zY9lEX-vgLwDAQM4TC2_p2UEI9XTk7JSzb_LYhNigFcnJb5dHLT3pPzJaNr6zWbgZ9egfgBo0Rq1oszQmTCpOZ29IA50zJoZvF1_N1d3tUVfxhIJJDFyXtRXeYjJ8CTSRsx8W_fyhe0pQlm0R5JewXAhKgVKatkdXnaTdiSmXf3BpTYaChHqTq3-89NWdbpj0L9mtyV4XlEtIhnLeVkdYx19D4HumCFyvvuIcn3AaD9QDKNmsUueYwAeLrU7ymlTJixKUOiVupTJQsjy5bmiEQtdcx-nFjIAB6lJU9X3chZa3JGf4uXVAezSsX-0nGlpiODgarCbtjrDdeZW_Z5eoZOpuYjCaFflGIEhsZi4S8lqD9cjCBDTTvUmRO0XNAwS7zn_-Le1um8k21LRICc1kDEom5GhD6qGl16iDAuN0T9kbkCEB8JhMnpiNfHBXg7S6hjriQcLKjzNHc0dLfdrvLQzv7KgniNXtZmrZmZsanHrDftechYTl8wcmGaElsAsNzRc7M8JAPVTaEy5mLBQgfUH6V9EPzwrbyN9aeSvElTz3V6v42-t5vCcgkX6bjzQ7t7zAiEgSpNKEUzzbMhcPJGQKdIqhssbgwh3v89UeEQ_MYNTw5YbJi67im2q6_tiEg7NvqiyuOdPtDGHtA9l-B0Wr2vQNya6TzZRBKtd2SD2mRIbtsWDGVeXyqAZhEIQ7ABUWf6OXZFdlKp_1pJNGBp6mGoM3JPnGqDu953j2KjWm0Zdy34LSB7NmNeRZAhYANkGM0yUrbRT-hVoelesyXuoYjYVb6ELaYrAaIcieUQdi2rtSZupsMa2_ocbXJfUD1LOZ7w5_ToF4LUZGwUhNxZYNlsVn_BBlRs7kcdTbTG66ZcFc8JcNtoBM7rvvquG18io7Ngyw6cvxHVrOGRVmzJQtL-qAdsJsILy0LecYpCgu3PK5zNLU5V_i41IiQ5LM1d1Jqc-0-6vN-Ao2a90_p4e2HJ9aVR_uHIGIQPyvjgoESvegh1Y_vjHmZbxdp5fi8ULOFwazmfRpiolaPasMhSDIBrDU6C0Rt4XSJArqmAp27jNs5Od9UfG93PtFAPnEIqmqSYWkUxMSZqK6eChmsZdpQufNvUYNk7qGQwOktOrJULdXnFjFy0ZhiGUA0gQPE8ZJR1CEKx89u6cGiv3toGzA8vC3ccZ_NTXNOOdF2qGMaDJz_T8c3GkEqx_1XNpMHcIoGaoaFd-7zizCJtM9Jj4uZDXigOxvIH3M9uXe1pHXDRP4v--vdjF5SLL4gBeEDXHTegap-CJn107n6VCtbIQPxYEL7NFjKMh8rcZxzus071HpG4bQXvQWFInGEjphNJkRwtcJEyZGq_qCDxQkNv75-SI6Q6DOTpARWbltWlJ4LILcHyQCs_Fw51wveMhhX51d5no_eA4FFprVwI5b7pDMd8qZQfT5wsw9Uq8ZuDJJ84KJ_35tpBnRKKE9yd8DK3XKkwHHvyV3ALzd_zFciC05n_SEZYMUZaU5ld8tuldbF-s2HrzZ6XWGe4boYBNR1sp0FvV_vWLDdU4TrxZby0DEGAVWAfLnJzJTAwZzxbDNKFvghb-0qYXv0zdrV5pu9REUV_E_JnVHgW_HizOrSVN0k6Knrael6RQvD3OVaMSg3rw_T2guvl5mEuYiRgl2fRCseoQoEiRApmhxRNGH1WyMmQQfiJeFVPHi1lzDUG0V7Ow12DLCtp0bq5L04rr4X1smsP0Xd7skLNmeNatl6JthrShUW1frRxQb2o4mFqjzVR4InQZY987EC-TocOCjXz0fIhAjbt0iwgFs3oCCVq61YZN6x0Lty7qWlSakFJ_TleCOJtwOwGiMpZT_0ZnkyiGuu-ZCchFmt8ZAf7Xw2gU4B9JP8JGF1Z-DFo5T63zvwr22FEIJoXFdQpqT8S0n20Q7Cg-kR8D8S3ikwYBflAFljS7jjZLGcOyvuc4TT6gFzlAGPk2N5odzsl9QXadsUkmGxI2FMk2sRjNu_36vz1DUZtfvi8hnreXqEHnmxbOWIGcR5vx8IprkDt1P9ChUTzfcZMf8rlAkE8azMQgZMsV5nHku56xOSiwG4H35Wihu-jdhc30oLcStsnkces2IDuutx_CakoMev_hd_KXDdzEnjW89vQmk1mk_D3BY3Erv63X2BqYQPNNnZwIU-l8kE0pgCKi7HktN7fcyQ_jsddG_j9JhNSKQ6sLTJk1kWqo8r8qrc98QhBJ9fP3PbJCyUOKT_duNtz0-2aEk49KUCP4h3lSznchqIxpL05elw8ZfkSdjH4Plemb6kU0-Uc61407r0GeeR0vt8y5FgD-DRrocLXgBQMlTdKfpzP4MHJbqzUdFAsajGS6F7WZrOT9WqOucsJ1TqoKtJ6Uv7qeGUEbuMPKbMKr1wQBzx9lHQkp8m_3RQQviduzDdIaoTFCtHSADOwW4xT42hSedC-NSDttrPjTOjJd9psTkBLupLEqRgnmAKZDGjdT3FcGxyi38Riw4Ii55k2zJ49buM9F-SeY4SSvKTVKoA7Lo6I2rQ\n",
      "3 Millionaire-Maker Biotech Stocks https://finance.yahoo.com/news/3-millionaire-maker-biotech-stocks-143000558.html\n",
      "20 Counties with the Highest Cancer Rates in the US https://finance.yahoo.com/news/20-counties-highest-cancer-rates-132018759.html\n",
      "Iovance Biotherapeutics to Present Clinical and Translational Data at 2024 ASCO Annual Meeting https://finance.yahoo.com/news/iovance-biotherapeutics-present-clinical-translational-200100263.html\n",
      "These Biotech Stocks Could Soar 120% and 295%, According to Wall Street https://finance.yahoo.com/news/biotech-stocks-could-soar-120-090800027.html\n",
      "AI Bot Flips Wall Street on Its Head: Turns $1K into $50K... https://a.beap.gemini.yahoo.com/mbclk?bv=3.0.0&es=AQAAAMZRakmfW1wiEsFhGbk9ISb2c7ncA50D76kGVDL6eMvQx0no2Uq8ZV4w0UliwJchFljmhaS0yiknkDPzOJXGgT2EVsuM9EC3yHWjd7llyTVU9PKhUVt0_cLR0JAFXsQ1ms9zyVnijU9cIIyL9q_X25bJJwxp6YUOGN12Rz_mjSiOZHc1rpViDE3IN3B1ULjLQYJb6t6oX5v62h0xC8gIfGZbedjAlmpWkGGWe3d44fjHczKWD5pRiGMV6ohWq_pi8gCiP73XaGcN9fm0RF5uHPV9hy4_VioeOL23u7Ls3lGl6MDzQpWyaSj5vEjR4kao7TxuG6odFFxGDiVEgO5k4FQj3hewsWSuVGN9dytZD2PzbygsZTu9pLz6kCSrxYeRuNRl1Sfa9NpayafUx-oXivM7Dx41pA15Xrcj4LrjzScIhWtis2D2A9iYYxu90xTa7uWJweHOz9abbiKlz4F4RreykZ25Zt1aBiuRH5Ag38jlxuvebrbAwzTv30gw_Ci3NqtUdc-0OXITXRL7OVKY9jX_4_a8NMX_oJqx2hdwCbyAvHUYHaDryrLjLpB766P2VZav-VAOaphMd5TM2-6_pKJUs3DOz0-hdev5aKWdyCYuBZhYlA1w-sRz9RVNUG4Fk-bI5L6gXhbA83x87j4V8eDPQM7Xdu8ciI_6qTIsazXm_pPLmFkrisYOhKZ49cOT3cNgxbsBb8ZBrXcpr-i_E3mKb1n_JIBYUaDsbZ3g8XZrp7fhD6iwTQ_WcH2ExqZfGVayrC5DnkQ5el-HX9I9HTNMLK-XUqpR-6bPtD80vRLdFYz5MIvFqChZNAmBgzewMWUOpp-QYuiN00lP7StTfGKvfY0LHaHH3FpJIqgM-fFMyjuT3GR4qZXp7U972CN6pTNbiAMtvjeNwIfABqMPhLgGCNH-47vVzXT0_vE5c0uPgcqeG930tRzMTep0C2VP0Lv8JIQQ9dCjU6UiZyNWzY_uuISCH_F0RJhFLGkKgeln4tUd8OhfNuntRZ4-3O8b1sVWn8B-4mDWtGNtusO-Q21cZ4Ges38li7Xg6raNucYHfxWLT659RHlGp5CrouY2zZHoZHHbPYs22dS1dA_kOyQS3r9qBFHKGDXxtvfYhHg8CHUKZoxXVni4WXKaxGYotUPUr5rZfMJz1MPj1ch00iJkMvcWvvpu7nVc4MT6HDQuiVBHDUS1ncVYVfqeGF9HI7bKwXzE470hEmR5M129CPDGtVI_8YurJeyTriBZiusCf2Tsgoq2qgGkobDyRG9neGNnSlvsguVW6bvzxhzTciEko9voTwOeUbLOHm0-GwjJ4XAOle2paaD2GnM6T24oW549txE6hp2W0-KCxpT9XVtPG0JUDX0kxwjrJzo3IFy4PUTA7DCOZaREmOhbedrWWGCNlMF7AwvzfIJAU8Rqw4c8zZtx0sDUNxH8tSCyugdboVP-gST-YdYpUbJR2vI037KApqQBk--e9B5xHHnb2knqpQp917tM_5NQB584QH5zwG4SyWX5rQRuG3K5VtXtHYs9mIJLc8XGdxGpd4zBvEqATEgebsuRp4K8D2JNimhcGWfGyH1ReMZjQX1Lx_2yaV1-RPAenTE6yTHUV15ikJCp6ZV4B1bGHXtutSQzj_KaXooSmr6lfgNHOcrqnRHU0fSwfaukXRjsIjOMwRKNlrbs_lNPTCWBNF2nk-phwxVqHvT4L6fR7fnkwSaR77sc-ic26lcVObEYwVv7VE5Aa4E6TY46OMOJGUrcAGsRjZCgGv1xoamlzOx0yLrfvyEXKuPHTvqX6PzsAP8T7h_Zr6sQXEsnvkqhW8Gpxqbo67MGLC2fp0WWH0hz1W31XTrIdlDN6PtfYEJ-6qBsANnOLlLX5o5rkYIJSFi_TrHrGphiQ7rpjdACrwBZh9ze-l49CCCiFP6_NAt_m0Viz7AIJnQfNIJBo5Igm0BjtIF6J-v9x0yptM_vFpZMmB2NT2Kj_c3FTzSeIcC3CwqfsbwvrOwr_Zjjz-iTNxEqxqwLMU_QNefwAiRUjWdYzsFXi4LXAQ8zpIN-kRQ7ui1TZKTMuBIxY5wL7Y75qO1gA9ym0NrpIbkBkqYMF3UamnpoOreTxg_NNaY2yejQblzCYNZ-N8Tn9jiPTGsTEq8KJPn4Fj1bBgq3SbLoyL7mNWRo1fjDxCcCMfMf6q7nU3XX_3uhyuoWXIkMWWYwmGeSHEmIYK8J2zfGtHAmG_a2YYDeyeWLsGpw94rl9w69U51YnLLuYiVAwmHPZyB7QSnnUHO6Va27HJDS4VA7QMLd36id4IP59sOM-v_bBigUCIaN2gXW88qrCvE_87QiqrAAlW3ec5xeOnP5jsMvZGLVfnr3i_qtmAbDsIj4cedj5gfDNjpSBzzVDWdft7jWp-vmkifxMFcyOsFeq2SlNzLOyJWOJNR3z5ZB5CAPJmUG7H9JcDbK_8ixkvrpU3nrhy1LBeY97Q18ynIpq2oOGCpebEBEnHh5ROEhjOhMLg77QmRx-pvUlgF5U39Qmh3xhoZyWGD2LMtyQ9_qvj_ZecwgG4qnozNFTjNtHAft3OMu2WQLHrkqkLVBxLJYlLuIuEFPC7Lq4o3qMtlOpvt2-z_IkimPmd2MyYBfHbo7qKL4dPywg3vqFNmowiyxbQqogD7e-Fxc0_WzM2R1-TVgFOpOWWRAfWER4GGenu7ElekQa3Ff8W6iIdvWXFMbncCIyEdaMSKCsqOcSFJL_EH-auNSAsQGMSvd5j3BVd6hwXe73czxF1Gi_lQrMhsc6iYzqcBODG0WsE_l-PtBRi8QQHLEKzfTG1R5rwj-wZspUKfNRMRLRE6JVHa-fn8G42KCQJNq0Rm2udYqfRYKU4_m-O842eR0dFcqlXIJmoxqg58cIh03wVAlbVerRTGoJJriAz23K4tMICKE_5Iqsx83Xf3PYgQ0uIabdjLrDyubA2WHXpp0D7W_nX9Pw5m6ucLJ5VX4d_8j67qQ5g\n",
      "Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) https://finance.yahoo.com/news/iovance-biotherapeutics-reports-inducement-grants-211500874.html\n",
      "Is Iovance Biotherapeutics Stock a Buy Now? https://finance.yahoo.com/news/iovance-biotherapeutics-stock-buy-now-134500285.html\n",
      "Market Sentiment Around Loss-Making Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) https://finance.yahoo.com/news/market-sentiment-around-loss-making-115624021.html\n",
      "Iovance (IOVA) Stock Surges More Than 60% YTD: Here's Why https://finance.yahoo.com/news/iovance-iova-stock-surges-more-175100561.html\n",
      "Buying Nvidia? Wall Street Legend Issues Urgent A.I.... https://a.beap.gemini.yahoo.com/mbclk?bv=3.0.0&es=AQAAAO6LQmp3vHup5lXX0iDPkp5OYiUnCJewJQ_IHnWUxfApnZ8O7uaPZgKNeqdl_6p7B6Cq7V0WQ6LVoukSzaxiO1e3tIbfp9h-tFqwbhZX70E88zJHR3Ph5KpKOFbdPlzDetsLP6WCyL5vRE_nbIJh_YvLC-HPcRhUPttaxVth6j4-PKCxE77f9oL6u7OkHNeNZFG2JafZVsadURXqeEbA_7l7LZQTZkW1x3g-DHd56RVKTA8EDAVrXdrm01Ah731sTiWNPQS-gqbSt1s4M5l03ECgPuQBOd2qTipwDgP-5170GjFmLhuqaW-BE3fFvy_fXpb0aNTF91sDdExcJp-sKK18XRLWvpbyz0RupNuLoZiyybKPo59aeT1XG0MdAGU3YXnUjxDywIjFiMCl706ojskpOaUwxyNq90lfxBN5tQDu0kco-DEqzEitCwpIghXh8ITdgVc67fvY6qkK4Yl3tjvpPMSRfkHLT0X1PXkXIphMtsbzc2oN-wcp3r8X5tmubiDea3Hhgd5BRerY3HmfjSc96SBaGR83xHCQz_RYPQ0DrxwrdZh5HzkbefkaQUTcWefFCt7mpa-WIE2dLxfqTVpsWScKjBUSjWuHHZ_CzwHFvlMI208YXBwSOJO3TaLpOepiHkmL5gcEiJRaN-cx23jnHJQ6N21wLNEQhlhWK3elk65ABxL_dypNHSkcj-BIBLA8XIu21jIreIz3Gg5CJ_oO8nzw50dXkIn6wf1BdyAaMInJgXrlLouoJQHfJCeYhr-ZfHKhUFaAOugdo9i7uo-o0vlzziJ3z3_bu6vddo5UxSZmIGvIn_ZZuWxXrWTfUjiWoHveAPVXNzLSxGjTzzwFTCT8TrgKYC8kps51GsgqZMIkZYp_dW1QaPwCL5E_2oyXukVnZ7ogug5c4craBlS66buN722GQV7XHfklU9YqXa02xGblwsmCa5NJYzsU4FEPowCePMIWrMrlR7iqVNAr0yCilrs9Mj8R9wWfNpaIYTOt_X1d6h8Pg7nAu_42mQ2XeSyzKjAyqUbFqstojkQ8WnftZGAmpe156rtdiViDtYkKcJjWAK5zyd9BQE39ItwUx4l3KI_rJt0GmFPDsCUOJyOvMMONfQ6EQ2LPm_JsOrE88FvVvR2VD_Hw1N4nZciY74Yy9mdr30h0yPwTaqSESrpMBxCMIrlHD2zo2yO09ABOhs6WWXEIDCKZU6EX51EYNhBKrRpVS1tgwJfdHK9n4KvqnSI6NlTw-1IF4SvgQRyTAxurF9lKCWPXHr-gxth5LE8qHU-kZVz_XI8YwTOFFRnYzBdcdQx4Td3KY3vzA-4i03mYd74CocwFxRRkiNLdBdMDSdbr88TJ_H8-kAH-kI6ev0-d9CObB7gkKk7wOo-dxmWSlDsDg4PZEW0mrWtuW7lkKkoz2SbVtHFClQwPU7Z4H49ZXyMeXI28SJQZrNyfrl90OluIqQ4YizFQWwuMGdSspR_V7Cmel12SUbSEmeANfZmiDEcAKmDjq0nlOxKm3rXb4yHl88NvadJ5cPNAxhjoy44bBcWjjffhLChUkJ7oLjMw9QF3G0YCKM-H_cXO7MM8u_N-0O8MpKDqqlZKtNWvtgeXgnqsP_M-CFS_ZdukSmtXJtaYMFI4rzqUIaGSrE8XUIltG0k7uFTTmwtYQdnmis8IGvStywhWQay-m8nuXKU2aQN-LTntFmzyY90uuUmvSuhC46Exh8gJwYvnEEyTUABd-f6bTbIEE-UEwu4n4IjAIHbDdDGXVYSfBnKPj3hNXpPVzbn85sa_rzw6CV7oQkqDAE-BKtd1VIDnLRu0owV7IEl1iH8z98X79vxbM14CYSFypcHfsiQ9plp7s0yJw-ttVA5m-We-eYQERa0or6r0ukddotBhXPtGUiWxuSIoJ-ioRc8ViEtcCghw98VmFFbTzFUTgjsn7z9pocvJqS0PwzsTPxkqpRlOrympaO3OOY5_HZmyDUMA4AnE-3wnrVicMq42vXKjiaXE9s_zTDuoQ0nfo9cVKSwmdrhMK59oC9zHZJunQkNCYsxwGp1jgye5tuyWbo9mt_U-gAEWUwqbORAxhM4fHk9yErPBStZ71jw819mmhPEchJYdvU3qq5pwg3E-fpWLCydj9jvvMPYD6ID6IBAFqQoaKUdDkSTH3qlL5X6e6Vb_KHd1feL859CXXd3GW3Ib7kXlX4fFzqkv9GLooyPxHqwef31vOq99hfvOpm-1sLbXv2-hGFaJG15OdTGumtgbAti0ZzslVamLbg8-9iwp9SMaOwlmeneNPpn-6Tq1Rkf6Vr4OvvbY6KPkNPumHYlxzvc7X7URVV80bgOsEQvYM-pihoFWJ6LgP0lZFXPFv0iFknYFa1zNzl_krE_d_L8yxEF3Dg-4zJ2tLy3bubEO-sqlkUWAAQM0HD8HgHMAuXN7x2Q-UwUrVU2hVYPyxr_MFUjGYJTnqUm678JnKdRmVYeK1_48zOjKlPPVZA_wFl4xQmqBsZjBU0lTskLNLPgIksPLN2-12sRhiRKkXMTly1LnuUQwVP4iCQZbv24n3t8rHako9HUmZeM2lAlmHgwNPfXrIh4MNIIEnCfpf9TZO2d4HnjzYTDQShXCguBhN7W9yuZ0-uHOnHKSfrOrRMuCdcAh85mq58TFhZfedhzEueoUu3IQLqwd1GfOMKp66smafL3s4jG2C1XOOTKmvjAhvqqTJcl73gxtEafK7KY018ADaeUZS9ppej9qF8hgiyuvSMgqxxl4-9e3kUpZA6urHp_oXPY1OqYErkokw-K_YyJUHAoKeVe5Zxp-HO-b_d94V4BHYJe1dX0BZTV2mlGsnH3-p1ha27RGHaJ_oqp2sYIF-qAOb7WsQKWbRSUsbCu3KI_r3glI1EPHm-fq3P1FYM4yTj9bsI3YRWHUoH4QWuyvaEd2C7j4TcUHkqf4QLYeC6qlIfz-BC_nWEX3AG8TCjwuTJXKUjNevrhhPXm9YY8EzD9Z79AWzIrH4jByHCE9OPyUXjzuyeSgtttg3N_ipl7OcqMSYwADmODb-UvW2MY\n",
      "Better Growth Biotech Buy: Iovance Biotherapeutics vs CRISPR Therapeutics https://finance.yahoo.com/news/better-growth-biotech-buy-iovance-090300902.html\n",
      "Iovance Biotherapeutics (IOVA) Down 6.9% Since Last Earnings Report: Can It Rebound? https://finance.yahoo.com/news/iovance-biotherapeutics-iova-down-6-153031851.html\n",
      "2 Soaring Growth Stocks That Could Climb Another 47% to 73%, According to Wall Street https://finance.yahoo.com/news/2-soaring-growth-stocks-could-081100448.html\n",
      "U.S.-China Decoupling Poses Supply-Chain Risks for Drug Companies https://finance.yahoo.com/m/f08d4daf-7718-38e0-8b02-1c63f72093c7/u-s-china-decoupling-poses.html\n",
      "Who Has The Cheapest Car Insurance in Texas https://a.beap.gemini.yahoo.com/mbclk?bv=3.0.0&es=AQAAAPmhkSDQQLk6zPHLsiQunA5Gr61LIEoAdDrtluVBdFU3sRzCKeHf8Z-rgQYX8aRs25AGWhINgKAFCO_ksETnNIg6cRuoLgb-X9-BbzyN-FHFNrTYNdrK-c0DsRCjx7QItH_MVcxeXk74YiZSthlCGvuz8KL_U1sXp8PaeKT0_ijEXRSD66HXnQiWS_OZyfdomRZkZY1gGXRqkvovhxHD5CwLDVPVhB5Kt8YZ5CMgVlDBbpUiAzbP-Slta7fuEnn6FgT4ErgAhmNbvJWNQVHm4IW9CB3n7eYY3JSsC_qXIY4PBpNUKT4qUBxg4SOj0KTfRxsHqlU6osIZ3MoAW5dCc6I_XXZ4GWtuY4v8bJAH7pqPhni0EGTq5n0OPeF6jnnjAKSIWwNfqDYlZEMfeI0RoJG85bjpR7NyRkwjwetN8KxHV9-wYvxpRWvFEh9n3Me1LZnFrPZGyZ_CmsvZJvcpsgo2lBt2TURpqlMOVR4a5KaZ9cTIN2ql3kVrYq1cUcPbdxSSl4rmYI6s0F_P8lvnQYbymNNZTiRHrtlkwkzws6Em9L2dGxkL5brh1vnZby14KBzSd2yw-xqQXBOpuvPoK7anAJuuoiDWIoCtZA30Z3_6MQBF8lv7MkjcuLZyYvIyMRpiV5j7L0nJiyo2RQfyrG2zWMC6YFnfEBlCVw-H_qVgBG_ft64LY8ywKelMgrASCDQabyMOj8siMGCoXwL0UDGqhfb9Fc3vCE7nhmDQQSa6BQ7YCDNqqBktxu3rn0m_VIjj-eTh87_KNNhXEgSajbgKbwDuxN06rfXcMQwuTyiYq8HAJyvfWmyTerJAxy6rSi-_yXNMn39FvSEpj6H4I9oQ0zm1MEcho-5BggRA7WDJchQxWn4M3BjvAY1t6gpepxErwzswsjKrIn4ePXQBEwqCnJIi3AOUBWN79ba3WtxYvUJS2bZDDtEmSHYNvkQeMHjahBwqQiw9tJX4Uy-tkrpsJBi4sSSPsRKwu9aUKIreSTaM7zEHEs9KD2MrGa3w5NB7wufQHWPTpPOieGgA7bsOtEXBT1DA3HHLVSX7IJuJe5jXeqmIPqVGi6hM_XqyWiedYJkxClUdgyW_LceSKKBVy2Fp861lY-iY9-xt073FCAdTyyig4JN51OnKjRTwqVhypNvMHsvmarVSPqTiGJtQlGJtXE0GkoIbgNhI0BO-qG7SpglX2VjlMub_Zc1pQdG77bg7Y5LKzQKZAOtO7Vw0BFn2FTJ-XdtQqM3h7yTfdPtyX83hWlQk2mtCtw8AoQOS9sD1XIwLKUBuXYeaZNIJ4fZ0qgz_G4l7Bjt_tvYHvs70WpXZqZRtVmvY9LILQUF7txu2BvEBVobk9X-Uo9nIG8ooG37BVaegozKCxgyQldWcHkNjgbt2d5rAh36gD18_80EPKvj1GGSe0Wqar9cxVS1Nf8ZaDcaVYRmXmPLF4qnXJtO86GjeUfdVPc8zKunDAJPdRaxQ73HPDEnMCC30tQFQvYOkMU6ZtyU_71G1cEqsdPvu8HWZl9rhr4HFsIeAq7lUFNzQnhHzUQjP2vkwz_o8BNRqqyFcoUNrTSrHL7iI73Tc_ly3qCcONaCKl9V7FU82nukgcj06JJoGj5Wo_9UVMQqd3HcpWK4iN0WQKaBXTc4MztxLtaZxmQZNfgJjNoNUWpxvwUq7e9fQ0JNHm1fcKUHhipCGyGmKRz08rRgiw6h_MCv1MzKkfJoQist74bdQ8ziSk41JsEr_NnLKw2i7lcX320agHovLbQHMxTJ8P7ESsObR9_QYKcl6Hq_HQeVeHbbJIaBXfpV7WKFE-00Y5UX4bKQ7JzSZTZIurjkaPF7meIUal6y1Gc-I3j2YsDUsiMRTR-GGxgvsMjOgecQS9Lh8WAKYMLj0ry2wlRveMXRzsJ2kSQFId-gPB6U47Qs_L0ACENey3fDOn3Arre1Z6PxMKUNvDeaRu8Bxz0nBNLqqA5MQwxV-BIWiWBs5TrMV2SjNV-8CNpC-jEdTheu71toNKzXfiuuaKH8xWP3KFb6lIDgAnDfBk5Eup0Z3Sg6xOW1EW1BNskBEqkMxLko29E73B3TboaWRaQadmNkT1CFQJMGiqhxqou-TOVhS6KUQqokJUvRNLW60xe9cp8XxBOnPnCbUskfnRzBpm760k6mbsHYRV7NfaPQGRC7DSQkg4Lggs8EiyRx7sbUAcAI9uf_BWsn7r1avZHlxpJxo0LOG2MEvzMWG7JhnBTvBpNA-PtrDo4h0sQK7hfuvodDIwwB4yq_iHUzQdF23O2_wy-yQ9xPgAILYy5IrNfu22q7mJzuPx5uqQ9BQlGn6RSCancPCSwPJB1p88IAHn33OV-S8gz53mu-GtN2yuEIsO0uzDg7wG0jT9BabucNn1te1kK6YNGC03j2eyy7k3rYcf6Y5tTxdDzi3OAvpSCSnv1CnPzPTPjdyk0kUT5smTTYKn_8HgojpJ18BpMumggkvZa04TXFaFmEOorzN-sTBg3dD_8OYvfR37TCaarn92XoYx4ur8mPrQDztykuG17z11E00pFgKxsGumdwYTW7K8uqYzotdH9qIsgT-mw4EFHVlBLegRoV7pHC-6sxKfrzyC3JjYyd-vBsWGcBn49_1hAO8y5m20svE6zP4sjvlv6FEd8bdzYpOCx7p1NWuNWPjVvyMKoSLkmmMiUXO8LlhTTl7s2NAoEcOKT2hmEgRaosJf18YAlonK2ZPdJT7weMmrTSxGJ7sdz27hbsxbUgcsCcOpFJ93OTmju7CpP36ZDDnuFDbk7EA8VWiixqGO9ra963_V6RvkxceTrLjHIy0NpZ6GnZuUmmokFZWoPJ-Mj_HoYjw1M4RtYZ8UBV7H7iCvuutXcC6AFLHK53-zsWZpfJa7ufv_VXXMAvPNCW37QclAXNd9d8mS-TDtbLE8olNLBltZpHe3QQurzSSM_mZxC7w12fQ4awTQtAiaMBfz330moFRdAZKxSjgiOaFkaXKzJTgxUF_88b-kzmo0r_o3z0VOgIzYUywLIMWaNH7gV2aJwZGgUtJATzFqxOcc45Msw4JYvUDuEqwsyKiIe6JdoJhGFrotEnCg53titnXZY51cnzKROVTyB4\n",
      "Iovance Biotherapeutics (NASDAQ:IOVA) shareholders are still up 122% over 1 year despite pulling back 7.1% in the past week https://finance.yahoo.com/news/iovance-biotherapeutics-nasdaq-iova-shareholders-195224743.html\n",
      "7 Biotech Stocks Ready to Ride the Sector’s Resurgence https://finance.yahoo.com/news/7-biotech-stocks-ready-ride-000133276.html\n",
      "Forget Eli Lilly. Buy This Magnificent Biotech Stock Instead https://finance.yahoo.com/news/forget-eli-lilly-buy-magnificent-060000866.html\n",
      "Billionaire Paul Tudor Jones and Insiders Love These 10 Stocks https://finance.yahoo.com/news/billionaire-paul-tudor-jones-insiders-121824032.html\n",
      "Here’s The Average Cost Of Gutter Guards For Smaller Homes https://a.beap.gemini.yahoo.com/mbclk?bv=3.0.0&es=AQAAAP7_g_1SExB8x23JEVymjmMhN2GXLY8XYNiGwXjhlB1waPe_ePzla1RpCzJnH3o4Of5wnFt1pYZRlU3vwqILu4E8rveJX-u3s40bc56P0CAS8t6BW_3_aY3RR76x8ZqffG5N32Hsoef9RAfIyAgKpn7xk3o4y-NlfOFyyAeIt4svHwd_YgY0M8rV2Ly_rSX0i2ejAAMJx9OFecuwKAcudG44dLtT3okBF04W6vqAxo_tPPp7e0i0taKCRV_kDsHToL1ctaMWa50hWxkeTn6A-A8T_EcRvgwRKLZGB_nJhhUzQf-2C1PNSL6FwjBUMd_rKOGWPYSnBFCk9AgXnVaNMzeZ344COoVmNztCUkNyqRJeOyyDaZXEKzgl2JEWDHciO41RKxUW_k5OCH5VwNVJLyfDwAhNVmv2VxgLl6LYRJPu_MRV-_fzDGyKeBjMOvZfIniw-17NcY-6rgrnrmouPEw7_e_ut5ZGyTca92Up0KfMRw6vA8q2YbwaT-soZuuCIobvQn3VgOjEgxjc0ePW5xhAxAUG1D9aa4caMrXtw2r0u5n_7GysVXO-uAm-smBrKFcSSndsQ_nLJTuggcKCzbZ5uEGCw5xFW2WFClhP2H5pOxve-kmDwu-Pq4MLHCqr9Mtj_2Ry79zaj4IfD3EpIdG_PUHMVYbinZpfF8ugatYRsEEGSt4d1ljU-yg95xHRX8HDRQAaMaolJXiiEoBfTrnnJ68rkoaA_ZxCR911MkLGwnJXYwe_v_rSc09xxruy1ja65wlIOlovrabyGRTGxMvEb5Gcw8bRNwUeoAC8lBgz4byjUH4K81ZQaDdSC2SyXDcn_Js4_IbhLTvhJ5CEcEISMVhEvnNqQQxewg031FLYnN2yjEBkRfMq_K7pfc7dXc8Js0TteJObU7a3O7UqdJpcN62kGJlNY-8zSUnzD-Z-VT-6O5IMzbw8tI673NvaGq0Q7_4UTyO9aOl36HZ9F2XpK5-bzwwaIFvy7xnlEGl4cDksY4xZbMDLme1jCO9trpjc-5S4ycNYowxRbDEc-sysmUKXx6ohuzjvYIjxovFvks5940-H-4-4i1PCTemSRJDajdy-vswzm5cnYDYSFiMwDhlJdogz-2O8sQ3jeBuDDh9GRnUK6RSKouvOMNwirawCXL2j6p6eYfL53vgMHszOqIkkMvJMPOJjdLx7KfXzHKR1gilL2I8mVrVQZf0AQUvjl35wi_IzRqj0tdLBmCR8FGRdCT2gxF2JVTF1orASKVP6Uqvv1EghueXgrhaEfjqBTjeBm6LYVW51C-mCNGNWWBz6xijrvkcf6ZhuaCUdtNyp2ekEE9JGKiJE0CqvJotrl-orVYcmo9OKCRVA6pxNptSL5KrXpUZbl7lYPGhz_2LwaYG4Ke22RYDlZI2m9Gak1waeiNfKslb7tjTsVoDefSQGlUuLJT7J-czYSiZx_36MvhSf6BRoRhAULezKtpEl9nwYFd_WrjAN19_hXlDTLJoSqsMl1l3-2O_IP2S62QwJhDBL2p5e4jRVZ5ZZT6q83T0fwAFQ__3vn2HNBThCMS2Fgf4j3MSzGd8q8ysvmQVzjQhOD4jatsaBu_c-QHh77sRzFNfhgpmi-TqJOiQz2nJCY8DV0oU21SRFEuFtxOciNOKjfrLqAWKealPuerAcjzAxA_cX0mvb9uxQtjyjJqg_ZBURs4ju50wIC2-sZQvb0gdIqbwMrkV1AeZhTQ1hJZqNxeC4xujOEZNYbjZw_XgeRU3vz7krNIFeCb3BzkTl3WBSAT51XkdHKqM4Axuv_X80-XwT-zHfliQkGHti6vZk2ljhIbl9Jzrz0uJgpmFY4TzgpNE_YszHxLzU7ftA9wkuor6pGaVKevxv9m6s8wOrnbOKDM2Rv9C8sqg3owMn5wIOan5-EDNtabjj8jQaW-5bBqpBmfGjUr32G3KG0GF3bGoPjIFIKEC9qIouVBaKYbzrJztxiJoe4-wy2Jv1gM2H8vaxWhH2d6vP24x8WDxpVKp7xVxNchD0vyipuSOVeNWpynpF14p2SyjXfuGLTyYQ7QgY8mxywNzRb6f5-bmHAK_ASg1gYY2gRFsSzg23jx_RlCBHhGu93LhV1CfROTTq9BzCbKi7RL9so3smIBAz2myfgN2OkEnGlIGig61yU0cpGtPfX8mRM9IvbLoU7jCBGaz5Xn0zwwQehbPZjxO7cLdkmExVWn1aOxWeV3-KUj2bSaHwgENXiIElioADbpLC_vnQQcbUDQ_UWtedbSafPQoA9Sw2-FVwQ4M4NbvZUQiGg0p1y_ZKz84zqFqSPvul6BCTjU9yxAszE0nO2UXX09kw46RLR-Ge6AQxgXwnmvcCY437vlpJHMDK-ClLYjvakTlQ0nzyWUBA0kZ9xP1_aMiZSh8QVaUpIqPsEAp5HUI7qKBAbVE_4xXzEwTgHrbQBUIu2x_K2ATqaWhjza1Bv0sIyf0gCkHYuNOyQQDo0fVl6GT-oeaGhebRbPDJZl5nduCv4fT0HqRRrRT0_xjiu47CayF3GPNb8Z4SEbe7JUSW6-Km94REFCTt3VYneD7ncdQ5cehXgt6hY8F_HTA5Y9AGrAd6pFXH5ibpXLPduxQM_lQvbulhQsUMKLSyBQA6MNNEWSx1lPvQPgJaAlQTAHOak26PqK5IA2N8pcl4iXeud1BMiW9PAvW5fplkk-4gjQb3kxknxjoX1tRBDtwAGeAfx9d33uW4YBm5c5vEknPJerwrg0m_FqJau43C3yezpGBq6CpMPqVLzHZsCDvEoe9prCevAMbtm_MaZGWH2iObT7vPijM1Bt7HCppgfYVRpzBSDYPjkGddC2Usb-7spoESWno_bsn4mOQYhFAy_QsVlW1G77AZ5oAsBQ-h6dWTZa1HgL731Wzx4DdaVmcUuX21o_pgYnVPTxEiHJV1cG-EA70t1Dq3uHT4F77cujqUSC-SMYgW1YcGpW0bqmj3rmJoaTCFAwv1Dq70zaMNFoY3mKxLLuGBRVpwzXE-7TG3R0zyYBKCwCDHqwW2uStuKQ6jkqXR3iR0QXfEoVqVSHWYZoiXwCnd9ULr-FaMRR9dZdIe3EU1e11PGb7A35-uSNLMDiNHlBqblA8fFMm1_tlbkO2FMljcqy3RbplizfMb8HtXnJ82k1asfEcB7TholRa_2RDp4yi5DbT4jVL_G_HCa5e6cblgLdonOYOSfhPdvAtXVPIx\n",
      "1 Wall Street Analyst Thinks Iovance Biotherapeutics Stock Is Going to $32. Is It a Buy Around $17? https://finance.yahoo.com/news/1-wall-street-analyst-thinks-110100310.html\n",
      "Iovance Biotherapeutics Stock Has 22% Upside, According to 1 Wall Street Analyst https://finance.yahoo.com/news/iovance-biotherapeutics-stock-22-upside-094200391.html\n",
      "FDA Lifts Clinical Hold on Iovance's (IOVA) Lung Cancer Study https://finance.yahoo.com/news/fda-lifts-clinical-hold-iovances-180000809.html\n",
      "Iovance Biotherapeutics Announces FDA has Lifted Clinical Hold on the IOV-LUN-202 Registrational Trial in Non-Small Cell Lung Cancer https://finance.yahoo.com/news/iovance-biotherapeutics-announces-fda-lifted-113000422.html\n",
      "Could Iovance Biotherapeutics Stock Help You Become a Millionaire? https://finance.yahoo.com/news/could-iovance-biotherapeutics-stock-help-115000803.html\n",
      "Why Iovance Biotherapeutics Stock Got Trounced on Thursday https://finance.yahoo.com/news/why-iovance-biotherapeutics-stock-got-224700780.html\n",
      "Q4 2023 Iovance Biotherapeutics Inc Earnings Call https://finance.yahoo.com/news/q4-2023-iovance-biotherapeutics-inc-171754791.html\n",
      "Iovance's (IOVA) Q4 Earnings & Sales Fall Short of Estimates https://finance.yahoo.com/news/iovances-iova-q4-earnings-sales-153700502.html\n",
      "You don’t need to refinance to get cash https://a.beap.gemini.yahoo.com/mbclk?bv=3.0.0&es=AQAAAB1HUOc10nNYYliUUoa6kIP0BH9a2uboGRRtw3Iwlffq2NUlp8Hhntdm2JhCXuW-iD2wt-pMvHWHlyyc4zDaAWjTVzsz1z22KFX9myDeUjNqUZ7UHsyv4g_nMA_7KFWpGDKWDZ3Fo2Zw6oLl_R2JpTo5yRnyQnR0kpPsaFvq6YE0cmMAqiAwuEzr7mUwmXaWgZnvUS0L-zIwkvZCJirYdFOwWPr6r8bvKeFlURXAUn4M88JM3gb_BlWk7j25cTsgf4Yhwq3yAYcxEru4oqLAY4F-534bQqsXh8w0sZQFx08mSdhF89N-ym26_zu-ieblb7pNGLjStU9ZxCcOujD41P6mMwwl9_gmNuHQeP4zCqtHqE6UD-sr6PqmCEtZQgmfDklLwEj8IYBcpPcjV_F8t5tPCSd3ofU0bF4A8NSvYUO6VzY1Y8XAli6k9bY3eiM4cKieod72Fa4CRiVwuLWJIWeOitnDplgUH-6EeltAfbg66B9u8TzE3LFawSAoR21hDR2z_EM0lX-hEAlsE9OgHwwd7tVkc7zMHPJKzjsoIDLvfdEJs0gnOHhSwlWdhPNGsz9rHEdAZMNjDo99VxE9vTigmQpMBiH6hJA5XOXj6WCMZz2XxH5JQAYAOqa0UXGCYmJThcDJsvFw90pklFm3S4FXN4kx3xUvW4wPQxXnrrS4STdnxdckPT8-F5UViKntN8u2ZvVtCTfeZ5JSLFhSdXF9h8Nmue39JhZne1PRag1NqETjh2niPdt8FwGNkOH-OAtGT5KmuZRXHyrwWkMlllcwFh-uYcXrSxgh7uFN-6yQtwcbNm1BHyIM_3uks9kpSmOzCiH3pIl63ux75f8yFAmg5omKF8tBrmNnZy_Ib5ljKtHAkBOJv0KShndygvYgTWPv8q_aCx9F_cbL4mS2oeY5fQIlWewMpJRYjhOAsj4Spa40iORvSdHC9g2HOjbZe948jR-AstYerKJ9STyNx2kPNINRI2cxfDTe5VeNdH5sJ4ogB9KQqxPaiNMI-G2o4ySNfbhljr1r_zX2U5SfbvSlREWjsEH-znmpziiqmdDS79CM4FIPcUL_rINf1IWyj8QqGQc1JaZphyIjs3mDUELd7Wmynfzfi8_cfOYb3PICCyNM9dUeHIhACLJgAE4c7L8aAES-VzaoApghgwohAVaZVVsvSdr06iThAGW07DmoVn5gBL1OrngtparolAewioNd82EQknFo4NQtg86GI3NehDudbpSBclP1i9MVvkVOqBKrCSJigR63c2tKZfqPE0Rnh-ZQqYoWYV26nSfVFlwkgNJl2VQ-JBBNwgkGqE-Rogq9Ch4JlTyrfEpcXBncBNgNOcyAM717YcrtyPms7OqRm4xXZaFTgjewyDxh6kSRvHJTdmh8hvbNRA2Ucw_MJseq6v_Fs0dvW2WyN_6sgRkt7hcwtLinww1b7hZbC__rK2UrCJ43APjBbOVJVT7_EqlMgJk4hS0UchLI_jdk2_LLNfpjs_yw1XhdHp4f0HE5HQQ8Ou72ER1G8_jc8Kr6FT7feJJxbuGqU3A-x-n36nK6vUQQoRstk6pZHVvSMpyxN1CvcezPeHHDFfQZxshRiPZVyVBy6iNzsqJitvS4-dacyKnByeQOxMZdW7fhnQTrlrVpW4_iLuNhsXUvJr0qDNWxk4rn_H_uLab5CMdiOWv2S5ltr3sfnFRHAb1dCw2DsrGVkH4cPGe6UdcczyEN3VhR9zQSqHHcEtaD0NJcGg7dwHHxrh54imFWkFv-TDfWkAhbNIJ10hRHxpp2aOtVl9sr9isE7O_-w43gVd2VPbkH8ByG6ePe8tAeEE_Xgd77Qw9Qr0lsbYo_hZBEGTboqaiOyCS90NqjA14P6wOPmaQ8z7gGC-7bT1lGTBr0f1Zq_C-o-Yl1hP-d2ho_W6_iMCrPtJuuct-OrEsU4T-WuoCNzv-EpQK-hdTr2AgWG3djBgJs-yxwz1S6oiYTFaBz6FS6H2qNPWl5-FIbei2sfRu007E2jPy2l3KsMBtcjLLde3-uNYHH-v6MGCaWaZa4iE5KD7B5mpq9ndrZocE_zEBcU3u0V_h4ORIgmEVwPXEyBhM-_VWbO5KBw00_fV59Xn27SUISSV1j9T1u0_HAfE6SPqcGZ-pRoTQiImGJoZP5NBuw3XAY3CVAn-pz4sNlt0aBnPNgY056x-xAlVBuhyzs5FjjxOV4xnFHi5KH9C9fBnyJ9H5GLYN3W7KH3WiI6YAFn6GTTqmdGjsfQEw0VkvREPFLaQSr1vTcn6Dj6W7WBegPz47ALy6jjvdPoRDzZoScviNy6QbH7spDhip2EDgvaD3NxPLzZfMbHcH_9z3Dao2EkugG0YMxZQdCyUUGVagh_6SioeAYm003rwaO0ljNh72OWz8_jDE2HpzMLycuwVVIeApQU0AG8A_jK72iI5MvBiRT4sFXBQ8y3DxbWusmTbhydNabtI9Rq-rFe9GhvA3v063zYVsy3SMwpgt_QvPaFyx3qtmAIveMvNEwRuW74Gbl12z7pNFarEjIXh6t2qZgOx-twudAT2IHghhRiQGsnph0LDK15XWVEINtkApq3O5Sg38smwInGB7SvV3Ph80dZP2jWImrgd-pxsZ_PiemjI_umkoz29k6LtPuzpJdfKyaygT5dnqsxDg-5MtgvlALcZFqs08yFhOIYUzhvDYqrf23F2kLKCx3zdZLYPD5xmgc3Jgre_3qLO8nfjf2DYFgLVCIHupDIx16eGrriWvVkXMSRONmoCH9A5SD3puKQ6ylObUh-5JVn1McSUeUyMBAJeqqaMHYfJSqc_DmsnfZjiMU05UpUlMX5Tz92tuCPPAxZgpxP_Pbawg\n",
      "Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q4 2023 Earnings Call Transcript https://finance.yahoo.com/news/iovance-biotherapeutics-inc-nasdaq-iova-144450082.html\n",
      "Iovance Therapeutics Stock Has Skyrocketed Over 100% so Far This Year. Is It Still a Buy? https://finance.yahoo.com/news/iovance-therapeutics-stock-skyrocketed-over-105100857.html\n",
      "Iovance Biotherapeutics (IOVA) Reports Q4 Loss, Misses Revenue Estimates https://finance.yahoo.com/news/iovance-biotherapeutics-iova-reports-q4-223504164.html\n",
      "Iovance Biotherapeutics Inc (IOVA) Reports Q4 and Full Year 2023 Financial Results https://finance.yahoo.com/news/iovance-biotherapeutics-inc-iova-reports-213524515.html\n",
      "Guard Your Wealth: Must-Read IRA Gold Strategy! https://a.beap.gemini.yahoo.com/mbclk?bv=3.0.0&es=AQAAADBGB5Wq1OGAQZp0YvBSr8zAhPSklhCyQ8tU1OcGnQXkZY190QXNRCSdtrnfmz-Ie_XQ1VivCJG3R3F9t4xmunZ5pPTgB0Sp_DFdcgfQsiSqqn28xopWtrWAKEgYxkH2e1V7yiw-QY2120OOYD-DDKQ7jBUrbyPlI3b-qkNJVNal_tBUK696Oa7a3RNMx-7647oBIXXtgL2588v_Uocg9OO6HSCIaAZamfiwTyYQj5qdzyPgFfF62awKuJRUbx_fenW_26DhoYv_j41Y6QhPoboESPckYgc4N81gEsephfxu0zli3_6WlKCCV_Tq_XF1bLPmoPo2ICRRRmmqh05v89P8j_jaAdgdD4VFpfZhbGB-SxXI99-B6SR_oOrpglSHmMEMHK2H_yCzH3I92yR_RRiNlST5NsdwtloNf8tdAGPAGOhpEcQNLbD4AubjbPgOToCRd41VRuHxQa7An4BBqmvau4FkHOLqTHlX9oEHkXQT5hR11w6OuJLyoJvdid_jGJfPnlNAUF1YsGUbX-Ws-7Cia4LvUJtihZWJGWbJCKUiZF9KROEPj_rCsOpb71LxcVd-e2LQjUDCNoakCGPKK6pQabGbJAldgFXB0HC1iHNDnqfDp7YsTZ0wNdfvtXM9cmtuVQfEOwstfoJDW_Z4rnf6KvWgx-GouBwgGJWQCt42f5hUlkDgPm1Z51DYHkvL9PTwjj9A4r9u08IrJR6iyEh_emLzkfJEjsfcKBK-CxQIsluvmozyAbCaB_-u1T2CTfbynLLWeekmf-5UIsuTnDR0hCoU4btvdVtLW573av4-BgeB35MOIZjEtaa_xstjzO-I4htemUO8Zru0FROQi0zat7CyAKTao8GSHxsS5CXWeSXy-qwme49gAg5wFJuC0K2BXgYhT1B4xoS82tKflbAk5cFWu4zzqTJb7WGJrSHIXGJOMcvWLCbtM8NhlNaPE-vrqlrmJ0Tf71lWDhC65UcQFG6FZY9k5o74na_TIP7NwKWk6DS4q8iW3U262W25ZJYG5Xh-qOnpBFFBmELnx7leulCarX7I7P0f-EY2brzbiOSmvyf5gmfX7Y_yDeXmduHlpyfofx2yE6KcIvtqLtoChk6moHbczSRvXL1BFFwn2YwyW1UIxz4sp7sIkTFcF0tUZudD24oUdh9VjiExxK_pnirCa8yYos0_ZIWLqk2gxso_nkqQ6I6K2viCQ0jG7-f6yVOdsFuRkesBCKzRrYrcOx2fCBa6N6Pp_oQo6gdaMD3_MqkK8Ehdec7rx1S2jfdKf_w_rAePkAMXFMfqfs_QTCetEzZ6ApE6Fj2NucGp5WD60zOWc_1g9E0AWaCWXru1Qr4I6LcxCMWCOk3ViRNO_Lh2wP4ACccVHqkXv9tuBYSdhx6P4dSw7-AHS4i1B4Ai6_GEwtPNieUcLJhHI-3rcDsvmBOzUTDcSUQmL8Q07HW7TrGxmBPRa96QP3_1afkwrF8AzvN4OO2UAJDh6EGgqAI2w4QQ1c02PQGD5JZJtSDzPYAD_PnByWXKHTerKA-_oWoi4m3Ug4nWQNIA8hVOQoWGUpzee4oJvzdjrX35usMsUrs4wmeVKl-DO08_wlDXdVslTB0LbiN2wjKvns9a2mbrRfnAgpUM-x8Pq4J_SX0xQzWTkP3-A2-1e5Rrzy96mVv-GKpD6lG-kVDp_Pj_E78d0TJ8nTTE5e9eFGU523uw3_6y975HT6nvqBtHvOv0hiYc6v-BaUkqUKYxHUuWNPhY7-mSo_hayrvUM5TC7Vj1MMR5ssTvQBNwkF5vh-gx5UlgJR4QoKCbWFxTNAUuurksjElF8jJgtIHBOAvt11--tvSw-kJSuogx1Pt7S15n_XPRErg8g0LXZboJlPEv2nRCHiK0lQ4qcaj0cC4FADz65hhRtxtbhtrWsqiFTX2VV1zutljaQnAiQy8J6HtWdrbOJUXG9Pq56NLjqz6LAKcG1Cwb-VFinpnBSJMvHP4JO5xxavifdqnn8t9i86SMKgg9dgM5enVYo9laiOIuJPipi6IIwRg8Utpcr9OzOH0sbaJdkox7_QsUHzwv4IOXd_UofLLzdrSdVd9o-jofxLcC7IfNiBlxzKEJBi9KshJnl_fU_lTnoSC3HHhtKZZ6voY0gywYXEH5seI1eyEx1DzGLPzdo3gAlkfZnsjzOMKNhlDMPbKwUMiHyurvz9WnqPsBRPcQ2eJiz_GP7vMZnHgD8L1ct5_jL9uGXgQyenx2izp6FPNSrnVXRa7XdS8iJwDelSOEzdpx8cEnnWttfitcn3giDR3OG5QRvWAxqMZ52ZK5uotG4V1a56u_IEt7PcAr0b_ahcL55cWE4pOTJfg_zEUj_m3Qf9w6s2Pjs55_nYOXC9l_Yea5ar5DbXL4ZSg2UWnE2HCjx3NsdBYI9dh7flaMasXCjL_2xGT0knjV-wdzky7gLb3UcnVuw2IMQRXhNoYt8jZClI4Dpk9P1aUKZCSf-mRM8MwdkVHLhLZnww0AmQ0Vmz9w_rmGwp8Zqq7ZX7sOcUJ5G7DL2Q8aBig7A1RwYoWud8WFO2Lgqkk5hF3W0gj7r0pJ8kYmegrfkxsweZwQAEJZf2otZ-E-AZF6IS9NOT92VWUasu_yRoYQmv8NZUCTxHeZIubq1n-I-qPJ8J4AMNItCaWC53WyYCksVqR3FXZEQGxykPhf5B8UKpwlaMcFNNIgTBkSNfodg5-NpuKSHVlrlrW4awsspEN0n_cHWfKUUjcHZWAlrr8tfNDFtgWnEcu6Un0KPBfmu7hYS1PSzuh-JXvJU875v_H-t0CKw4v8KmsTG4aZj5BGL1IKsXUM9lgO88Rt5O3lSwo80pnakZn70ue2v_fDJ1vF4L0CpSGR6WWTrB9EU4FaUxqDx3oFwBUQVNwc0otAy1RJd1kq81IC49AHAd2ix4YIkkmMHxxw-8dfsIRH4Y1SAfnJk11XNUtNvdudl9pkH-XdAtcaSdTAlttPzptvSWYHGm318USTywBTFLONFFLkqt8lzTfEfDcVps0SatByZZ4njfIUv7TeqCFKRUj1v34JFi9uot98XA1igx-GqTwKJlDdjO42cdQQ_ICyWj_gcsGAwVROaBRHrZkiOpnVhVRlPcPeYd6QDpvALk3XPRI3ymoGLVsCFBpfVPPqNbO5eVYvewnGarFWK_g2VLwemUEkJ4ebyxtofeQ__h1QoF2r1nSHAkrD7hzz-AtZ6MH-tQPtr-KSfw7sYIJCzrPUmN0\n",
      "Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates https://finance.yahoo.com/news/iovance-biotherapeutics-reports-fourth-quarter-210100078.html\n",
      "Why Iovance (IOVA) Might Surprise This Earnings Season https://finance.yahoo.com/news/why-iovance-iova-might-surprise-135200518.html\n",
      "3 Under-the-Radar Biotech Stocks With Upcoming Catalysts in 2024 https://finance.yahoo.com/news/3-under-radar-biotech-stocks-200400015.html\n",
      "1 Soaring Growth Stock That Could Rise Another 53%, According to Wall Street https://finance.yahoo.com/news/1-soaring-growth-stock-could-103900547.html\n",
      "Ask a Pro: \"Should I Convert My IRA to a Roth After Age 60?\" https://a.beap.gemini.yahoo.com/mbclk?bv=3.0.0&es=AQAAADPQKybybEzjf7IkOhUyf7Ria825lWeOjBdHV5j947OXw2bw_-wcfLaLa4NZ8YFL8mo8y_9DJlAAxF6jFJESzHJe3Qx-jcIAJrd9TR5-cjM0TGeLpgL_yJYDV_e3E8sgHU6EdOwHUgTi1NNmbT329fzvIaV4GvfJLXwszrJXg_AzOKC6E6gosOz6tYRnPabIFkqq_SgHnP2aun0L2TyWEVrjtClhQlF1lKBvFUAEPmGCmur7cF9dsCrcrmxCC8rMn5iBYOvwE6U6J07pbJAokNSVkBZT6nh4ZNddMqeM_D0LyujAXngN_BO0taeqqe6NnjnQ7TPPFLlMj8hneftIg0Tp7kssIFAavID6N8usDLaNUeNpVpOzCgdovYTkx7LcGxQFqS6HR2NBzK5zyUyiIazzlSExp8nQsVHj6xky-DI1_ryxpSHTy9ryz2_e8yHuClMAsHutOMm2yA8Hw7Hft9yYv5BoIDbSzVkZmo7Gwct5x8yN4xI7AYrOIgJ07kVWnfKGYTtTwVd7NdRFr2BwZkj3UYPuMEPwEPYMy0u9isi11JCH_Dh8uINZazg7RgLnMtcGt7J3CnX9hocXf5hYj5-cLTQxQBMdi0fsPlFWnvwWlBPyRNi_Zy6jTQ7eciudOrGaXcUTHLoIDv2NXONGh-nijdVcNlc5kCJqrLRvu_9oZoFfwDiiKOUJNOAIMzCfRlTu9RHwrfogoM205xSVRqqSZqGx8Ag4CBYru0t4BAGNEgPR7waxEA8N2JH6m8gW5U5gtlKeuHzf7vQ6sMryG_5xgmyQs_62XwcMJ1TINs89ul9JINDwsHl2HixZnetD6jzRPJ-tKxNXgAlBX-RwvmmtmvrOMOVF7ZRQu9JV-3-zRJAGrB8A8qPZNHfkmP3q6et5nYYek4-PwPX60SUxq8O7gRRx_UVqrz2DpgcuxZQ7lyVh2xSf_BTYAMFa1Au4lTGxSLpfaZlZSQUoyMVRsisFzFz1QS-AtFr2vM4kzsXcptnj_7KdukZEfoS20izUPSsoxK4ELcTcAx_2d-c-P2fu7xAUvFWW9rMOuI2Vvs6_cr2YuhPMGVVg9IEVDmlC4u1mAAm2Yn-IvdMWJa1AXAiWlbExGAGamtGILXrIAYrBnsliroQUzvWDygT_D_tIK7yGGvbm9nT57xN7Y9KMZ87RKrKInu8WzcBJ9q6pfjZqXEvRX11WxmtaAk1BaXoGoWYdryZAXBqlu60OBUKZmRbxHm_i8d1Zn2W2Zs57hiiRruAMe3JJk9ZFtED8Y98mrcW_kqxFeCgRdjx76ETnrR6v-HPNvKuKKVaSypDgX99j3dTuCGLeHG50ucLGidCYmRcz6W2snJTlq55uqlTtFu6MSRAET6yGypw5DtviGviRV8Op7ggph5KKNWghTc3tW5KN6xVYegg9GKRZG02NuEoQDOM5LTTFI22UHkUyVPh19tr_33FYq_tLze798ZmPZ-LpKvUk-DtngVv26enjQyTPJewTlEBjypw8qybA2wrBIyX5aflM8R0HyPnNhNnet0dVsNHqVE7YxFXeJPhShpFGPDwtedFED_9GBuyJFzjQ0GDLU1nGV_FvK9SlRAYIvGyrGbsvXXP4D-0SxCM5p-7sK_vnCgS3EtsTrI8_fw0uktsqiP8-pSad_C62yzaMr9SpVEPCTvhzTHM93kcNI6fr5ioSW-CTPILdwkKh6r8rPw3lJ7MjzKD_WYYTgBEDYzhuokoql_Zql78bLZ0euur2bBW7S0uN2ni4F_OlC6wTejuPvmMnWKsihaJGccvDPhm1dba5Bt5TlfTo6mduiyy_zb1ZG5lE9hkCcDiG-mUOo0tCsAuL_bJFXPAOj7AW1d8MqCMBXt-1Kt-BH4rpmjvz20DjBtHADNOxaJ7ilDfV69t12AuU700ZHF1dZU9HKGTLNbrrGv3R_nLS0jLw_nlmA-vCXZCCLgjC2lJygTN5ebFpcFyWvA4jI43yE0U-15XjvU6PXPIenLbMHIf642hDzCd8Jzhn3gTYZSGxVGY043jaQ1L-Av5YHqQH_QarQWaiPDHPQ_k5SqcLnkiz7R6ARdU1zXQ-211HPC7AYsuiOuo9RDFU2vnnjlZ3MKLNMjWc1SqghA6EgAWgD0jaHuL6fe6Y0jJRpdKO1QMv5GkSqQ__Caj1ZQeMxHgGoxo8M1lL6H3g2OM7-NBC_NhPJkQwXZgNZl6fq-YkoovszQGrQ5Tzi625Cop4xxbah34gz13YPyEshWeArZVYZuDkGRp5LJaAoilxgiMhOrQydnRm-zXFYbxzXs0560ZMXyvWsvVy8HvTOQOG-40e899AjrxRIOgnxPIeH-z5jNmc_kJAXVlgRzPlGrvk5scsyJ7_Aiy9YEpeVv3QtBarZeML-OLvLHbafL64eZsciNFVliTkoIO4d-yVSI2kLB__XL2XbCQkdhxq36YU3G_rbD9vB4atN8S7fuYIbHH57J69C-jZ3kes2HhJEkZm4sA32Cux5HUraOa-4lJK9RZdzu0aV4aaOyJo4tzZRm_pR2_JVUluAxNR8OmqMp4JKDv28YcOsgaoEVVZrWGLHjii-5psdYzMN1aBB0sEkEXXWrIaJAdJ3xCMRxMtoAsuUWD43d2n5xj_tPUq34rZscUotJIXoPJrizxeS8JM2REf_12sj0amugDLw4Ng-SGbCNX1RhOckJ1mib7Th76slD4H3wzdU9nS-Bo68mfYZQ2viC9UPqBDB-K7POpEEPS-elX_B2i5GQiSnseTaDruEju3SsMKhwq-LflyEmqoB11LK0Cb7Xa39xO2EhCg3u1X14EUouvzxg0Y4o_q0Wy8llQXw41jSnVgSbh1ZjWxUCke5NzTMS-dH3pPdMaF2mompAwUCW8pOohFL0Jk8_O8r_0a7pt7ksLQkyul1Nr9EbvOzCsw9GeP1Cxp9tmzRTZ7uWkEoonhkl-R3n7GYY2i3rxoTdlBp39wcTw4JSPRlB0pXIeKmS8cBjSUFpQRIeTeOQuN4jxfo7tnZ41zff7gixpcUgY9Qi2pQwd4oatm3GOW1yqyM-2mhQIOvj16XHm0TPsRAbZv0p9rM06il4CWD1wqKctGJCLNvvzsiPET-78DZ869zwJwBWHfL5RFk8nXQIDGfw_6_Lr1cm24QfbIGruqxFU2PVv-gyrInr25AB1UENtwua6ir7isBr1xySJJN70-cfEMkFhu0_jFRS3ZeWgDyeW0UCDqdu3etujWl47ni8pvDjSOpqPk3Lzw4yoi\n",
      "Insiders Pour Millions Into These 2 Buy-Rated Stocks; Here’s Why You Might Want to Follow Their Lead https://finance.yahoo.com/news/insiders-pour-millions-2-buy-130750978.html\n",
      "Is Iovance a Buy After Its First Regulatory Win? https://finance.yahoo.com/news/iovance-buy-first-regulatory-win-100100708.html\n",
      "This Biotech Stock Has 47% Upside, According to 1 Wall Street Analyst https://finance.yahoo.com/news/biotech-stock-47-upside-according-111400042.html\n",
      "The Zacks Analyst Blog Highlights Moderna, RAPT Therapeutics, Iovance, Sarepta Therapeutics and Regeneron https://finance.yahoo.com/news/zacks-analyst-blog-highlights-moderna-095800264.html\n",
      "Searching for income? https://a.beap.gemini.yahoo.com/mbclk?bv=3.0.0&es=AQAAAGU-IWG58lig5BN31akOnZ_2V2VwhviaoMqavRojEbuWeOWv-S0WUB97nicE6JQLQRNl8S4ztNoEo1pkE0qSFPSl-r2_ICvGXemjSE2TEKHlHnN21iW9lKSMjblQahKGzJ9aeQ_dwankpqivn6zVkkPVrh7RK7d1N0OQCCCFcyUGRB85SMh1q88A8DkVUBQN3AmRB0-TfCMMc_KtCpNG5DqpVl9FaNa8zHiAIMPAKxax4SXphrQnEEzlZx-FAQeV58yOmXodXDocwf7sNmzFoEplSa4frAZcw2-NzfK4iQXgVmeb0q6hLmnbbFGl0h5D3CttQnv1HMnRUp3FaokJXCzDijj-fgqNO4tnwYei7pN3piIOoJnIKV1nmHO9nhistvbQTWog4YK8vIyuJaFIuJwfn5EVp8Aja31XFIvtpnXHPvgyUICdMqy8mkQdwR7zg1FK1DXjXN_84Jkjh2ITYuZ03qoWfOLePqmM4Y3d4NcX33GOLQG8lLMYzaK0bBpbXrhwmsjVysCLZuYnO13oyFvaYBKp18PK9caywSo58y7XZ9mmNs7f9ZFmquTRtLWaccNOXUfrEwvwKg9iJUezvGZuccv38KfH-4BqItyA4t9FgeisP3rmbXYo3sWtoXKt2UMkxB1XC-tb1mDnFG4fp6aEsPns1oSgexpdOlC6obwQfE8mP5OHRApyRuUxR8jDxLlMaRLMAyQPfRJ0IjWxOKyocuAWAOduoaAqaQbTRdGp6Vp_w8c9IoTK7lS-aB2fPo-clwVxYTH6VLjPB0a7fSQSostFLv6H00UgTHEzL9TOx3RDXffwW2sPQ9duzSykE5VbjBzhiIdFx7gEyVC-VAQ-uSNWtBl9lzVrvOL4Zz6r-rz2Kjo_RG64WHGwiO4QK4x8HmtZjWrUd88_34t1CY4llvmSJG7t8wXNlGPeyWDgS5spoXxHmUjBkTX2H5xXczz65WxlhDKjcfeDW5BTBoTIWRkoGQLtZHJhv-Z6qqv-JI1GunhcSBnvhkOco-fndaHFEpwz62VcpRO1YP3C5PpxND6hzeB3Zawq_ZsN9MklBhrEE11WQpu5GTyUs3zl3T0t1fKIilVxSxTRoW2k5f1MvVZsIs0fGo_3Nt76mAr9HQkD9INBeDbcGRUv-gg9HXDeXNlzwx9r6VuyKHnmrxmnXmV_8x1RhC49ID3rzUqHIfSrjo-zPjCLvZqFBrEdFmr4QyfrJEuV0Gy54nwe-y6tI9i6X18r9vtNSyRrD-86joA557bAivlynr2Udpp3x2qzEedE7Iy9eEWyIeII51U98HExL_o0QFYaZX_nlHH1wDcV4E_wQRebDAW_-YpGJCMiyFx77csvNjMjEBpPGMhb4W06wBAcjRJVH5FMYagga8hc97HVrr1qfiqAyf0hUuhG9_pcvxLI_id0BBh7hMJ5eFJaafh01PaCsfvgGvNFZli39mMrMvsA4bjLSmc0oOsI3Q2yiuicY_Jc1GYuD00At6L_oQ5cQ2OShnRTSfDBt7WwXR7HBd348cfR5qTtjvQJFfnspqwZNwu_dJnLmzfwUQ6uFlQ1K0ZE5nB27mBZdwgxTMoMHtoBh5aI99GXOHNU50OroAITSw_8o3z022nNkrqx9M7yOh_g5OtREqAniELLLIiUTuX1-IWyfyRyXho5Qpj92xqfakw0PoRtyvWf1bPG50-0noxsIYe5l2e5L05XUr9Jsk69-IDLpInAM6SN3t8LqGdrlDKYt57ME6ao9ob-GSe59JMCdFlDwKIjpaQrKaqji0Odhv7hxL0jyfIYAzxhMqqtb3tPQt2KRy6hYCgroTOCoW1cM2z35a39521XTTvou-MPpGjbl_W77zrO4U6_u5si-J3YX7Q_gyEvlyQK1N0hYqPBOOb07XgBC4j5iq6XGA5TRo2vwe4wwIWuP0WUnNoPTS2PX3vGJo8_GbBkH1Mup5bN8fPkObQFS09GRztt3W0dG2xGz4XGNYGeWYjGTFZ1IZ8tOaRA3Ntb_6f7jJopSDxqLaLS9RdZYHtN5s1MhQ3936QnzmQ_5RTkJaNGn0_T6MMq4L33y6D-J3xTGQkqdDSTnKcthDgQfvaBrErYYmdGxRVFVSJsa5AxOs-ag15Hfb830cB9kt2JnGvtER2jq8K10ym-8J4kQ6-NUllTJMMJeFQzH_ARj_yq16iQdJNfH1ZBWQn7WBe0fkOwwg-UeuFGNK3s_iRCZiK3igYHMNvVonHh_m6591wEr5poVhbR40YQgo473y9bNYGU7UXsE1WT8abZhFffYRnSj5kOAZpuhV7sQEjYJvzfmgEGIvDBHRObEKYorcrqMsBPWbb6DgY2RXzdNc2vINspiqUNFPK09KCKeh63O6WfBITeXCYiFFaEHp4mF2LCF901lMh7DYhxTEIxSiSl3U9SAPiJNhrt3P1ECtsHaKIWWHH52viv0GjmJUE3OwXxJoHVcdyDJvuhP8A6mxO4gOA-lsvfwNzvBsgFKuXmemrNd_l92xkIGUZW6uV0iLKQwqdjxwstvtUhpVVXaWGP6xSWDdcYPQL79VlOpEOsspNXTb5b0brlIgC7y8EBa721w-5bvlvoI6U31uQTBocONwdDfu6R3aDinsHC_iDVwFbU4Q_AWirg_1pjDuh8SWlWlPkl7oaymQ1S093RRqiyhP_D9p3fbpn4x4AYpNHWF4hD1SQirD4_Wq5Aae-0M0LwPvJiW7970WuSoBDj4eBK2vvHZYkFUD9ESjhJKGaMZjAl9RgVd0zSKjgjVBhbESvSnqRuxwdX3uhK6S7EmMuSEQy6xeOec551mvk74Qvh3hfUaElJno5dudOvYu9IOE5_c-V5OCqVFhwqhbjIqBBefRw_aIP0YuaKr9EswY6x3p5uQQkyRfIzX6usKdZzIArup5or7KYEUl-rnMzEAHGhFsrtvJmKocqysXaMVCf0HyLi3y_ROaQgDcPA38rM6NEglBfDQDodSULo0WoFkDQfUFbWpXIIsIbJxISUBT08mNElCpXys8ac97y1YXGJTFVHpMKYgaQXpx7Ff0NhyR1bs4xpKOXpbvuwjIdNCItN_HSww_N_z9WNQW8kwJ9SrXxW5xw4eMhSsJoERN7PPL_C58TSanp9VLckEI9p7_YdMOpuFHkwZrR03sOwwv-d498Z5j3mEeLDPRJPjHYDXCu9a9ozajCtuZv7KrsoSAGAcUw7lU0oiXAty3tjxdmW5OzecowaDrGryqqZdmqyGMrrwfGqFd_-gAW2T_S5TRcCsogKqUxUkkooNydtTy8AotO3xP58FgwIGESAjp3bopqtDkvCgmCQxn5QFzLH08-9424nWRKLWLeb\n",
      "Iovance Biotherapeutics to Host Fourth Quarter and Full-Year 2023 Financial Results Conference Call and Webcast on Wednesday, February 28, 2024 https://finance.yahoo.com/news/iovance-biotherapeutics-host-fourth-quarter-134500649.html\n",
      "13 Best Short Squeeze Stocks To Buy Now https://finance.yahoo.com/news/13-best-short-squeeze-stocks-090055208.html\n",
      "Independent Director of Iovance Biotherapeutics Picks Up 22% More Stock https://finance.yahoo.com/news/independent-director-iovance-biotherapeutics-picks-193802923.html\n",
      "Iovance Biotherapeutics Stock Rockets 30% Higher https://finance.yahoo.com/m/5b11510e-abd7-3388-b423-c0c5b9f5e74e/iovance-biotherapeutics-stock.html\n",
      "Is Retiring With a $500k+ Portfolio Realistic? https://a.beap.gemini.yahoo.com/mbclk?bv=3.0.0&es=AQAAABQI1AxcqS5MIDkDgMvuyTG-YPgqnk-CUEtZO01adchNKfVNARPbMh0K3x34l7MZI-P8fiCohkaHm6_MH45rxCiHXujL_MtMMsZz4o823sdhtGOAQycHKgltzkjtYU6ENUkrs-QLjYUVxgbWbCriKwr1o9lBJ8tqgM246ueW_7NWYSHt0pqdjiPt74Fa8eu0UkN8xajbreaciUv9WHBx_t8OhUzknk6-LBwe0zBUmCernoQEYh6rzjB1ZdSIX9R-g-yk5fQ6Wda_IX77kwzYPkJpYyzTobPqM9-qhlz4kUXyrsf9pvmmYsBv5sWPxgWH3vPiAtQ6voeofW8b82tyRcR9fgE4DRpz3rJtWay55iMRCtx-IqfipqrlSaz1ZMWPVBx3gSm_vnTHT1QoTSmkjrl3p1GDoucAgcu1r2SevZic8CY2Y7umIzB3SrxJorkB20EoCMAR1EEnHT7NfDruDxRbOSoLh8Rcb40rL6_3sNOpLAZW4bmAlUvXr6hL92gTTdZ-WHt-_i2zxv59RA97eR5DGYTq8cGRsIYy2P94vaA7OVt10JUccwSLuVPJ_5bqALMguTphwVB9bCWZbP8deFqP60FXt7Mz5YWeYj0Yw7NrKOVoPpe1zPQocXB5TuEsEdAZFWQEanhf0yA1STLovvij5nhVU8MGYWIffjhregM_nHV5DpxcUfRDv7fCFSNY0eTgZpaVZ1_QlWfGpot_6AC8LJ7Sd7qhCBZJLWHRigghYr_inECVPvgxV5-u-_J-fvam6o8YtkZKSc0QMB6-O0w1_IocRfcNR96zKCn7TnxOJxzEQylMn5EykainvPqI6FcfCsQdckpyfq_HwLQ0PCwRkxOGxmVVnJHMPxyidQcJ-8N2Ip16DRTxc8awJgdCBEfphdZXxwVqA6sKqwjNPnL_2rwIwIsZPi1ni7DSR2XU70C8jP-_ta1cSUe2GvHON6njnsrnHcO3YGCEupNvMY4jEXoehurvJsF65F3EEf6hBh-GzGxJXRB3bWidzEFIyLEWfMuQJ3xPvDL3dANX_zLnCx-yI2I00h2ixvbuYoA90jFYtx9aYEYj3RS3Itf0RY7s78WIgEjtnRQslfECTKUtNZSW4KO21Po5N8Fs5iMZXJ75Oy_zqsY-fhg70T_4ogX97wLHvh9hXWwHSIpSEl8NkU5wd3qax3dlWevMeUobWTO3PYeOE-b4XC6syIxigYqkvg6sHkTPtO7H_-O9YN5sNMqNqUrCp9eCwEOKua68UjENp3wf0wm3x_9_Qx_wWKIwpkENv-KKIHI6t1eqG87IOPb6vBbC1MyEgaEbI8mUGH9NOD7VM_QNxOM8iQFTDAaQkV5S270Sh1dW9TL3X35OW1WhQdn1gHdqEJtt1z1s3m6cEH5pO0AWyve_Ek_4bHgR7DEhoaWAwk4j5w2pN5P7OXbrY5jKJ--iOPZp66lUnun9207qKw_y87h5XoZZglO3mIG_WhLUh5gXbnzdwaKmtUgy3SiHtEK9aV-Z79IbyyoKOoBKDQT0QWucrnIDNaLE0KO2_VhbVeFVhan4c1VKA8dk0ZNptJKNG_XG993ZrNVu_G06wReiBSxeoWGwiLKV5SjbmtQWCO3GzKyY30QN9GxaxSrGb9jKTUNH4EiK5zAQgDHPe4XPShi0GX7Bssej0izBvpuQozJ51SObr3bNuOet5MZs6J56C1wRaEUM3hIZF0sXYzghWGniYcxoZO7iIHN6Yg0RCjptKQ1oAQwtXXKXQktV59qUD2P7zpYJ36yO-luz_9W61hfwBG_KAwnIptX-cEMGioDqdI5ar_zlwbpzjtOP7TcyE5nQhaiix0Vme8JtMpauFXrHnMiFvCuFpYoYAdLIrgYCPZr1WpXA8pDNvw0CF43UEQVXh47uVib_efZwevotwqS-BBowHq2ZaDLKsD969UWqBHwZIYbeafhG9I0d2u3vlyIfn29GIBYsab0yhuGDgsN7iEwoMKmPzSkv75ONENUDn4EG-VDypJF-IH_9D883X63doA8jXxTxDZYSP1LX2sBzOyX2FNy5ELPXBXReDoHyS6YTU6-BBQKPrbxxTmQA4PDtHCo9_D-SQk2_8M3ujrY_Y7HGjznucT9Lbd2qgilaBBQIvhz2VhHb4CQXTmmvnsDJA7R8iPFZKJ_EU31qVszgWZ3VQK-Y8-JRwoOZAjud4gERowdTWufOPnslzuzTJtBYO4atIRDr0lCtGPDtvl2qfHAiWnsGQLmyQZKcW1r88hpf12ImYUhufjgbKFXc71zrG61OFPCzqRNCyW4Czss3ka0YPBVuVv-na9XoUK1IuafYOdi1tlIwZYaU5nch46eDoPc5--UhndeJ7QRTBz-hWMObpV75W0DbS-_7kLEVivMJcsoIP6BnL_6aee4y_2kDXAM4oeTRGdAEY2grJx3x2J9gDjduahCHY86eIz2704RQuw7DwuPIGDYEnMV6j5q1F0bQG7LP8llOfN4xqtmX2V5IX_QnnQ7vdI7zTzoCdNQJQM07a1f_cXD3T8rVtJo6DBkcka-LE1cYlOHk0jxD8GTlzayY_DBU1Rrf7VMxRD4lMqWg5eRLjxuB0BahBIdK143zCGs6Cwa-koBAo0oWkJsc9rA7P_wZBNKXc2wscdbnGr2v8I2de7jJ7YnhcaCEzaVWd1BLx4CMQuGoHIl28FHU4v90vDvSKEMfhXQ2nDw4ilF5wqLvBb-GKauEWF1xWDUWJEO3x8bmOB47UnRshPY5vhb8OrbVXiGfxIf5K3MgJFUwKO9HTOWURYGfuhtgWB8n8ESHl6YWjMLjO6EDlvMSHkNV6YcUBmTdFRgvnDETIk8ysOewbOMCLcba69nz0suU8wQZ5RcYv2-58uQYeNCmZT1WPnlXklE1F7esf8_MSJYuE7uObLoS6zgZx6ECfBQfaoeFgtbOwAtVBGeUIbnANkNQLFOxEUgA-0V18tot0F1_Wj5DmF4kKNyzBJ2f--z_ZWEIkiIc3vIUIoGzgschHc7RkEkQlzR666YzrAEkCUePxYKht84PhmTmCKk6WoAGEXQmTfO52SQCpwJOPhnqf7AWbg4lKbcFL_rDuriFql5KBBTPaBpaVGASqb77-WBt8LeXH3hrhAGwppae_w3L2_xuq9HqOIlD6XLjGVYzPsFCYH_ZJ54qVEzWEay-mecw1PhIaEasbemoEr5m3bneu5PYULPVpIxzhFBLaaqyAmvKXZHCzlJbqoP0np62nAG46pejB9b4wLazjgbdEmcToTyjJD6wrieZAxwnlboNOopgIz3rHpmo_-sHFupVqub8Tn8AY7sIY3_I2gbfjcWhK4rXBjAlaIxW_QZEHwyZJtgmmBcdtNST82-Hk7SFHCs0vlbP61NcboyJ5lCJKwF2DsiLzPZlGXpymgDRSXSRvkMz9d0MTe-NgS_kPiJR\n",
      "Why Iovance Biotherapeutics Stock Is Skyrocketing Today https://finance.yahoo.com/news/why-iovance-biotherapeutics-stock-skyrocketing-160233478.html\n",
      "Iovance Biotherapeutics, Inc. Announces Pricing of $211 Million Underwritten Offering of Common Stock https://finance.yahoo.com/news/iovance-biotherapeutics-inc-announces-pricing-113000900.html\n",
      "Iovance (IOVA) Stock Rises on FDA Nod for Melanoma Drug Amtagvi https://finance.yahoo.com/news/iovance-iova-stock-rises-fda-133600713.html\n",
      "UPDATE 3-US FDA grants accelerated approval for Iovance's skin cancer cell therapy https://finance.yahoo.com/news/1-us-fda-grants-accelerated-210427321.html\n",
      "Iovance Biotherapeutics to Host Conference Call and Webcast on Friday, February 16, 2024 https://finance.yahoo.com/news/iovance-biotherapeutics-host-conference-call-203800736.html\n",
      "Iovance’s AMTAGVI™ (lifileucel) Receives U.S. FDA Accelerated Approval for Advanced Melanoma https://finance.yahoo.com/news/iovance-amtagvi-lifileucel-receives-u-201900117.html\n",
      "3 Opportunities for Iovance Biotherapeutics Stock, and 1 Risk https://finance.yahoo.com/news/3-opportunities-iovance-biotherapeutics-stock-121400009.html\n",
      "Is Iovance Biotherapeutics a Buy Before This Key FDA Decision? https://finance.yahoo.com/news/iovance-biotherapeutics-buy-key-fda-101000466.html\n",
      "Dexcom G7®: Easy to apply, easy to set up, and easy to use https://a.beap.gemini.yahoo.com/mbclk?bv=3.0.0&es=AQAAACt6dtjlFr8o-qo2oK033WFN2GQxIarnBe2eJ1c1coQHDYcrW8kstVa3Nv_uZRtrlzDM_AlCy7bPGowq4RdnsxWsPkdMA-05PaE8FTjSmz7Nw5pfzHCChAfKjnviEpccLjSuCVB2XMf4w4vkEg5ukXA6Hikl6H7unH7jygqUmvm3KAHnz1x4PS1OrjyIIB-j3O-bTFduW1iFQvVxXiyq4bhxgzinSXUXhtjJKOaA_3yCZ0Vp6odgU_Q6BEF0VbCQ6ZOCYMOMj9kyw55lTGGRnmlk5a90aKwP38DUCgeG8Qx5Ew56y2Z07Lnh08gCMb7oXtFPZ4sz1i_L8QQ__NfK1XDMUvysIQqr1wdlzAEFdcMU_v37dQqvNKTdp0YRDOxGo0DJVjOhC_9W6cfoFdm1gOpb6nqVc2OAzb2toyu3r52JWnoR5mkVDgnr8jLZjky62hkWZeZEY8jmYZBRPF4dXe5Gzngb-tpnzdrpZSkqBT7HwtjX8t-4hzpQ2bzvlaWTi59rBcX9H3Fb6JhTV6G--yJTV3B7WR9whZXJj9HUSaLm_BsP_nUI9SFacr9fTNGwUA7jSvCXm5GtKnqDRN9nB0x0SNI1aZ3zu8QXEBz2GG99LmeoWz52oiOrNTp4oLJx17m6puT7VgpZdnJeJjQoHCvxez-okN9c_II-vzfghehHM0l6j5fh8PCiR6PtPd58qONex3hbfSj7ywLimYGz6-c3wZrp39YxQIX_Ad1gu4EjOysz60OO7JizLpcP9rZCHrBK2icPENkq_euZVHHz82UiDQMTrIbs7g6ZH5NNK0s4eBg0rLbizp0y191A61qpa7Uo_UMPt2SYnmnd1t9GkxyMNNC6NJTQskZVD6FWQWmaN5m0_nYsQmdzZUC06kENQNOaTpy1WroY5X8Ko-VANzqDt8yp6liVrl7h9-Uy8LBhRtIska7s0AwaZBI67Aauevg6CQk5f8QyJTzDqt5ufvfcyXsDbfUrHo4H7oAl1OOsrI_DEkcVtcD8rj__cVILnZo0hacXA8U_ShUcw_xQkK9BGcskidjYvi52dy7OGDrfnRMJcaYkRQf85OoMXWFgrlniQ7gFP79sjOr2AiHBFkH5bd8TN8U3pIK2hMtPyHQH-rWOGC4GcJ57AZnPKawMBJjQ3D5SpLPy2BUS2L1JUrFdrj4vLNz_rO6huxoJFq8mF04OcGJgn7kr_3luUzTS8ciwtv_s-wLvMniJWFAz4Lb19YK1P6B2zfMBHwm_bSU4kVuajij_09eNW3PCIT3I8xvc9GKLxhYvT6GZ7fKZrjYFDHjSf9fwXbJPzZp3zL1FC8yTRyCT0zwzjUT-5gNLRMtvuo0SVbgepb_CflDmxf-el8gTEm_ax32Azxa66lFHOEtYxyXS1BEcsXGKlnQczAe1wBpt6D-pHcnS4pR1gz8xz-DGUQ_E9kZeEGISz4ihXlbkkbxBf6uE5wltiYVP3M9pfcLVhMinzQJySJNWs7Z634AB4ECZ6brint48TKHoq1TxgDVilAUqabCbVfxK0nkPGpeMC1stiv9E67lQy5y7ayROChAf_pSaGV1UwU3YGjnSJdHMR71gcdQ4nF_T0Hi_QANHuEOsErDB0DXLZ106c9XdLEjvA0h41EUTWrGJS6R4SoYJCKgoYfN29nZheuFEMCq7asv09nHdTV-XXO6ABL2xYECxD6wR4fY7D4xJUoHQn-tKEUNT9bpih6Qa5XeKeVHsSrDFDEuwiq50yQ3wjmk4h7fx3B_DWQIySFv87y2zE7DttRZ2olitIzI-OJLKW6N7GhBv_3F5vDyM6ofZqquXG1KgUl8cb85YzcFukdTCrn0zIz9ICG4G6yM1xbRHOA-5B_6pIMJp4FxxzBgVb7U2CMTscv09lUoRwN4ZdW9UT2ORUSvXjLO6-va3jJXAbUtYcdC-O-7z2Mwp_gQ3zsaShf54m_8LJt9APwy_vhVRwi4gHAinGldtM-ZZXwVh2i7HCpoIQECt2ssZP769pZ6tuEk2WxS5IYOy9RzZsR1w2bO5LA1mXF1JYD_3UzZULbkmdPEn8EHIakNOIuHzPpXSTo5--UWfGB5m9_QnxFtBeY8j0cwmH4Ifci5ca6CdzLRUUPxaTjzGwNsgI41tchpenDR9k6F0W_s02Q32tebpmaK7ETxOJffYXt4cj5bqWDIUYahHlzZefgUDoMrZ0XqWie6j4Hxle5_2k3jtW2_SwUye-J3QhwdwdJsqVUCg25PWDZoFgZiv4PKMBX7F0buVqMGEqA54wT_DcGWRDW5LPB_RVrjIbgE5J0CSm4a-PnX2-IIEZHE8WQspomcQMRdExMX9dMfrgGbIcHeOx4P-5kYlc7LUVKhySQlTue_7LMdfNFLuwasSgPiCtgTuzPjLs2soIYQqC4QuD44tKYi4o_E5BOmPb8xZ3HKWrbHhoMfYoZRpZQT4B8a9B9KWymMy49uas_bNSO4WYoOAQKRy4dqApIdFGk9k-U98TE7rAkxfjZqrjZghmhDvll8l3fxalSflBCGvafG01d1UysHK7Mimh44b9bpKGpWrcpVOFUFMteT2LzQHg5cbxu70eP9jAw0x0LdRRWh4o26Hi_eljBHfnZEg9kvsxZkWojkKc1--AAxNaYPChDF8NYg52Z83jXqA9sqVlgi7M8FzXTUuPNyhyKlJOzVmfgdXaQVHMy28ReSgDeH9JjGpZ2mYkAXR6QtRqJAhfgnKJBkE0Pqs-IO2eWchNwZq0ft4WdlhCV9enJy-CNf9hpdD0o0RtxM_dopMOocA_JATemeAclzIrBLLvePLj4HjlEUSsK30smfCsIUqxbJDPQdWuIgBwlbnY4yICBGxM1wg1u-6lesVFp6_P7kahFBupXwNVAn46VOzCiltjv8nCa1fZ1Tqq-qS5jMhqf51vVA1WspNxiRz9TDR3bO06nsPq-iz5UtP9_ArBp-c6HGXp6wfzAMJxubTub_5GtpLnceBAxKr1pIjWsjSMuw_oFlNfO0k_tYuQQydFYtEdYeMj2lASWAQUC8ElNtw3SUzUp3vSgZ92EvASMphP-c4qEXWm-QV-dXy9bk35RmppO-dv6k9dO_hyE3bY_L-QsjO0QhwoSF6tW0zYAqlEAETWY-flogzmxbW4-WkyQDKkYZrmjk82k6bO80ICCgJaoMFjLAkC6hQnst4zqkQIECRwrHDB7-UzS-gRXIyrTRo\n",
      "A Bull Market Is Here: 2 Top Growth Stocks to Buy Hand Over Fist https://finance.yahoo.com/news/bull-market-2-top-growth-102500100.html\n",
      "What's Next for Iovance Biotherapeutics Stock? https://finance.yahoo.com/news/whats-next-iovance-biotherapeutics-stock-112700743.html\n",
      "Iovance (IOVA) Surges More Than 150% in 3 Months: Here's Why https://finance.yahoo.com/news/iovance-iova-surges-more-150-172700202.html\n",
      "Zacks.com featured highlights Universal Stainless & Alloy, Lakeland, NGL Energy and Iovance https://finance.yahoo.com/news/zacks-com-featured-highlights-universal-101000910.html\n",
      "Texas Launches New Policy For Cars Used Less Than 50... https://a.beap.gemini.yahoo.com/mbclk?bv=3.0.0&es=AQAAALhgh7As4HwKatXx21oiYgas6qR1uqId3mg7sWb9nz5afsV7PyDp8IL7BjT8ahrQg73NiXuyG0Kna4ARzpk2tJ4e8T_U1frTT5abUIlFGsOZk8ngddJNN0o5TqLTOP4knwehau-3R394YRuMLX_K3nkBSJdpJt8r7XHA8e7kjuTlNjoojTSeJYi_1_gkb35PcbnAvv7-kcW8L1fWII_dCjyVNmd-ICgBE-fggohhlIevOViTcEK9ZocSeBWRqK0nXvjj1n7JOP7B78SwxLuZbMYyPRGqZQacMwTNe4bjZVT6vARA0CciFXGajW71bXeSNIAhhgzwdrY6toCTaf6DenkT4o8SgEKpXvm4NcMlPNiRmWvTW0XyH432hF8NIRaLGMC9B1_fVOvj4VLv6BBB_fGbObRlXA8QSe63ViBbsScjIpkBzEBq5bUn5JT2rVt89O4oPwmNeK48_9mRY1WXSnaji8QIHWqB6zDV6STJDQRWKXUnNmlallAK2GUweqpGbRkl9Km1gGWnxzVIIcdG1SaIhwLiGlJB3HreoMlHMbYsFePXqa43KbKCehhn23qDFqaiFU-dGnWz2FLNGJTDCUFkBv5Y7VItzwsVC3KTp8Vh4va_PmS0JyxeXlfY7517tGE_phgbdp5saoJ5HFylj9eSqOhXRKuhaIcmDxNEb_JusHVhMTkjnDl9r65Okk4T0rvUbKcIWa01rRSFFu3KvG5Zd9N9RCXHCGGdOLH7RLH2e8zGRRcWI7KL6Wfy-ZywpLGRE1Qpwze2IG-SS79HfCe4UUFjfnLNbjnN2a7WL9d0cV6rcDKgCD-CHEJ-kZaAwG2xaeDI-emhB4si0Wm8eVVrIfS62ho9Ngs0uFeUk6wPjgl5W-a46t2_4ANCmCSXlWztt9GQ26oTZo7asGJHo-yWzeCoYi0x16KXRocr9WE4FUuNJUxhAGrf4s1H_W651huoVHwtGmRNszHGWD5-htGppCrkrfLSKNGnaCLh-4-fJdS8DvmjchY6SYXu-DqD4MEEzEbGhFf27iQ90UJLVS9FyjZ-N7J8LymNJAPa-rAXpNhnaUFgOteAscxoHTO8oqOa5C5WjbQNwHE6Vl-OITkFKexwhLjo76i42EmiTBmlAfBCyjhzKYmkc4400oVcUGjOZEnH3HkcrS8fUNXKj0YN0doOl8owkFY3mYqXdNZQSIMpbIJHHzkv7uITt5sVCvGscWgUcUlgdYguvrtU7aw-0mhqXXBMVORk63EsSv90OWxwRGyVKmgMWSUu4vK3GNr22I8573sstRNCi1hwP9PnRfkKQHw50Du-aTEP8wKCyJEneOse4zn_WEWmAzU9T1jOpukfjCryYAz9VnikQXSqxD2KS23vamxSf4g0D1vGfXIC47L6jDsvmNYCuERR8s0pE6ntnmYZrhGjEDXQAaRGPLw0C7l8qcCd7Pk0F6cOCC8hgb3QpIDygcTonMlkeDx4qiOF9vvlNbbaiAw1vLnnyZ3Ws38dih5NrIW_XFP8zGcst1jR6ZClxwjV7Qnw1a1SkNK40BZd0ee0IYy84EcxPPVGqZIMQV3DybCNWjj3q3qygXlgNYg3uyPf224qx-QROPoy2JeOSE94RhtMPAr5aMF0w-rcWRINdjOruirc-05uBaCZfX0gKDhzcLiUWu-VVMEWXvrzjlZ89U7KfJ8LrOsUJ6zh0N2V-CPhk8QmGgvc5c26pIf-pac1b-EIIjJVbHEq25h903n2zJ1_WxKYMMAha5z4McHU3WW5Sx9LNAx2hhZ_P3lHnYhzz9Cmn0y31eLVACHaAhySECV_9BakgMeA-b8FqMcDOhTEfLeJrVmVSnZwZO9wOJqKDExL9O0Jci48XMl0-uUnFNv5_GnjtNQuEHxVFevwGlRwCl9AqcVhz6xNN_GCp6hX8KAhOh10PGKWoE7f58Ge4bkBgqfOwDC085uupFmLbgh0AditWPciGNnhCQsSW3VhMfkgJV_hTEXNVQXab6kgGw8IIUSecUgjk3g0YhbE9drsb9VwhRUsz07uL5n8HD1ldtV6e0pFcxFu83g70iHuhB7XwdB5B1jFqh6CA_g3UT6wPe9Kig0LWlWaIVZwWN2c8QzhSyR7q326NBLfPeJdIT3PTHvvqMDGNHPPd4CQlAoyXVLQlzaH3CHD8e1QqBF_R2LGUvFRlNeZZXo0YySJ53_Cjw58DdGnQSmGzX2_ngXZiQICnDiU3yAZOdh1PEhRp8Yfhj6JIkL4GRqx9ue3ftf8xRmJhZrffI5Nj4Pnbd9k9OyKXTw_yCw3_PxLn5yAueAjMgBp1nFaWY8kmj9vtSWxL597qTRCjYzAgLzqfGUSR0qt_QFXfS7EeZaXXlXHtI3YfthSgWzR4tX-Mg4r9fOgTHY3URmrVCWMUMsryIbdEo-uH1_uz3cBH7Wt61bQPSlDZO0BVP8UtMz-dzNq9xjpAzqCXY0ziisMqg-lK6RrWtDoGEyU-3at7K_auJsgKEeFTNTxCXLci2nT0hNQewNG6smhF041sDkfu0lIcY3TP7H-9_cmzAwhEOFM8IbxmnBsiK0q-Z1GQ4862mgsoguCecC_fpwVFlFyMwr22_5RvyGgBMOIxRm-AsXy66PEPLOSP5a0WX42ILPWEd-LTFm8gwKPssSRpb_oxbCWif6iYrR1bh7GOgbN3qoyrpBYQaYvSYAmohy2cYVyW7_oMshQY5jZW5fpAO4ixn4Ts0J0HBWxjTiONh7oxWXM9PUYmIQ36dDp6N7pYi5t2HWXErde438MhhF72Qfz8KHYFBHhChu8V_5QnmjjMLjHNm9DuKR13VeCSV_DNRl3921BTubTxEaEZSCwWqSbqWLRm2X1dlBi52OnHiWoxjGix-RbsFRPyv2aU5RNZ6-tZF3J7O6KB7otQjlI4m9QhPazddMEZvOIgqRa_N-W_zp3QipnhT3dQvEzXwk-yLmrkK_Ou07J4l4yGCbuVLWhJqr1NWyP5OAARpEGHtxOUofJZUheT08b7T3E4RTjU3ZayyfpJrIynFmY7bJfbyMB87niMChJZ6Dc9AGon3pAytLl8hkvppEHvafXjp2Rwo3QxYl6L4e9mohuDAfR2JfkvQ_SuMfXipnqudd9EpYmbqhQ_jlT-Spoer-v2DWo6NnkL7ntov02sbV8coL-fDnkNRtNpzYyVLp7ANzK3uw5QyGAcRHNa5kDTCJ8uQPkd6c7ggzkLlxr1N_CtvY_-JhHtmgk2mOGvnFtp34cryDOmz-iNnoSODqbe8sizHMMAroYngqd86z0dtlWc5QwNayPfVJaJ7zVbFNnyUa0NxhX5nE_DfOc_uQdQjdMXhJZdyIm9EpGfFHJII8lWI_yW5_ro-6qYZ69V43DsChyENDVhEoPQOUjDSCh5RCZ51yEPI06eNBAuQm3AkJJBAn0URDeasA2gBS473h7NmDcue0qHksN-FK_3YPlxubyLn-QN8HoKVb_1we6yfEohuoOLHrPUM2z3keEqSYaYE3iv75Ysp-RyhNVT9dvEORk-dB0fDRGNsk\n",
      "4 Best Breakout Stocks to Buy for Stellar Returns https://finance.yahoo.com/news/4-best-breakout-stocks-buy-110500511.html\n",
      "2 Growth Stocks That Could Rocket 149% to 210% Higher in 2024, According to Wall Street https://finance.yahoo.com/news/2-growth-stocks-could-rocket-103100363.html\n",
      "Why Iovance Biotherapeutics Stock Popped Today https://finance.yahoo.com/news/why-iovance-biotherapeutics-stock-popped-225900430.html\n",
      "Iovance (IOVA) Falls After Clinical Update on Lung Cancer Drug https://finance.yahoo.com/news/iovance-iova-falls-clinical-lung-161300621.html\n",
      "7 Ways to Retire Comfortably With $500k https://a.beap.gemini.yahoo.com/mbclk?bv=3.0.0&es=AQAAAIudwKKC7-H9ghby9vTQbRmUNrNRTVa5yuw5LL9FGvB2ZDubpoyIVqICc7IlsD3RqH6V6AED0iK40RZd1C6sa4hx4X9zXsHvcGLrVDjiQtX2Wg_NjOc-7mF6Y8E6kl0ROZZDS8bfj4pN6Nk2fPuFkXY9zlQPnqBJlwM72BwEiG5JAHieiFGiPdfxC1VyyoagxRpT1VLtClBnFyEeaME7Jt5iiLKcHBp-W__BFRJsnf0wJtmyey_pGtNDu5Mr56mmO9Y08kFynkh_Xoa6KsZUF1UGlic3aJ9cmmRMBllPZu84tquKMaXRiWR4nEF0ANlDxx_zk6aNc8pTewkQKGIL8CiuLswnw6Oz5IH684T8k4qA9GACwRFGEqwKQBsnGtyh1H524XwcS8r-1Hn4mPdQlnBaI_sV5KJj688W71mQBnx8FA2jle1dZZUahW_P6R7HJ6Q1tqiLpLzd-uPK9wRs378dtCsAV00FmC9VHyKi0dJXX05r3QLbpDMVHe3r-R0s5yjAUxVTTEIcE8pc-_bhlj8aFEt4oNBiEwKc3Qg0hrVvh552N9ZMlcxGKVmCScfhryVKce8rhKsmQGOVry2IypAUc2LCabBdJUlOe_ly9W0UY0F7R2fQ_yVJlkvqg75rOORW1xK2VB6hq3adBWKWRtrzcgdF029R9SanVu7HDSsvCe1y6TF1xv92e_oKnkXRXS5aSa7GmAIb8Qqpa2y0xFlKUuZix48YfCc3gNniINR7etgGEJmHGi4Z8JlTdbyVpPwzNv9qMXMn6EsOagqIEYhUiHiIOC-regZfB0rMxFsrjgiPO2JliWAMK2teZFW2tDeceu7Mje9wBDkdtS3AScJIzorSmiWvjeaU050R4N8D6gKrJIlcDRv0kc7oPV8BmnC23KLTUYi2TZFu0TQtr6OgiwbtpPJqPLw2QaG4cXqtRDdN8tY_cH5GW1Aee9618c3w6DKHcnt1-IvMtPSJb_kgR4gppe382ydO5gt1EBbdWL8w4IfeZawSgwd8wQsrKt4slAPpMf942Nzg6uQ3KEjn5_E9A72CnceNBhsGDE2iMIUHqssWvl14ICEulc7IP7rl4MMbTQdAyHETFXsbN9xXkJfzng7ZTDx6JmjYpI3iq_9BxPPFZSH6zDe20oIfup0Sn-p3aDkX4oyB7mb0kYH8OOHQqGX9UqQvncuFx8JdPrvnT8wii-yEwXm05xpqFQ15oIKQFTgPt-hIgg1g2lCjxqHWT3MnA-5tIgcgohdRoqeZwmLymyE0QYRVlLZnY6qXSc5Wh16icPkpTMIzzdhpO_Jzx6IFl9sXRCpic_-LnmVnqjjVeRpAEesC9SB7-k99dxgXc2qZTmR5kTiTOPCXBorzXune2mtl-wYAmHro7quyF2VG2ZqDgCIctA2fMaOd83BrlasqMBJj8okMkKCMeUrFU4MmSJgfSjpEEMN9E9O-RC_YvZlKGNJ0k1TTTKe7BojUiJRRb59pUcDC_6dy-gBv56BbB4PfzKCotDKmoqJNar2hNi-9e4CKgd0Db7UKzUzw2WDmTbnk3dq2gWkZKBoqTOpWb_aSWJjUg4MFqKnfV_SKjqxtqnbm789nK6uk9qOTyT7zDvVt3KVaApkkY5ai6ERkkuwf-b1qSL8YHD4YKqSQcNIieD98PyPEPOFIlRhS6oNGDLNY3p_WjODkqfMEx0kfBFFkJ5RU3iuA8xbSV3d0ysm7ejdvIRayZ828MzXvHLZAvWifVgFlrzrOtb0GHPcFzxUANtDoMC-E7b_3qqrawtYjUVu7j9ZWEZx-VbCrTix3rrPZnfg_7Log893Vbx7GrI-gRFaxUu-gswLYEa1dj1_-lXbRJNLcq5q6q5akYaZdJGBxKzWaepWIBo39ft1OKKmcPSl7UVy4j6BbN1i_3kvmhbX-RDgsLwyknpHZh4DSY8Ivpf7pnwMdS85o4pU5Vm1ZtUu3EEdeR7jAKGSHZY0FH-TQ_UVwL3q3yQK3JEeWQ6SyoG7Rslp_NvwjHVM0iQd1WGhcyDXWVG6gFVmFl9ebCx_wqqLjpu4UCh7LKAydFiLb24tWMUAADO1TpRxbIrzd5lg58IWO14PAicawdFgfVZZ2_ol_E3sSwPX4sylK8EuxW7nHIp2F-ldUAi8VwdCzLCKwbgrhXh-JRSy9cCj487mbUzEPpYfzwd9jzRDFcpXdRaHbELCfp6cwUv1BLlEyzBVRweiA7L6P8kY9tawPaeys4gyDwd5Qyrl4aIv8m-BQhuf8_V-ApdvPT5KmjMR_gYuqFOUXKyJokNVAS6cXxX-vPZkdJtuQzz5lUG21uGxU0wPjlwjr3V3g8pMarReCPxTdrnOgczry_KWcviG3EL6fRcsGqwtAPcfUTNzoNjT7PikzThnFb4IRx0BaznA9p3Kd2pHZBIpl6-w7r17H-ZSIaRpqFFms0Drn8RYAUrQ_maxdVMFVWg_dbPl-L51ub6yCGHzjQwwYXmpBhPcMfV5Dd7M8BpVmUNcgq0tJDS70ne7DEqT1tiTLJuIuuxqbS7k-ETwqHQ0bYX7bebQY0GjtUY6o6qQtTaBro4PX8SPbYsfgAHa1lusONmof3nqjyS7umljOJXKSHKUB3-D5MYJYVptKnS3JmVCdsUICgkYLq1nkzIVP2i3yEh5bucYnJlihu7ny8ygkbEdcVGVajp3nZCi6G7t-VIeckO2aOWXm8XpAbQRSAoKe7o-2Tnt3sF8zNNqJVXg1giURgeT1WFCmfrTZie2-KzWsTUN6QUNXhes7QqjldAfF50MLe9nHoZ6Qq5YPs2Quuq_ZHm9Qy4YySqh-IYsvy47msv9ZCIjzClOcM2TrwLmfxbgaHBbQMZMCwR6IjjL9fLtNlblzikswf9QvmuCk21gBnkXJRfB-EUzvT4Ds6qmM9ZfJS3r-5JsX3IZHVRAZKC7ZRJ7lpnItNt-mQs4zFGQl2UHA3_Ficif9kd0gxUVAFD1-W_iHAHQ-karFt08MSs62nVV8lLFOD1Obx1UYGfg0_JNEL4alK5yhQ57lsMyMZRQouBpZVvdizz-97y3zzsA2K2sXhvS8zRpE3d7E-v_ueRkzJFxAt0CQXlEyN1_ksdMWc8sGueZDbrMlkcD-q0fv6TKit8ahY_r55q5cg8TD32ZHgcBZ2fqFistkCMURH-CV0DdQpPl8Ryc6swwDJFe0KLXNmYsywcdOs0hXikn7GlduJ9paTOHC3GAAj1ovQ2DPxU3kSvCb1GvKzSvF5ahpqzhQE3ZCzwy-7WyC2kBNNCc1G2mStHLFjKV0cavq8jU7BOO1OMKHjQFt69Ic7M2mR_VxwF-SVAs1oCmdBR9IYfJgDbJD\n",
      "Gold nears $2100, biotech stocks on the move: Trending tickers https://finance.yahoo.com/video/gold-nears-2100-biotech-stocks-222638608.html\n",
      "FDA Slaps Clinical Hold On Iovance Biotherapeutics' Lung Cancer Study After Patient Death https://finance.yahoo.com/news/fda-slaps-clinical-hold-iovance-172113146.html\n",
      "Iovance Biotherapeutics Announces Clinical Program Update for LN-145 in Non-Small Cell Lung Cancer https://finance.yahoo.com/news/iovance-biotherapeutics-announces-clinical-program-120000403.html\n",
      "12 Most Promising Cancer Stocks According to Analysts https://finance.yahoo.com/news/12-most-promising-cancer-stocks-195805509.html\n",
      "A card so good, our experts signed up personally https://a.beap.gemini.yahoo.com/mbclk?bv=3.0.0&es=AQAAAOdCNQv5fJ7uvGWdKBasBuXYwhmVrPmajQZnlz4ueZ1KubrFSIaLeyGXAxLSpaads2puhIAAuTr05-v5-ntGWx7SvyYDZfCob3sJxkGD5Whr-_FBd6JWUbIcoBVxR5md8nWT-lDDBWBYXuLkLUAmKTN18vEoG5W-1jXwt20V7u2ECBB6vwcRtFDxpnu5FiApKqFU3h9XDIi-HyK3tdUY8Dj6mWnAuqVdvekHhT_40JfRtr3vYSm0GxhUukgsfkvFkOVIxq2ob0VItERmLwuZqZqvSsX3yaTq93Gs3bLwx5j-CRgYMX1Uqsv0A-NLaAe_OHFM6Yjc4cCIMLaHNf95tG1oxOEvmuMB5OXwxJoiaQakURwOJ_umxoZRrwKPTk8tOJo1XR81foq2eaxNFDxMYmqJbE9bvpztUymgwn3WV7Evi9A6OTdAEMVnkXYhahPPJF9BMT4ClNnkZtToL7Dko8fe0D9f0tqUsjzCHDgStEXf6Sf7los_1X2O2hi_8Hq5MZhwT-BvLHLEcVBQyc1qpypIt1LucbhVoC34qql2lHR2CA__SDYN-tHbohCxojQ2YyrxS6IZ7jak4hWZRKvfHGsSnWHYL3aQYZRukRLfOdBegGdAEK1dBsxlP9-Nsu5LRTiI0XvxG-_fhdrFp7fgniZrm166Z0--kyZtg8V0wlnKEJVnoh_c6iIfJj1d1xY1Ut2kVhubEnMnbduLSATMRd0r62tm6Tlg1PfMk_Q1XGLqgIHmTzqPRjnuynaTd6oxW753pe5ohch2ScO6DBM03x3nVhHOWhdjb_nkdxbjC-v3oHV-GyvQCzkrvMMTuMIwQ2JHocsihOT7XsUpNTlhPT_8ymME75IsE1Xg9iHDKVGkXtB0dKFuqlqGd_i9Vd8x55PzKce8nMhA0qqbj2iUn2lSU1_fYiH2Dd6LiHjk-MJ8meTSSuVOgzgOY1oZo6mKvacn9xo_DwHgksmoSCfGwkjEny5ao6Yj4UNjHbkLvXbbOXEUjbijQKqkxsywUoeEgYpKYpj7rJ49NKvBRh7M3AfHrIQ7ewKEXljWrT59o8xonWErRL1egElr7YJXivwLRfElYLLYxTXCL-I6ecCPqcsxTC2_KfHxqmCTqJ0K2iYo4tHbKLXyQQktDc3LXoaOEalX_e5JuNZVAL7gDzt8Q9AISduGvm-r4HnH6pWQ61tdZDIxAcTZsna7K9byhV_3SYS4XAoXrPbcFXsa7UuzR-P50ILoxPG2SBaLbVGVfbhzFqqtvXIP54E68M7DkGHJ0wbRd4BqqFfX9bF5E76MKCdjClHxrg7POz3AK6KxPmPUPSgwF8gYIZtnthwVbHTKN-AmqjMQcApTxKrvVKkbG6X5MbtM1_chQOmICl7kSJrtWAC4dtDICoEP4uT78GDCcrgO-j0Xy1ejw7xei1YOnD11HYC-0d45yRS1IbggLvyqZ8jwH2PmyMGCwAVFDM-1ZgMHfSyin8lfli-6-YYyNPZJXC02dtB8yj5Dc57nI5SWldqj1iB3mAIZxungcHIjVlypb5dM7yV_9hTIFfU2nOlX1bY6xjeERDrxieRBe5K0HnemcFU5OgVhhIofo83o4mpCvPFYy6PHEqXOeZB4mD7oOmUs6MF62AINaT7EChKwjJyHK8ybz3g9M0lhn0Vfb00Fj7FZid7sDG8gE5OC4xtOQtmiA5NPyksSJ9yNxGO1Gusli5DpfXKA5m_rse9kW6ZIcR8mQmxu6-b7ge1Cp4BX2vWOI8TPeZuSc094Cuolc6bIl79kYindaoZ8hg7YwmI-pWdRzCdQjOi9w4Ti7gFbWvAMs5oxjHBYzTU_cdmiOOTYvKaACOLoQoUb_aci9P6qNF5E8T7Afstx-ceZWaR5irytq7u_PQhMFO7KJVKpS36fRGver6nHwHuL44dAuMmiF6EsrWqbwuSlcQryUWDa5hH14WuvRV_gs3_v7-yMbhBijXV7JF9NUZc5YbDxz-5acKZB1Nj1hTTYKQmQDdTAA0vmUQkqMkrWDVAtnNwMNXwxIveM9mqbgnfjSpt75voAIgroooEYy5BTMbG9iEeql2gjqBBVCsP37UAffFNnKxP3l4V2qWH98mrGyjsN9JLRKOJythavTogiBrhDGT6HIXzAg-Vu9c8ugce441z6wJH9KUHuCLwfbTdeRi8sGQRSWSGtqeUDP1Yjomt2Jh1ZGlhDlI218jdon7EI1B9rQjebUIk-ES5EMMfhHBK_5ZDkyQ1Q178KNzaZkZln-WN_IUSoAlF88gQkTQEj7kbhk78cW19nnOfkBGWuZkLWcjNC7dCZ2Cd8lwN_wNl9sDxKrzHe6c_SxGgf7oFVk5r2QApuV4ZbUslBJDJ6LLissWlqt7hFjSEXqA7W-7Uc3etOsdu1uuZ5vOvO8b0zPgPBBhV3NgCqtJEDA5rl_3Y8wcd9CDAUT5bPb8h9CA6an08ZIgkxNvmXdIwjZHkFRbjdy4rkNtrVWgFeS0t4pM5FNSJt2G96OAAIQLOCXxVOf7IIgE116RI27c2ivMcQY850aTkXvwKZFvzYJ8ll6iPheHxuxqK1UI68dC-DsKB9tKMSdKla5zA5SzQUowlxIJliNtDQtc-cfcBvghwhEsbPRQ1S0_ogdxS8H4iQdeF2Dr0jYhZtXwQAnMt0-NiPXd8ST3BiRdX4agtwOyN-Vm6ndwVYh5zRcdChzzJnkRJRMHdlsNW5TOvYvTDY7-S3EzGSjYWy0tTj8MrHAvRWFgih2wmHUfa5M9auUdcGXEdBlrJQWSYivDOOWDf3EvlAsBFD1PHVeMVstT0reM7VUtDEojYVd1NHRxkf_tJBsY_jYMCfKrkt8KVQmF18cH77O8FXbB53b450s_f_EFfomS6UMhCYVSR_EznhdPahMBMg7DAsRDZ8bR5thqZNtcWFaVy4c6nRR1NV1VYZJfdqIpT_gmnj8uOvKB6WJz_7gLiLs2nQU5X3j1-aI1RsAiACGQ_VavHJMMIBdMyJc2RF7fHi0o5qape-fWzCyYeHuO2OUAJCdNIKDTBB-tUsZI4XSls9dCKFp1psTH7Uq-qL68cT-HAqmBWg7fCl4hYEvlKiCTQkskY_F-MR1zbrnj-YunsIOwj0PaxxMF1TFIg29ICybar0f-4qYJpwGAirQ2eC7usMRjnMHoOa3d67ZSsbf-eyovcdTgICzlBM8_F6_0XVk4GLf6VQll4pMBxxyCN7TsH-MkohWO9cogDrrI37cLwf2g_4kubHMm7OUlfNQQ82tMF-vNZBI-HoL1SVd4_sVutU324Fs1FFGEqiboj6OdVvAz-V-vEuuq-TQxgovVQ3Oan4VFES9boQG2nKwnkM84tsBHWvcMy1CO37ZA\n",
      "Better Growth Stock: Viking Therapeutics or Iovance Biotherapeutics? https://finance.yahoo.com/news/better-growth-stock-viking-therapeutics-134500443.html\n",
      "A Bull Market Is Coming: 1 Stock That Could Rocket 219% Higher in 2024, According to Wall Street https://finance.yahoo.com/news/bull-market-coming-1-stock-102900994.html\n",
      "Why Is Iovance Biotherapeutics (IOVA) Up 53% Since Last Earnings Report? https://finance.yahoo.com/news/why-iovance-biotherapeutics-iova-53-163102625.html\n",
      "Why Iovance Biotherapeutics Stock Is Jumping Today https://finance.yahoo.com/m/a44a0397-2f28-3111-a420-fcd60aca8990/why-iovance-biotherapeutics.html\n",
      "With 75% ownership, Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) boasts of strong institutional backing https://finance.yahoo.com/news/75-ownership-iovance-biotherapeutics-inc-133208031.html\n",
      "Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q3 2023 Earnings Call Transcript https://finance.yahoo.com/news/iovance-biotherapeutics-inc-nasdaq-iova-220444227.html\n",
      "Why Iovance Biotherapeutics Stock Is Marching Higher Today https://finance.yahoo.com/m/ff60968a-d855-3b0a-afa5-c922e93c849c/why-iovance-biotherapeutics.html\n",
      "Iovance's (IOVA) Meets Q3 Earnings, Lags Sales Estimates https://finance.yahoo.com/news/iovances-iova-meets-q3-earnings-125500859.html\n",
      "FBI and Pentagon consultant: Move your money now https://a.beap.gemini.yahoo.com/mbclk?bv=3.0.0&es=AQAAALLiB5nfQtUIXehfiHjxCMV_F0sftTRwz-ZrLpqkYoSRMpLhB5wLYZj8IzIzXKn2owxGESnCdnHCy9cDIrBbkZ2PSuBD7VmOi5Z19ErD75tOTsuWq6PfEkNttJi_qJyjX3UXstA34Wc2cgnyEcsqo7g1CqaT4yEMV8zOi01nTQ2fMQ_p_V1K8khSqE8IUk-YPGPx4oimldCzJC9mG9gLYfc7DzDfYhGl9IeHhKDMhNlU-Me0AgpC2b7bDlx_NwnojUiSXvPoZgla42Afbmava4DlBRNGzbt2SLPK-o2ZpFAD3IEelMuWZVwci-jIqhvn3sCWNuiHYxsIfK3WSDMzemKDGmwVHgLgy9OXCTmo7KBK-hdbR1XZLJ5WKBos7IBp6VvRVWRs1TEfNv48zCeqwmQqokJlHnl_2XaXVx0Ty92Eaunl4CkPO-BseiHAhgMKWsvNUwEd_0nK7npcVlt7dy4Fi-n68mOQXt7-1kA3jJzBiffTIvtS94hgXjYvGkL12bOhhYZAW-zBPnhc-zVmOe0Bn4DDI7mVayvRZIzjkgmUH7fbl7Smyd8KKtc4MUiJaN48UiHXFwVpHUgbN6PppCnta4MOcHrSsdxmMNAo2uuPpEVy6Rg56TiTiIjArI2MpR-KXr_ldtbWdofwvS2cv2TGn4a7YSVQxPsXYKT2lrA4xuGHXeB04nX7ItvInunMsbwPcIG_y5N_6cIcrfAMt0QQaulEVL_XMCDx8MS9p38qPq-17IqC2Fhiywqwe5dc04ZeToAt85K_8XnbpGQO5ul02biAslwUe3_UZzghzCrZs8fV5MX99h6tsah1DnkOP3xp9lb782MmntkRlaFscdUGobx0XJIdRA26rSGMR47_lIgXLMu1T_22bczbCuEHVhIGibebRF1ehPOzNdouPECliJlpKMbzAjxtAvhuD439P3y4JMzldhcaDuA2s6WicZouuYw4bDREKqxcQ1pCgKQBzcLi2wqAYECFRHyD5gNa6WaU8JfOhBf_WqWbVl7vs_RGYzuyR73S_b8vPrITIrTMNU1ucd_3SW_S5nXV_al-4AUhqbDWQV1LnOzNvtLhP7ND0MRc-IrSJ0a_7vzRcQzh8lA0CNq6frNyRgbSASyJt43nOeZ083bMVLVuys6aa3id9fSfJzz77np5L-TnbqNFzT4IIQC5HQSKs7QKgsxp0KxspVDm2BiOyFyJ6J7z6FshHvfOqUtcTqI-wIwzCB2dXntyvP0FLmMQzDT7lF9Log_trqIqJUxOPGNHZ3bUbj41I4JAAl6MTTYkcGJlZ3BMmoQQMwAv9B2G48_3vsUq4m4zVThbaaqmtYgFOXiTtZ8jXifqY0Y-de2jbIVq72d3-zpzXRORIqCKqW1CvtAjPPK2-DxM3B6hOTerpDYk7Hk40F6wtJiUU_TBkKBST7G3ppA5NaCCsPSga5EF-QzNdqLDCx8b1jolJozsZi5Kg9EU42iAcT4lp_FhAi2M6UGQlpF4ppnh1o3ApZ35cWQ4TzfzKVDhegsX9tUJodcQd19s1ILNCnmqBlLSt8980agXUiEDs_6uWH8iaVI9xO6bz2yFbWvKgnkKGScys1Ieyq-ppQpLQaov24HH54dWGOHckAjvUXgxSrAwW4QwM65m1jjSvJZo-EbW0TpwmA0IjCEyPtpl86gmorAsYjqXxVSzRap-9s6l6YOc__s4hTgAfY_9VHm6i2DaZErEv9A14Kzrh4Y6Y4R6vHqzwFgDuUTxEXA0Jfu-PtkE1aLFtd4L25TAs98WcaBlEmEG0pGwDa9jg41dP-z8gYWNII6iPc6YzUnNm0m7ye_x_mdL5upuZxgL6EuLID_SkTJKxvsUR9cQiS_pvmttbV_V1NxuQ0Cscb4M_41dRWhAuyM-NX7QbfpYZxAxe6GIe8T438fgCObPUmuE_Jk2-BrTNClENjoQqsVmFmmh_2tn8EOi8VTlMyqRaQsjOn2E1CtVjJvGI1q9Um9h9DPPSoVcHqLRMNog_X-GiHiDjowdjE5OFDud_LY_sYRWRH3Ttn-TB8oA-4jdwUedMM4TyPtPa8OckMcVF7CnuJ4jD01LKiLilUYzKJgwC-7hCzQerhfkmn7J8IZ9410JHUp4Mx0peb_5Fq5sN-rdJnBRrSm-7-F3caqjyjLXHuv00xRmfudbDYa6U9BBfi2chrL3VdKgHyYKIPIeg2ijxlcr2DVwLiQ6qW7VuiUQGJcr2qJt5WGhSNEWgr5Tx1_80h3bw3g2NIjcxHniecdzzYxdJFb2959VWBaAiyxMXRoanhkCDRQJTvRdTVy4YrPGYB1skvJkgAjws6He2rOvly__InfhWmmNm-QNAhFENgkrRLf8axRRcMJgZ0V76bN-mpomrMIzgVk7JBg_G9ubLdokgm17bnm07E841fZnn6iOsIDgVUl4sQ3_dCPqFFRBdF8P1ihYZ4sSumDexFJDiPmrMc833US2d3H4xW0hngPzwXgVQ1atgtudzEzNB6ngHe9yga6dZ473qpbcnBi-1_dykKRQ1tib9ApulH5LS--hXj-ZkDsZ6bY_wclOmfFZRVg4Sa5DPUPTNsKOIXHTyOb4tOCPFWDlfT9A2qHJyu66HkWiF6lDHU34-nDRYdAPjthsINKJnoH_-gfaN9yGcE1dgOraULFZbUWidOgNVzzTmUqdjWRRj-gVdmuuX6Xz2WnCQtCKc2FqxsGFIqCVOtE5HxMI3KbeE4pZQ512yDlh7KCOYdA2o_DRbonRPMC-e7PynCGmCazjqmh2VYTqKh3pJ7kU1NYuoAO7zfCrD0cD6CX1-6hxtKX1CIR25r3xPslrLNikp-kWdmiWtBWZ_SgP5dU9sgEmq456myDvRkNqOlZgkeGokXqZET8\n",
      "Iovance Biotherapeutics Reports Third Quarter and Year-to-Date 2023 Financial Results and Corporate Updates https://finance.yahoo.com/news/iovance-biotherapeutics-reports-third-quarter-210100239.html\n",
      "Iovance Biotherapeutics to Host Third Quarter and Year-to-Date 2023 Financial Results Conference Call and Webcast on Tuesday, November 7, 2023 https://finance.yahoo.com/news/iovance-biotherapeutics-host-third-quarter-200100417.html\n",
      "Iovance Biotherapeutics to Present Clinical and Pre-Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Therapies at Society for Tumor Immunotherapy of Cancer’s (SITC) 38th Annual Meeting https://finance.yahoo.com/news/iovance-biotherapeutics-present-clinical-pre-130500859.html\n",
      "Should You Exit Iovance Biotherapeutics (IOVA) Following the Recent Uncertainty? https://finance.yahoo.com/news/exit-iovance-biotherapeutics-inc-iova-105452357.html\n",
      "2 Cards Charging 0% Interest Until Nearly 2026 https://a.beap.gemini.yahoo.com/mbclk?bv=3.0.0&es=AQAAANVt4mPNQE5hYN8vK9Mnv-zQhad4qRKq4LXu-9TKtgC7wq0P0m_Zn-O7SiZmRYWf5MJxCD08NeCHoyeiGz2GXbyA1vYh_7wKOuBzpYvZ0wMBrWbu3j0T3k17uY9nQfj5pDXneImswWMu0lezF8U8jUogubocPCESMW2maRCuMISr3igWaljXwk9zDtdFNRl-caXgtrJzcv8SfunsFeki4EomDaH7u1XzZuWFnb7QTmhCrBsWkqqqkXGUzBUjFrZaY29IhOFRNh9qtd6l7esK_PtlNrEyqT9e9s9xCCD7ah9iYqlRl6-10HKsLgAbu8y2yKbgKANjMSiY4TAkMWphgAV9xABA7PFGluqzrvZJYrOB3ab9nNt9EJl2akDQy-EhuwQzNN3qvjzZtY6DYr0PRUymqO1a1RKGeVC3i7a2NFhzBUrQtKO3-sib02t8MQ9TlGYNiPUyOhpJAOC0MML1nXrGjswT8CcuP-3d8nQGfASLQpxRXJz4OmD8CQblmBJ1IYXYfM7cT6DBWzW8k0tjnj3JSLYizIOs12en8aPsOU8Kuqo16iOR9BUQCi_r_BMtH6wBCWiEqtoRhHaFhQNAzMotEC1PgniafqQC2F499G7fhxTd0wCWMzhHvgiMhcxDkvhmZJE04f-txEopKhRHactuKd4hR7CLk7kpdkWox4mZI2qxvalhpJwNUgj2Z_SIs8EtKKhPCzY6epPfV5HPETEWEZfNtpAotDxtUG-AbrnWGZeIJ13tis9EGpfSIJ4iFrpcKCPkHQbSQRf_TtxOduvGAVciySofiaCVC0xtrW_74nYDQhQKFprc6etnD4KsGDWUnL8GkARvEcS6y8Jb9wYpgHC2Z7ZMVvb6xhnq16nx5nDSeuQEJJvaXtfSoq7UcuSLaJmtdSkQRm1kODQ3GwQMo_0zkYwtA1dLyaPs688LuFVcrtKJbMshtTwSxVKxTHfncrsRQwepW2GEHii-LPMKqKQUtj--TSMfDCY1MsqS4ZRje9BCqUjObDWsBoYjiSRkQzHRU2LprezMx0Tzdnrmu5QcdRFceV28qye-Vu2DErkYZRoK44o1QgTmOiNEykUkkl29j4iQ0mJdR6hVVrT43-AMVsAHVejjFWPWN5gW2AfA3Ux1zv30rt2X3dsGw6BRv7ggxS77mxXPntxruOMrzpZxlnpinRc37mCTow_2SP3Lxz1xM6dUYmVnfQTsVjU83sgp8GfcRgk_K4S1qNfT9-IwpUCTIA_R89GEjxYwz5J32V__6g4265hsxTbcA1wn5Qiccinf2Lza6VpHVtZmxLuoyRT9C6_HrAkJ9Ty6wmjnsb8ZetPz5myxtKxonnTzJ7BGHH1aeUYYzRfvJDDT94aXI9QniGrWuXX9wG3NdVrdsL1u4HutQKqYRrkJVcoK3r3BwflMopzb--MrRxKWWWhCmmDbNdCDntBKlczsDFsMsmWoMMUzFyhRpiUCGe3ADDOqchHpiRX5WLKMpBfwNn3znIfKayFlc5B8yYiq0-bNPQEmKEcbLLey5hM9t9I1bq4tklSDtiup90gDZggKv8vrDYJUKcNAEhD03WYayo3HCycNzXgCv7KtVjBW5I-au9vYm9qzGsg4j2ywv5m0a0xPiNqGAWTo75nUz9V_s5qpDhW51lhsDTBBf8H9TyhRXLjRYwFH27xIzh-Yi_lF3NyIDxWeja2EU8Wd7DW4MD6TBYlDfvzllslzXCtPqvfvMBNIOw40vnJlYvuoKAEgJl26nvC1H67FgnhRaXb4dRS-IQQfSwPH_u6E3mh3d0ZO0p74kaG9YJnmg9km7ChYpVmP37FBdxDxCPVlL0qZKDBpH5GKebu1AAR7aCW53y591PlF-Doepw9lB_RmJinPSoFQ6G09skbf4_QwvFl-QdRZ0szw_BBOVTOuR8d7YAjaEvENY6_bh-8rerM4vqy4j6Hj6F1Au4Phk9eqgxP33S8DWUSFLlc3ctxEUZV5jX9BdeCZAkODROQo7NeFrKqMY-RAh4gU82EMwE0kIzmnF4uZ1QFWDAI2E2gIt2K0lRMKH7PqsfbHKWbalhKDPDI1-caIZxM3fXQ9F-8LdDP2yQzLRg04ME5MXFI86IKcPCPqOzyrAd1zgeWp5wsNAiTv1fdotH0EpifTJN79yLRZazfbyVv0ButYvHV_jnjRPlljZNW5oLZq4qdKXlgiObGyQBxYz5_Rz6cPXmUxEm69phI3lFDk2d8_2o0TRHJ9t6pTkZ51ZWFRzNuEO-NlrgcFEsp1Wn-_YTCDeuHrJ5lAnysNucUTUJJfryzBNdhJmg35e9UU99rWNX6Nj-6zEytP-bPq3vj3H-0IfhoJgxSmHEyM3E2xuWIYeJUT2X9O--XW2XLNTmNCLspotxniAA-mNFCIUSbfSTl6woKRuYTTz_wj9cjbJK0aawm2ORgEyy9z4AE3xBS1smfGIEsG7w78ygAiUTiJb7feRoStEaTcOUQqzmhBy33q5TC938ydOqdaPTMWLRzxyq0agV_jyZs2yKOebsMmAOA_QpnAslwPrjmhgmBXjk6LfaMXLwixv4v6MhTtapBew_8moF73Zr8sT5z-Tvkke0eupTmtLtkmGl5LZqBmoqf06kLcXqsIekhoevQRpFyrvAQmJhPFqLyCyRM299wyslBEN-awnu7owB9Pbdrl0UXFh_IT0FkvwqFJk-ZP8zNXZ07bW_fGjvqR9n5Iv_wZMuLJHxa8rpTAwbEkOoffcX3Ta8COrRyqHyZ25em1eEBd4mBjQKzyy700c2busDeLiUN1Qr6pmW4WRA67iNDh9epzT1vu6l6eLy2tjkShKPqv6dz8gskMiZUG6Y6GpVUUEVrv2i95VLkzi4cPXWRnL_ZPyDkUGNbrDcVJQNlb5KvsFry4fp8Cp3qMQPZAaag_fkfc4BbUlJ4o0F02UTYeGOBcobzw4QY09A0mNF0g_omzhHiQvp3B93-jz7AxUbU_1G0zT4diSgDmWDvmWaU-gr7y9pfFhhj8Qwj-jMS0c9RiMOU1VpuVt20IiFkRmgfqhfEl1K8_nGRm3fbH04cHl8sXaIUd-BDqW5YEHUdZC1y8ZjW5psql_eMesaj2Q_IhGri0cWmNQtA--N60Vt7NNOQvRIhZ9hhUY3bizKiltJrJXVv45HqwOh6X6aaFAjQ2AG2D2wREG4_c7-DLPmOcR481Fach9QDY2nTwbeufZK3DUeonyReejSYX6zb3D8_v0mc8e3f_rZk3ke6XF_bqoHsAPAAdVv3u3WYipPw5ldOCHf4BjDXieQMpTFl5LHXDTa5QHPDxv3LFf0YVi1bX9m8ISGO3C6eoVBcHvDFMxsp3sqXTj6PFvymhbjgoSfN1atXlyXblL_WHFB7014flO9q_NwSXnDHlmYKUQpHX_j8ks7czw5TExMX8mWZ8bFJDFqWWvWcsUW4bDvjgA0kAiRzn0vfLEV-pXMjuGs02vMBFFh34AzHiEbla87asK2CKp0-UmQzGLE4hZgV0sxxhf3-9ecDPCZVQkVCHcLik54iYRrv4GkQV1zQW7STTXlutxXJv\n",
      "Iovance Biotherapeutics Announces Clinical Data for Lifileucel in Advanced Mucosal Melanoma at the European Society for Medical Oncology (ESMO) Congress https://finance.yahoo.com/news/iovance-biotherapeutics-announces-clinical-data-121500499.html\n",
      "Independent Director of Iovance Biotherapeutics Wayne Rothbaum Buys 28% More Shares https://finance.yahoo.com/news/independent-director-iovance-biotherapeutics-wayne-100338236.html\n",
      "Why Iovance Biotherapeutics Stock Rocketed 13% Higher Today https://finance.yahoo.com/m/1a51a51c-9d46-301b-8836-9977a6929e20/why-iovance-biotherapeutics.html\n",
      "Iovance (IOVA) Up Despite FDA's Delayed Decision on Melanoma Drug https://finance.yahoo.com/news/iovance-iova-despite-fdas-delayed-112600929.html\n",
      "Texas Residents With Credit Card Debt Should Read This https://a.beap.gemini.yahoo.com/mbclk?bv=3.0.0&es=AQAAANDwjDLAFowgsI7nJ_PL00NifV4jbyFA6zpZVzQ-jXIR9ITsFv8MGpWm2njJr9xS30HfPnx-REvTU6QosZK5r6To-U9IxRJraXtjBmNAf7KiNlVQ8vTedAxZ71zfo3s_elxcAcEKhvLjNQWLuyy0aEsEGEpuMLdIrZcjetzaA1PoSAAuGCeZnuLhy_w-xDT7tntoKa_J_BYCAnKuZxsXPDrtw9_leCKf5gQkQjR9X_Fgr39Dq4Q1YJ7w6qRuvi9wUAaphRHSyhbj90ess3vSUn-xRwrBlIViTpN6vu5Rt8lA8gCgr0-YUv-ccwUZ-lXynq-h27eucL-D4QUUL2RnIpqhTDdFkVQyJSQB-XenNsxfAXLgPoFJHw0WSeV5fWURni_GsYkajSt504oNleqmHd9INlPceeHDoRVyO0lpctEyRDQhfXwbHhKs_E12qAXExQQPTzjyMKi-QbihqSbZzRzuTOOhTZfZWu1WWI-9ctI7U3qFqIDgLmQioFVX99fswDJMVbxX6QyKiMfHLPmzBZgZyStL_yCYUVLw4_V6hIVQu7_MV9PJdkx2FHugeWeUJUu-p2-o9Ox5d3VpQ8HzYHhpf4UMpcn5AtACz9tV8Y4h6oXlt20TFhmA6es6h6A6-qYe5kGKlCAnxGDKpqtREgAJWzvT8wgJxersBEBgKDDYXc1jts7UgD7nEOQxuRju1rOJmQm9-5S-6jo9z-vJst6XC2KjCPcV0HwqGYWu-jVaVoD6NrvLT3RToOOK6yQZ-E6Gk5KnJFM6opTKksTVAaNUYfqWXrsxllgP0BcgA46aYzLNNB13HJF_DFhdRHNUPFg4SQYXvnBi8awLhwc-yQJ28Eu6GPIQ72YuSV9BSAXB0tD90dBnHNuzevrMcqt3OPWfBEjd4qm5YvloGWR6fm2Id04uz3buP9szya1K6m0o08JOtAOA4BBFmpJdQAjZXS0J_-mnak_PTJzvisaSsa6Y760GLYSuKLGw4_dwynzxJf7sRXtqZzH8MHbJMv_XSe5jCsn6EUwnZNjPrx5aKot_nCBSDlMWENKiiqAUsZPeyRSGJaz5fcho3cDNErNrgd_xc23g6jqMy98De5GhYhSudZ3dgwKpFbyHsEtNqI8-u_M882FVHILPKhkfTjpP_-xXbVHv2pGghhfG3zc9npQBTDt8ZxO4TEtlnrQG38MPWjqr6pIPX7PEHihO2MAHzd5KFARXz1Q9M_ZaNm7Rms2k_J1tdW-9-PLKnRA9tsQJN9eOJLHHoudGyULPXK2kRnRAAcDLd1lR49m4Adeb88Ov6b5QCsBNxqiNMtlbtjDOTRCv-Npv_o2MBT6KttRQ7v6jg6usaYV2xH9cML4UixUFMdFdLAJg73fWuI0C-oIylDeuoaQZLdQh0_StfA2Bs-8R25rS06w9yqMpUI4vo6gmCoGMNBwWXex5lj8pjkvzkRWBBhwMtwpoxDA9Z8Cg9XmdqWnPQia0QrpstpalJNnZrSN81c_E8GdNmgSY7STT-UX_sSAx1t2M6PFjExmh9qH1iQa5kRWaZbRhhSDUVp46N-jTelVD9h1HQEpENzcyfN4eo94d-JSAVKMNxN2xREF6xLJCARE_HqGKhkPdxpKp3-0oJKBD0A9GoazeCi9TPXI5wgyDUhgKulqtjOZDgVHFApMFVRERYa2pqAvNr_AjD_M8IAyZx0rbmm_IAqYa4c-l0u2GRCKgmTzziSytk_tXz--yIAFgCbyihhykupDD_-5YV9mkh4IDnUjfIzIAKTByMifn9dxO3jkt3wODumy1JUkhyEZ9UBy_9kL800M8Ok_caWV8iCePem2MT_rreT9surx70Ywyg6YPFXcSH-2PVLxjt0XEBizYnWgGeNa1t_Mo5WkV8189a_83MQ6S0Vm04EzypfEHdai75APigiSJVkcQnAKDN3xOYumMkIwIyJ3bCWW9SsKLyhsWQg07hC1-8dvVVxiUjZKtxBH-f37B89avbyLeIpKLJHHcT05l-Tlle-1lcThTsOGlkJsmY2rViwLrD4zTnDeQeIJru2WIbf8VUxruUnzaLwjHHG6FhRw5dF758laboDkKDtbPIf4mowYUIrknhfDVT_zb9id_jH4W3XOii2TnulC5sdV5vaLv4nMhQ4f6W7JUu1MHbQ-Sk_nCkZqfNMLmwdw6LXixWT2tSlSbtGEJx76oa2Fttizcy-I_ac2yydzLXPaJcnCJu1c_bdXGWasM9CoO1KFtHNBNrYi4TpQcKXIoW-rp8Pn47fR-SFpK-k4RFKBwd7jD5TbLUMwGXG7pSzsDu7hwy94Qc4iIPT6OaWB_rJbY3EbT-HCCLxU6DHWWKDsXOCJk2c98rRuzmE1tOrkut6-GKgRz-Vd8sFwnWrol-JhgNyYD7EP-otJtsJ7GLkVJGi7D0wbkx-qutYTzVTlPvgWk2Jzr7wqhyhfp6VkOFbKW535ht6RYv5Mnb4DvZaMH8mfJVJ06761ZgCaxiQQK81T01H8PwDSiF3K2XXR_Jz2a7CwggDmNCk5rT7S-IljX7QiJWcH02EsDUlpsm5QpT74I2VD04Wpl_nXrsHPfwm_cEg9HGc-ctTCa1LN8VZ0Zu71os3z3BnscYn_CecLRNFnHVc2j4d2MdvtoHr4c9CyjzfkZ16qLGxhduzm-7ZAlFQ4eFygbi-xzDT1kqO3E_RAB3Ff2RfmuP_sCuQ38gSuwxbXE7wvuQLe3jcIzc-4iFWeb4PVz7JLWo9px_2B1UFC8agEmH47csfigryUosnk_B6KULJfE7Xgt5qLZiG4_-OW3AsF-50Xw2tdIJQAxzEBd4R12oJDJ7MXFzjsyJ7EoMlkpzpS-fRT4pnJYKk9zUdi8GWknq6OsLF8Yh1bFYpo6_54WmZpgKuAWrP2M3yceJM6qFirI03Y6_KuxNpEemtJG4aGZI-OmaOaPXzcsU6ZF3223FOV8kdUuUeElYLrU-y2AUtzSkyQJDKhNMdmYGO7p7ncp_N_dAgnyre67Qk9ETFLnLM1FDCDqGNxNo0UIbHrNgdg_YAVZnKTulUl6liiV-2AqgVHwtTDR7hJI7Gu4xrCd3BQ0tid2CxK8dxeOt7zIwjTfEx42kJGst0RXAlqNUx_uyjttlibu9FbzTdsfJ0qrzFq6_2iRwSoBMcjzerRVFO7oJLqyWhZ8c4IEmY8TcbvsnIbJ1wpr_NZLKdXiimmNhlgruj1RD42K-QmZavE1LT2OWG_qg16MrVbVzo8hmy0Np_eao1lpnFyaSmvMZgcFEFgRhumSmCPPWk7ssvZYFVCg1-Ay0rVTpuwXSvEDRundS-X9QPowfMeK1f6hQ6XYFsD_s6Fs-pXDABMFQ5RlJSidlhqerNmEvYuzrU3qce-leY7zNHgDHhrTVyFIXj1Fn1RU8odkf3tP1NAqZW90JwVJ62eD7HX_0kj3jSWaejQzP5svJfbsj_YhEIQ3SbsO4ZXczrxJCJesj6RCgF0uYWUsqknVM0SgNa2MmpVzWSwv0xgrLiyLDG8KHJVtD0_XitvGj1TxlvWmNhQC_9Jy03AxBvYCT-_i7DGUI0geioPf-6Nd3hltDgSoSZSgn40KgpH5tWTFAnwmbrwWtjvjKptmBU396f8Aq4qFhCijwaQJDO3R8K3gLAcAj7jFIAWpGH6gXogBBEZDXMIBIOIGQ9moEWxqJ1N5KMbICXw\n",
      "U.S. Food and Drug Administration Updates Prescription Drug User Fee Act (PDUFA) Action Date for Lifileucel for the Treatment of Advanced Melanoma https://finance.yahoo.com/news/u-food-drug-administration-updates-221000095.html\n",
      "Why Shares of Iovance Biotherapeutics Dropped Thursday https://finance.yahoo.com/m/b820ad4f-a181-3fac-b99c-212b49bd7c59/why-shares-of-iovance.html\n",
      "Why Is Iovance Biotherapeutics (IOVA) Down 21.2% Since Last Earnings Report? https://finance.yahoo.com/news/why-iovance-biotherapeutics-iova-down-153058352.html\n",
      "Iovance Biotherapeutics to Present at 2023 Wells Fargo Healthcare Conference https://finance.yahoo.com/news/iovance-biotherapeutics-present-2023-wells-113100129.html\n",
      "7 Wealth Tips Once Your Portfolio Reaches $1 Million https://a.beap.gemini.yahoo.com/mbclk?bv=3.0.0&es=AQAAAKdRuf8GbDmV_lN7flA05GKbbB9R6YifXKlEXPoqRXjZ4eUKvAzGMN1vvAyQK0gzWQF0sxujzo0YqUPmbfTGGEk8Ot-5TKG4sFpoTpV5aAYWDQoac-92GfFQAzvdjdjpP0CKWUPlhreQXo6PFJWVOKUPzSIjKE4OyO_8wlWUbehAVl6Bdaln2DQTtmfffPFRUQRyhCRLVc3OI-NRvAH8e4m38pXDJoF9X9F9l035FHM_oG2pMaozUzsfRVWJmSndLgyBOGmuZyNtbY1jl1R6oWvzEE_PqovRn3qxzWyqVytIHoQI0STir07sVbkBBZdguieImhv90hw-dl1BEuCprNZ8NRRHENnwf4frHyR0l8N2ntUzDVlMsDaJPdxhLV2HHLh86JUWbGGaIL0UzYj6qZPL9yAChTy979QiHCvMvENgQvOK1jDBMi3s5TwnqpwzUCz8hpRIbmIVmV3dArOyRGEHfS6QQjxsbmHRSItGz5fOSOlmRm_31J_4VQIiqeh4KJEsprrRcZ6S6ZgIqQ0fFGa4b9i_ridoamo84F18_nYLnStqvUYy8qSaIAvsWBlFDH-HMORQuaT1Ep5OMOvrI5g3EEHE1PzBrqG6-wARWDb1MbsaaHSdMch3ogGxmPH15ac2TEacQSGZON95F-ZGDFG2vJ-CIPjd5x7asr8Q_zi9PzMRd2ZDTXSg_UJuQVeOqhp1ftg0GdjUwm22S44dnz5HpU5Tv-LtEJwfmIA3FyH2IRG3SmmJx25W8UnzQB0VZcpJYcj6g1yEdhBgNhPVnbAUiE7iqVKqwNsG0Rm_uLmtyo2Ip-Drv__UfPq-nGJjmEK_4r_8NCyIgXDtcEVKmKzPIOmrl9rcsb-yFUR9gom2UKmdZ7TgIknjEACM0AByISfpcLJbxi927-vsh3dmd0s074DaQyWPjSKqEgE8C2KLM-W2IdME9Xn1biv84Wcjp4DOXx1BGo5CVo73TwWEgnph1goBzHKQIZYX1PH_s_Hvk2vToMdj_jHcLncRqwN4H6cttQC73rrJPSzrbJHyAiKk9t_uOWunoWdu7KSXLcxeJx9FKRT6zitST6JZkDNLthFuXLvHijXQGRdY-RPNBwTjBG1jt4pk5uKNAieTtYvXllbJ6j4nInrPYiGgMd_JyNe4zE5szaHlT3-utTLC339JIvcTMHmoQnXrttkWf14m3y8sTCI3XIXfb1xvaFdBcaAftqFKZ7w4SCRKDN-cLE3-KDPSBzk7ifl8rN8KB54s15l9SNZOE76-uRoUTL8PVXpdGKx8B-wvmS_XCZwq5i0Lgihh7kZB4f6Rz9BXcvqaGeGUVPanEbgsx_RiRN4dcey0e3diSIk3X5WHTAb-rXZTMk4Do3PAzkCyW78r9rZzJVwSokfKPXi8B4LcYLVVqSMJGhvKRfO88mvAUnOlumK8fTbqH1c6jPJ_LAOJiUXTEaKYyncPDK-tOJH0d58URA5aiVS89O84HywFak6v3Cs16UQDHlLLStQ7PtIR4jM2icLXwkmK32P8V8MK4TynK9aNNBg9Qeh3TZ7IJoslll2BtvfHaFV5OpxuIOQazuILoKvTLXfXBVyjPa2-zl2ReIcmOvoxDLQA0LbZjYFe9O04PDmZhtVbxMiGXLIBf2fob9pTgejZv97x3rX7t7WtbkcEQrWN-Y8Si3EbgRfRJ46UjtkBpw-6T_qQDUiSxZNXj2f8E6yD6A-WlZ75Q6i0-_EXiNJhUogDt7NBFUF258-d5h_f2Le2KvhuRTah63odPUPJOhUEb1mg0jnb9bVd4uYSDMYUm_bN9AbM0CiohFTmyO2ReL5yhLu3U3_Dexgn4hEi4vPfAFl6tp9lahdao92rOUH4NyC3b5jnPQRF_BV9X6GzeYG_rBp5qaBs-A9i1Q0aRG8VmEMcbZFyOOUjJ-u4bTTMXphLIvQFb-2Muog7OCelNo_5pXGD7kizZqGyX2_IYPBlWKrEXg61ckoa6U3haan7DhMLatvBCYD922jcgsJQbShBb9IpPW_ppxdlawq-hDlHhLRnG9pRYzLgLlvdVceCG9br0lbJHSU2z9x1tK0chINeluSx2J0v56_mmJn398gdiJ_jhySa9fGDEEXZzvqj1E42PF5JO-t7Wb8hyZXo7PhilNxcu7t4i9KPMV3h9gFanhOy9ipAnlhHF2v76DtXLBEs97fsiNvcqOICCZgAM7mQgpIKAUxcRyLwPVcQVLm8Jh6X5P_t587-wa-qmFK_TM4ifpBB0pEKNoWvFxRBnSSt8zCP9W3g6t_1ctYl3JssF7SPii5549-JrWYPVVdZ2WQhx9cV_zBzFx3t99XLxmUfSrvGulMb6AVlPteakLWZbxmIZTynRwGKHCOjRyEAr5VoStV6gemjSGx6K0EvfvsbughQOig_yuFF1K1f--F5uTCzNhCXsFc7xCrQOdVKGKXrlK5a8Zl3qEsnOMNJA2ftvpmGqS-TiXWdJKbvtTJAMgwKLJ42II_R8NbjTebT873KYIP_58is-113HzahjJcYFby-4rjKrEnNwUYje5m2OibB3rDjWI_7KWUZTuyUW056kRlY0eJfYTqJuJyDI5eo-xuwQCJMz087rkel9Hkeo5uOCnqTiHUM2idhq9gSDsA34yxIi-P-jhlOIujugPDvXfxTC0M_OW4_gB6IwEGS1yBfu5KMjcKNKekapUhDN2SfBE-kpxgwqQC9Bk7qX86mDOQXQKknB3El1T01OoJWPAq5BPIq27hD_oo7WOL-mzujlIY9nqZ7von1ZoQyKuS4aYQ4N4Kg9VZc3Hwy3GBGRK08qcIVkM87INdUA8m-zTc-x0vLrYP1D9h-kWo0tgZ04rpaPM7tiIkiZaEyEApFuGwfRqYgfADcxFEbcZnLOHq0UGCycannkz9a7nUr_hqtat7EIUyjiMXqQDEh-oLfd0WcRIE_FS1fAX6HJwZxEBJ-LRuAr8gh2SvbdXKiGLzzWoKejLzt2LrAaA4fsRse19DAS2Ha2AwMI7O0HCu2o_OZKVyc_Boc1v2NUs03xyTDqqlvg9wrq79OvcWx4r98RRQ4lbWBHbUvpV5iaUJlQzm7CpEfOLZ0CmWvATxDeHzybqky_CJLfA6cqiHVjIuHuD04kaVFKdctFGV2Qdlw9t7KBHJ-x5BBhSFoBMOLYIZKY35oP0GO_1VczwwtDW1jrWapftOWwl6bS0vnRVHJJgvxxuTfeiSxMkKRE_ivNRYbTT6-feKnfP9H2onb4l-XNRTDBbTXy-52yVhM0-nxsYOvfI5F8rDyke49VLAhjedRmtViw-Fd_YjgDFIeERUwDKR-SNusxV204g8mwTRbuGzaHlmJDDgf2QtfhiMYPcmBuHPM\n",
      "12 Best High Risk High Reward Stocks To Buy Now https://finance.yahoo.com/news/12-best-high-risk-high-021627516.html\n",
      "3 Up-and-Coming Biotech Stocks to Put on Your Must-Buy List https://finance.yahoo.com/news/3-coming-biotech-stocks-put-035359006.html\n",
      "Iovance (IOVA) Posts Narrower-Than-Expected Loss in Q2 https://finance.yahoo.com/news/iovance-iova-posts-narrower-expected-151400195.html\n",
      "Iovance Biotherapeutics (IOVA) Reports Q2 Loss, Lags Revenue Estimates https://finance.yahoo.com/news/iovance-biotherapeutics-iova-reports-q2-215021459.html\n",
      "Iovance Biotherapeutics Reports Second Quarter and First Half 2023 Financial Results and Corporate Updates https://finance.yahoo.com/news/iovance-biotherapeutics-reports-second-quarter-200100890.html\n",
      "7 Healthcare Stocks to Ditch Before They Make Your Portfolio Sick https://finance.yahoo.com/news/7-healthcare-stocks-ditch-portfolio-101005792.html\n",
      "Iovance Biotherapeutics to Present Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Therapy at IASLC 2023 World Conference on Lung Cancer https://finance.yahoo.com/news/iovance-biotherapeutics-present-clinical-data-200100159.html\n",
      "Iovance Biotherapeutics to Host Second Quarter 2023 Financial Results Conference Call and Webcast on Tuesday, August 8, 2023 https://finance.yahoo.com/news/iovance-biotherapeutics-host-second-quarter-200100291.html\n",
      "Iovance Biotherapeutics Announces Closing of $172.5 Million Common Stock Public Offering https://finance.yahoo.com/news/iovance-biotherapeutics-announces-closing-172-200100415.html\n",
      "Why Iovance Biotherapeutics Stock Is Dropping Tuesday https://finance.yahoo.com/m/9c4ef1bc-cf84-3751-85f7-666348a50578/why-iovance-biotherapeutics.html\n",
      "Iovance (IOVA) Gets Positive FDA Feedback on Lung Cancer Drug https://finance.yahoo.com/news/iovance-iova-gets-positive-fda-145300101.html\n",
      "Why These 2 Nasdaq Biotech Stocks Fell Hard Tuesday Morning https://finance.yahoo.com/m/715d5b27-e862-386a-be1a-20420beb7285/why-these-2-nasdaq-biotech.html\n",
      "Save big on electricity https://a.beap.gemini.yahoo.com/mbclk?bv=3.0.0&es=AQAAALNeLXXLuEnWLv34kw_7rTnxzbqtXpVAfEj1BNeJa9Ci0s6U69WqdjEzdqoRWnDXChSfsnPo-gGNod-xNtdPQAwCkn8cjvxPOnXqqI3rQT3QDxJOM6d30Llxesglzsvd6bFhNUxbiQ87S_OvVcu3JyqmoEsYFvHs_g1zNrQeLxwY-POYj4Cb2Jyvc1bypBRawE_Y4GTjXNkEh-TAJjV9s_tLHivhq0AQQVs5og1-dd2tAL5eEJ9JrIY05Pw6HJp93Pu79o2ZNgCEcsf9p6-CHLOzHcEHEzAo-p_K-Km5bKQ87xflYSA11Yd8pABXTG3bkRAs84amfq9gOqZu4Pe0LCfLW0_ESqaIB4p7iP5VFJnm3Eg2OMQYGFWjUJWZSS7SNLdXelsCGQbjKssdnX_N-pAVUISbXzd93QqSDZNme_hmS3Hb2AkH6OBEjZ3SvDDZYstHTIR-w7tvkStlNORDEh7NQTdXdWAOzv4qh7HBHjRqfqIOLBqYKFJw4Lvwl_GadXzoXuHl0vmMyfPwYH09qja5KaxQvqEln7STqKLUgUVupHn2dII2kqzte4k54zsn2zCQD42asesN_uQa51tIhsEqs-TyUmAcN2SQfeAUOGFoxRYpVKjYjsF8o2Y86QxtpKr4A1_s7ySQDUyWdi0i9RpBzr6-R5ScIrVj_QzPLU5KMuUVt5SjHvGH4QN_ERkpaXI7H5y1O37O6fcFPn00ex3k39cCk--gurGTr5tziq6C079GZpnq2Q0ulrC0h15WapMhtwJxvFPpG-zHfsOtiEib3f5YElb5UG7Gi4e91xo2jhyAjDppMf942UyIkFQH4L72ezVh5yInGt2GzvxQ7h8c4bJOZ8-XbusaTdwJTdnjnaE1-5fne30nLSz7TJMzhbe4Et5QKoOUCuu3uRdfKEB1EEBhTj_ykx6XOvPnxY0_jq9ryDmUL-1FJj6jxKwXQF270RPMeQnVNbbYTswnOgdWXB3lUv_ipxY9HVFCPEMUG92662fvYYtGn8VZwXwxqVqkivtx4AAUiVBxm3TouT1OvPSEoY3e-eIIecYaoBAlf5jGXfZOP_qJA97kHafFlYC-_thnHoT3-TkokzJY5X9gEZCfT9fajO2iY3jATDk1KanDx_YoWA1Tc2BUkwzmd_5z1x3caOnLR1TcvaLmZPkrf8jSoxclcear9zcZwTgLph8yFqfnp82EuRh75LfF0CcGHCKE_na8GLj-OYA58FUeJ4I7v5N5b0UQMvYrqR8KJCvruCfuWzGCcGxQUFLrZjFNIIMn0qmO2UD_JhdxwXfF4Jt7WHMgcmK6fAeRm36y6L1BBrC2AE4ZMQg7ZoD6O47UDcmTiOG07aSajlZEoWFzjpHpiBqmZYNGTYVQk-PgFNpEgaypy0i4oPB7WUA-gOxg4lDaAnXIty4phkgoP63Hw6fMiNN11QUaFNZlfTooOpN2kj61VQvzHufnBl4Y-czR2m7QPHK-7Etd3x2dnpgIaRjE85oSz2-xV4IPSACYkQji66Q_5eD8thqAXIp4gPdGhCBorBFU0YvAiYMYddyBqKhg1yUYHX9UIhlDoJlriBrVPI5c6kbzBKMsUb5nsfUzjq7tgAUofVK8m0ktR27uUUC1QEVbkw0AYY0aChN0UDX71dUfKuAj4qqbtRlNfxGBpaUUc5sXRgUMIMTL-dukgk_N9KdhBMSevNqZh8CioDGBPFSADgeNe6qxTGTDirToOoCfumYYRO96lfbww7BBU__GwVC12BLYrv-KzJMFvX8alsef3IvgHR898cFcpGRuMIDlRJjSv_YSKn_flEqTL0yQCETAbYwjXDej13UTl4VUPgLxzfOX_papkJKYf_TFKDze50KmxtW0gquum-Vq52hdvgZdVPVFCsw10037UTynq201UYL4pj583C56OHE5j5JdGMXkfeSf5tGES702-jNYCHri0vqNP8aHQF0KWNQP54wViZd3QUlfvxSrMcfMsdUkDQohTjuIxFy1GuSDqgovrqOYPiNXcV3ELCwDtgSuuLb8zHnFuiqqyJ6U1KAoLpOc873QY95a1FWfhJ0CkVRqFbDSxJ0-Qz6pNNF6W-WCoLdmI973sRTv7DTZnEf4XIimPl32TuRj4mfuXiUu7uxaQh9ysEDpV2aMylKaXn0h9tWWDLVdTjJPC-oyinHgDVLxMtxg_CgvPDsGdHh6skVrO0Qg0p4eFRFBexS1S3bz0DjAE7beNDx_4-1te7f2CE5EsIAoZ6ElVbAgiE7pQRJyYxNGMmLhus5iH5zd_Xx9L-xOroRKX7F7EGL2xzU_DZHKP5KXpYVpSjDPaD-SJOln4IPg8Lt_PONvoV6f1XpTC7hGdLem6JXeTzHm709WtDcZ2tjZ0rRsV4ZWW5D8UBYD_yGcB4RSPuMgf39Q3-DOdHC_AD7HDgxui3sI3dBFt1kjIGXmRbptvjt-KYhjhARxa4CKDbI-_qpbUVsWVWLN9P_CuDv5k2ZgUs2_gFU6UMK5QpjBSpZxR97q6mZVGKBCF01r74pt4FCyrg9w4dSOulGPmHAYULQQ5T20J-_4EwSwmf7u5RANSFbWIL8KMkcNSHZbCw059laiQvozvquUrxYCFfr-WlEEnBRd_ZTuuAy7GGz08ZJO_iZuLeMZxgM88I9LSqyrJXjDOcP80UmL_utk74pu_l6-zoutN3VM0u3L76-KbQNdXfW9_CpihvalulgW2DqMijdo-s3ai4Nlwji9eXUYHI3ARHDU9V9SaPhmMcN4yKpqfE3B2yQxS2vshKyj6Eg4NV9RPVSs3TWIPsh1o1f4A3Ww7zgaFpWc_5qhAyhoPiAcOtRxU9265N9BAyvU621BmRl6NJoZwVw3DzDrfGujp_OZiw3JvKXr11kmjgqA9_wCtU5P8MdWmaZGaK8LGR8Bja_4MDrZtp6Ojka-ArBvstwWRh2kdr8O3sCgLFBsG8GGt1l0FAZ8S8Feg1WHSD_FJvsMA_lVpRq7kSs7-TjDSl7OW_4ebwf2LVol1nRUwUehPie0yZaz7SSIcJ6AT9tGphUfVjmPN0jPOO8dCiUIJjgZtbuSqncZMtMpC4iDWMJJgh4hKP2i2LiPmG06uOKGMkLob-dmfyb908uN7QEomK7uuQ\n",
      "Iovance Biotherapeutics slips after $150 million stock offering price announced https://finance.yahoo.com/news/iovance-biotherapeutics-slips-150-million-085603740.html\n",
      "Iovance Biotherapeutics, Inc. Announces Pricing of Its Public Offering of $150 Million of Common Stock https://finance.yahoo.com/news/iovance-biotherapeutics-inc-announces-pricing-014600403.html\n",
      "Iovance Biotherapeutics, Inc. Announces Proposed Public Offering of Common Stock https://finance.yahoo.com/news/iovance-biotherapeutics-inc-announces-proposed-203400166.html\n",
      "Iovance Biotherapeutics Announces Regulatory and Clinical Updates for TIL Therapy in Advanced Non-Small Cell Lung Cancer https://finance.yahoo.com/news/iovance-biotherapeutics-announces-regulatory-clinical-110000701.html\n",
      "Why These Billionaires Dumped Nvidia https://a.beap.gemini.yahoo.com/mbclk?bv=3.0.0&es=AQAAAD8Hung79mFIcDXzjjSngZtHJFG5LdqCQ_Ud83q39wwQHmXjszbSax3XZQGNjioGfaTc5gKWwcqYkTZAUsDBIMk89ZcJF2iBwXV18Dz089rFjjG-gnscCHls8fWo1jr-wNEJtvpHO5MRotUza6MN5Z9DT205YNNaWYQWxEcrnvQ32uh2tnoHKfuV-e5M_zM3d9nQZkryQLrLuTdLhEa5n2Q3Btl4a9K_hhC3CeDZaiXL5Rxg0b-GyJLE0M17lgFtJUoBDrX4WaMcidDAbtGT_F8wGSZVJi-0GI2kmjI5X2AGDHRA--LO6r0Ph0w9shzt0xNALg1kRvAtwc_2IXVWm4dGsOJzE6Qc2dehsarGfHQ-PqRVtIxARhUXRuSaQVNX8sNMp0VB6Z1VIh_DQu7dkZZcLSZoJhj__x6LBmXW45HQeOV7tIeLPt-yGBA7rV0Lfa7aEERpQUg_zJhKyhlhXvOOI37uYGIs6sMfQxzejhuGZIsJRMYb3hDeKUNbazpxrnLYCAUMrN0G5a9UUNXbgNkpXofyG9smvheTKH7CH4lgm658768mUhaKQVdjEDEHY0bf45klnWmG9a7yShkRYd-rpOXKAMNjCzmlwQ0eq0ZeIwgAfOrlw7krmbt56sZlrvgOQibR5p6TOstmQXCAQRn3rIPX3WXsLUuR9OniUDdhm8ukhHE45CdxchHyk9cm94B0y5Z3rPcymltdXYTjxYHQiVxtWOLgmyBK8ZgnYhTEWAzyZm-d4ytOxUXVc42YPTcKNTdC_rqUW76x8LV3ZNxvJqW8uY1uawYzhkdMjpANz326RAMB2OiEFXIf9e_jDCh4WaX4cWyDyYD-G86PK-ftiiODBfu-Qn7j_-CNnDDIzBbDrdW_nhgYFm5SGiT0h2Co-szxhUMQ1DeOaZ547EWNKSeEHtPf4ErycUQVBNpyRZ1FoCquYg-vBjE6-_H5ME3Un-1nd3jpgrxT6AXGBDdrhcAJp-DTJ3lpN43nOQXl0-mqpfyMXqq0srwvo1FZDTjyGl6z8lf5kKDLcb8ub9zpA_hd7cGXv7ZPIAtwGmzz7EWrb3slzibLC73jGfOdIOugM6Qy0ZC3SYkJR22KB3TuFFXVwwP93c50Ckc9o5P3GswHclrk8h9rDcn8C7JYOmObNdxDwo4V4yvOLTq-vkAomG6atVlkeEk096stEbuh5mAOnsTpRlj7m_yuLKWaRlyCkl38azEjCkeZ1agv9PC41-O88wnYVF3fafuI1KomOrpLCRAPT-ERmkYdHcxQPdgu_iFL0Oo8s0BKSr3nsmhkPbQYge9FGOssz2vl43lzZ3nRAdjD5LC-g8jrwMXadro-hKEXUOylnkRARmCE1qYPMTP9YuQI2HQ3OyV6Bx-C0smP6r5_pDXsPgWi7JZ6FpUV8SJFLGoPod3jz262tOM91oOKLSRsOwZtO0KKq_CnPGrm2aWaTvLoDcF6hRbHXlY2YGPGcjQ7RALst-KEWoVVQTmF-cJHOOOdvvQt3a05XUcnnq_9kZHxUOYNEG2-XLSF6GWVISfITtlYF8wtFXU_U8gRF6BHLgOwPR185l7cfm6nRryfJK9unyYCzeCNDRPsBRwTQt6GubV5mx4x0YkmYZC-dRMEOCBBHrd9n7aSH9KlkfEKM582TO9dUH9lRhWw4QDzo42Y2hyPUjJw1mLi_frzg2tbhbVWQiCuQpLyyK2z9CkgD8o0WhbrwKXcG6GcKtVqquA8Rsb0FLDCtO7fJke2oOINJFuMHQxS4R_2675YkbwrtyZxsc7-HhX_y2SAcCFQSdfGALRpz7BIEbN9B_nMX0HMtDJafYf3uJC7e47OdZJzQzrYteocre_IF24bY6BZOShdqYj-BznEgeGs8PcQn7jPjp5Vo_VsmKU1pr45IT3VZfjE2wBPY0M0G6XP6mYXG4cIIsfLDh258gDpvj6_B9KVFK3WjKtlBVQ4VXyooawZR-ayFls4c_4NCB4M9cjxvCMjy4RXoCvO8aT0rgO_YB97v54TB_ZtmvdXI7Tv6sri0kyJ6Op5mmhyTT4SPjcpjL8XSretqwg52ATEiaglWzHZhP6Vhh7ojlITtSQgVqoB6fULhYaXDwkm-XIFZffuelniduacLkd9nGLnd4BI7LDh1YZMRqxQ0-1gCfwVvqx8r6I74ZVW9aY6HrgEz0PjNVRUbwSKQygXUQ8zUpLM06aO3zFxM92Lw3g-Ox49NLQNqncDBBv3Vh2Ya5gy3O8157-TFw67j4wOcKzRTxsbNDJpik5tizDk4H112QUPPA3lnpSk_IdUKLlzwLyRHM50_koclrNz-DcCf8PGrirfeaMmjJ9T-NpCp7AYLcyJgN0qE_RsJxTJdotidiSir3tjXnv8YXe55mvqyGRb-_8J17DJ_S2pJ_oqC4Mn40rfmMdtT_JDXlgUpQ1o7r2MurmBGTtw1Ebp15EE8qO-nLC1oqFOiW4V3raXHmvnA00oi__PX4xzvtBSXcMdu2Guh-pVyS0_9JdS76wMrGlOah76yB-3rUES8roNjLl2p2ID37kcKKx3_LVY9cn1tTGJwiJtoDXa5VI0JO6hDFP_DCShWbem6B0XkcKlwRMNqWR6h-BRVJ2S3JLpIqDm5re6P8XvfcgCAE_nLcZB58k8BiMKX4uGUgjB6gaF-iHRNldDS4Uy84sHvjf6tyh7Y7Zg-qHLM-08TTDQ0N2BdEiyS3At6_n76ajioueQbgvA8sUxvD9I0btKCd5nP2jicZR6Z263hamjelV3g2aZkAiC7DcioGwFS2-cVKtfr22i1zW0o4p2-Nyx23FehV1KGPTYmEydZr0-zwgROvvimNuwBORvQYjO_kJly8ph3Nyw6vhcV7LFLMZmoQhyllb3lREQ\n",
      "11 Best Medical  Stocks Under $10 https://finance.yahoo.com/news/11-best-medical-stocks-under-191941442.html\n",
      "Iovance Biotherapeutics to Host Virtual Roundtable with Key Opinion Leaders to Discuss Melanoma Treatment Landscape https://finance.yahoo.com/news/iovance-biotherapeutics-host-virtual-roundtable-110100289.html\n",
      "Iovance (IOVA) Updates on Combo Drug in Advanced Melanoma Study https://finance.yahoo.com/news/iovance-iova-updates-combo-drug-123900365.html\n",
      "Iovance Biotherapeutics Announces First Patient Randomized in Phase 3 TILVANCE-301 Trial in Frontline Advanced Melanoma https://finance.yahoo.com/news/iovance-biotherapeutics-announces-first-patient-110100849.html\n",
      "Stafford: Seniors Over 60 Only Pay $100 For Brand New... https://a.beap.gemini.yahoo.com/mbclk?bv=3.0.0&es=AQAAAPsOlulNCEExm8QYzULQVDVUKPdtfbuk7LW5NY4bGsBHHaE0TIrt_l47GM2RWU6JpbsFZSZFhvjD55KCVIAKGVDK_rD4HgNLhyq_m5qHExWmHUSVgGWHF03Xmyjh_ca5gb4VaxXSk7qN57O1YWMgh-henIL6SygEUFES_zYQ8lQZVFCj2y1w0OrPdKu9xYxnMw3Z2RgjP_B_kODxU_d0TeZq0g1ohnko1tOLsu_t0kWiipC8I0Q-fu4LhxdNNA_OvAsk6xfkl9nPmBXLglngW-uf_McWSmMSAY7IJwHrZOUH_8QPQ9fERxduTa2PzzvkZvba3LpnbSSuS5sve3T_k4ZFwJEf60zbl0zdTibsjf_kh9AL4Q3ROyKt1n1HgQFqZfMOuhK8TfLxOO2mxHPmY-H-t2qHF87Ta3f5Nr3jrR0aukMdQUM2SylahEbTxYyv48qrG7Tje9ouvbyrKl4r59EvC3nOGZQtYPr20-a86zGOgPTTfb9x_5Idig-PCxkaMJJIsETgEP47afCcoip_cj2Ayi12GNk5uh-pSAdyPwDIlwuKnOLwo245-4wVJ6plIuROe3cYeFIzbe5ijrisv2FZsuFyVVd9i3ypSV8ksHLs5ksQ0D7Cvp6ztbz8LsLV_5h8mxHybj1d6sjJwvg0mWpadoaaJoKumRHLKkgau9NkTicObxXECjToZRYCjfP2eZe9QNwgn-D11mB4k4t8H3C7DPFzdCjh4BzjjgpHfaCOn8mY-0fmgC-M0-xhYCwLQUaAlKE8Cpnzfqgk6g7zj3VVLb41WZuds5544rvNlPjXnwxKgz7xfkWd6s7YmpLxe83TyWO56BnKL_l08NnhTIYZB5t9TlMbUtuWwXXrMkq_WriVykCM9ps1wQ6_COlSNVtXYywRMP9VCD2kE_KxlDTj9Gsg3c9hU3hET8j95ab-FYBHr_xjjfRmpySim0fY6v7hWf5BLrBSwXlBrDI6LsVhHhaIUogrqg6trP0SJlUGOxUVb1nChxzsoktvbGEe7k2R4d59A_X4yQIVGj4nk_xjDxCrMtj06rLcHZFHpSqhx412e-FhwIPvmVcmiJ8XVKavELt0brUATzPvnEGgGjToMwh7o6NqLW-hzqmp8bB_3YyzW4T_FoMn_VtGd2oUTj0w1GfpDi1f-sjuNwF3V8QC6RXeaPYkm1wRDFQHvHhzx7V6CoxNBcY6P8WctuBXETnjwxUGQzKJ6XVDz_zL0l3M5iqOCv-BdkkF2WrMCLNdSsHvyi8ln0ueq4_FdvkwGNWjUO1WfOtJb3iTDN3BJ0TzXzKXdrn1_M2YhKuz9-VULr-4TzqreX34Bb_7n7Aa5dfqG2OYDKuRgkhlRranTgPspp-CqvTxRHdONGYqhpZga3btDC9lw-_kwCBHgKJDl5siry4HznwzpgDJyDJBOMaybma8bM7H9QHNSL64f0YkV-72YDDvRA-ZzS-bE3jv3zkXXG-J0QM_vFLuOY6bOMVUPEwSdnsDSty_D0NyTS2Iz1ACsLMSpo6twLi7X_dAQ-NOuZVsy3grZ5QPVf0SC2h0iPCrqa2OzOmJ5cwqLXMmQFLXvqB9FtqISkMRPKIvNm-h6brLmk6SCzNYyPQQTNBy2pyYWu1VXZSThenVX0ouv1o5T--hhbwDTfihNOd0eKkFHj27GfrSRU8TetmZQ3KbZ-uEaIj7hkQgUjqz2EBfokFfsVvF2wlcGy4B-yzjOENXtQ1LNvKfidKTz-bhJUqz1LFWqbHQh9AFhzVpAqwWXxc6oXYv6Ghcrct8vNjy6PJzy9ijD2TTfXZJ4CQ36QSVml4PoD9OPIJTi_mdqS10f1w0gEPqEqgMe3a5xoKl81R_lVLFhV7bjc7Mt-o_iT_9QSIBHhj-w4zMNbDLNDWd76YZFxHGlOE94o7hxlB1qjpF2C1dkITfInPTM2AVp4rih-44eZbpJOnfXOIgjyNdZpHGbDw4YiAmzShdBd5-mcPHHvXylNKhHL4RueozK7FMQE252SqgWd9Lw-EoeaAPw94qhUjx1BVmaNrwRIXgfSxmmgbaey4Evgta1U3O8zgCxcKNb7yQgnZfJXvsUIOovEk2W0rwQjgyv5BGLJYS0DmmK91RskaJqREQ0pbI9lUW_sKtspR9zdWdnVhGggwUEEox1tBRwLBahPTpdObzwx24i-Pc5vRaEVhGNHyjOMGEmqpjsSyr7bTn7K0FhWMoPHVfLxXL9m-nNaFaz4oNb7sJBbTZvOZenxnZ_7Hw4OZbZ4m5lAjcUBcBhNKmdbUdApd1DTbw0NDGPXUfJPV-ermj0qffVZ5KZVji1QRDfGU1oHVqw_bjmVH_zZ77ExNagUhSmRazVXastS8yXb2iW7neF8diYyC2rw_7taNW5vnk6K0eCVSrlNeTCD49LAEP93FiXNw2CpfIuFo464lUMBDVlyTZFIl6MBY5s6Gmge9vSCZo3nxNXqnd3KmALZ5g2luYtW3nXpU_5_0KUBzhWa0BTPfFZbDzlr5Zay-vGnLZvmJBosMWxEJkmWutV5FA1o0Whf4cu7l-8p8ewEpr2MZTLRxuQ-xO0rwqzfqQsKx9DSyrz_ynhjTI3x0LWw47oDjycK2xkOAQET5zgy2Dy82_dT1k2sWozigoOAUc6fU0SA-_UwdkIZECVf3R2uBIIOP5qZeImX5NNaCkNL6EoUcgYORS7xRjuiVnsipV21vnUvNjLijQ-XxfhET3rALpGx4n5QMkBBrJcunVubxpyxrW2kh705A7RVU6qoMpNCkOX4ky72SlcX_VZWT85ye7kLP4C7ljh8GzLJ3Hf0owiBIhbRv3puadww8B3rAg08rRcAMxaQTC5HWT-mcOr23AQwFx-EpB8X8ZG8_nnQeHkxwH8hwzEvx9cAW65ZaxTk5DAr998C_I22wLlFu4o-kRbt4453-wPAEEA6ttLedWcvh5o_cWUGsOv4q2yD7N4D5bjCh4l8nmh87Q3GkrTAWTYJkZ_0JuSiXoOa8uc56tyxdUVPJleWZBc7HXDOK1LPNURfJP16v7uYGsa7a7GL3XnqAJLoHIKGMHMZ_t4eBOsJ_EcfbHBkXm4lxm4RPrQh2hQ6ff3X_UI2eCvd9wP0VPq2kGP0L3jmM_PmZ7aMuAE1rxK5-FfADUSk9Hvy01UjI-ojlJPbSxOEXD94gAK2DoQv9UuWhkC77N3KhdE-rql5uM9YMiKg\n",
      "Iovance Biotherapeutics to Present at Jefferies Global Healthcare Conference https://finance.yahoo.com/news/iovance-biotherapeutics-present-jefferies-global-110100550.html\n",
      "Why Is Iovance Biotherapeutics (IOVA) Up 7.9% Since Last Earnings Report? https://finance.yahoo.com/news/why-iovance-biotherapeutics-iova-7-153057564.html\n",
      "Why Shares of Iovance Biotherapeutics Jumped Tuesday https://finance.yahoo.com/m/1f8c3d1c-cb46-30b2-980a-e89380828c79/why-shares-of-iovance.html\n",
      "FDA Accepts Iovance's (IOVA) BLA Filing for Melanoma Drug https://finance.yahoo.com/news/fda-accepts-iovances-iova-bla-140800542.html\n",
      "Iovance Biotherapeutics Announces U.S. Food and Drug Administration Acceptance of the Biologics License Application of Lifileucel for the Treatment of Advanced Melanoma https://finance.yahoo.com/news/iovance-biotherapeutics-announces-u-food-213000317.html\n",
      "A US$352m Market Cap Boost Pleasing ToIovance Biotherapeutics Insiders \\ https://finance.yahoo.com/news/us-352m-market-cap-boost-160357759.html\n",
      "Billionaire Steve Cohen Snaps Up These 2 ‘Strong Buy’ Stocks — Here’s Why You Might Want to Ride His Coattails https://finance.yahoo.com/news/billionaire-steve-cohen-snaps-2-132544475.html\n"
     ]
    }
   ],
   "source": [
    "from selenium import webdriver\n",
    "from selenium.webdriver.common.by import By\n",
    "from selenium.webdriver.common.keys import Keys\n",
    "from selenium.webdriver.chrome.service import Service\n",
    "from selenium.webdriver.support.ui import WebDriverWait\n",
    "from selenium.webdriver.support import expected_conditions as EC\n",
    "from time import sleep\n",
    "\n",
    "def get_yahoo_finance_news(stock_symbol):\n",
    "    # Setup WebDriver\n",
    "    service = Service('/usr/local/bin/chromedriver')  # Update this path to where your chromedriver is located\n",
    "    driver = webdriver.Chrome(service=service)\n",
    "    url = f\"https://finance.yahoo.com/quote/{stock_symbol}/news\"\n",
    "    driver.get(url)\n",
    "\n",
    "    try:\n",
    "        # Wait for the page to load\n",
    "        wait = WebDriverWait(driver, 10)\n",
    "        wait.until(EC.presence_of_element_located((By.TAG_NAME, \"body\")))\n",
    "\n",
    "        # Scroll down to load all content\n",
    "        last_height = driver.execute_script(\"return document.body.scrollHeight\")\n",
    "        while True:\n",
    "            # Scroll down to the bottom of the page\n",
    "            driver.execute_script(\"window.scrollTo(0, document.body.scrollHeight);\")\n",
    "\n",
    "            # Wait to load the page\n",
    "            sleep(3)\n",
    "\n",
    "            # Calculate new scroll height and compare with last scroll height\n",
    "            new_height = driver.execute_script(\"return document.body.scrollHeight\")\n",
    "            if new_height == last_height:\n",
    "                break\n",
    "            last_height = new_height\n",
    "\n",
    "        # Now that the page is fully loaded, we can find the news articles\n",
    "        news_list = []\n",
    "        articles = driver.find_elements(By.CSS_SELECTOR, \"h3.clamp.svelte-1v1zaak\")\n",
    "        for article in articles:\n",
    "            title = article.text\n",
    "            link = article.find_element(By.XPATH, '..').get_attribute('href')\n",
    "            news_list.append({'title': title, 'url': link})\n",
    "\n",
    "    finally:\n",
    "        driver.quit()\n",
    "\n",
    "    return news_list\n",
    "\n",
    "# Example usage:\n",
    "stock_symbol = 'IOVA'\n",
    "news = get_yahoo_finance_news(stock_symbol)\n",
    "for item in news:\n",
    "    print(item['title'], item['url'])\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Why Iovance Stock Is Down 18% Today\n",
      "Who normally has the cheapest car insurance?\n",
      "Iovance Biotherapeutics' Patient Selection for Amtagvi Launch Minimizing Attrition, Truist Securities Says\n",
      "Iovance Biotherapeutics Inc (IOVA) Q1 2024 Earnings: Aligns with EPS Projections Amidst Strong ...\n",
      "Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q1 2024 Earnings Call Transcript\n",
      "Iovance (IOVA) Q1 Earnings Surpass, Sales Lag Estimates\n",
      "Step into Spring With a Guided Adventure in Oregon\n",
      "Iovance Biotherapeutics Reports First Quarter 2024 Financial Results and Corporate Updates\n",
      "Watch These 5 Drug Stocks for Q1 Earnings: Beat or Miss?\n",
      "Iovance (IOVA) Gears Up for Q1 Earnings: Here's What to Expect\n",
      "Iovance Biotherapeutics to Host First Quarter 2024 Financial Results Conference Call and Webcast on Thursday, May 9, 2024\n",
      "Who Normally Has the Cheapest Car Insurance?\n",
      "Iovance Biotherapeutics to Present at Upcoming Conferences\n",
      "With 63% ownership of the shares, Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is heavily dominated by institutional owners\n",
      "Where Will Iovance Biotherapeutics Stock Be in 5 Years?\n",
      "The Top 3 Biotech Stocks to Buy in April 2024\n",
      "Pay 0% Interest for Up to 21 Months\n",
      "3 Millionaire-Maker Biotech Stocks\n",
      "20 Counties with the Highest Cancer Rates in the US\n",
      "Iovance Biotherapeutics to Present Clinical and Translational Data at 2024 ASCO Annual Meeting\n",
      "These Biotech Stocks Could Soar 120% and 295%, According to Wall Street\n",
      "AI Bot Flips Wall Street on Its Head: Turns $1K into $50K...\n",
      "Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)\n",
      "Is Iovance Biotherapeutics Stock a Buy Now?\n",
      "Market Sentiment Around Loss-Making Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)\n",
      "Iovance (IOVA) Stock Surges More Than 60% YTD: Here's Why\n",
      "Buying Nvidia? Wall Street Legend Issues Urgent A.I....\n",
      "Better Growth Biotech Buy: Iovance Biotherapeutics vs CRISPR Therapeutics\n",
      "Iovance Biotherapeutics (IOVA) Down 6.9% Since Last Earnings Report: Can It Rebound?\n",
      "2 Soaring Growth Stocks That Could Climb Another 47% to 73%, According to Wall Street\n",
      "U.S.-China Decoupling Poses Supply-Chain Risks for Drug Companies\n",
      "Who Has The Cheapest Car Insurance in Texas\n",
      "Iovance Biotherapeutics (NASDAQ:IOVA) shareholders are still up 122% over 1 year despite pulling back 7.1% in the past week\n",
      "7 Biotech Stocks Ready to Ride the Sector’s Resurgence\n",
      "Forget Eli Lilly. Buy This Magnificent Biotech Stock Instead\n",
      "Billionaire Paul Tudor Jones and Insiders Love These 10 Stocks\n",
      "Here’s The Average Cost Of Gutter Guards For Smaller Homes\n",
      "1 Wall Street Analyst Thinks Iovance Biotherapeutics Stock Is Going to $32. Is It a Buy Around $17?\n",
      "Iovance Biotherapeutics Stock Has 22% Upside, According to 1 Wall Street Analyst\n",
      "FDA Lifts Clinical Hold on Iovance's (IOVA) Lung Cancer Study\n",
      "Iovance Biotherapeutics Announces FDA has Lifted Clinical Hold on the IOV-LUN-202 Registrational Trial in Non-Small Cell Lung Cancer\n",
      "Could Iovance Biotherapeutics Stock Help You Become a Millionaire?\n",
      "Why Iovance Biotherapeutics Stock Got Trounced on Thursday\n",
      "Q4 2023 Iovance Biotherapeutics Inc Earnings Call\n",
      "Iovance's (IOVA) Q4 Earnings & Sales Fall Short of Estimates\n",
      "You don’t need to refinance to get cash\n",
      "Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q4 2023 Earnings Call Transcript\n",
      "Iovance Therapeutics Stock Has Skyrocketed Over 100% so Far This Year. Is It Still a Buy?\n",
      "Iovance Biotherapeutics (IOVA) Reports Q4 Loss, Misses Revenue Estimates\n",
      "Iovance Biotherapeutics Inc (IOVA) Reports Q4 and Full Year 2023 Financial Results\n",
      "Guard Your Wealth: Must-Read IRA Gold Strategy!\n",
      "Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates\n",
      "Why Iovance (IOVA) Might Surprise This Earnings Season\n",
      "3 Under-the-Radar Biotech Stocks With Upcoming Catalysts in 2024\n",
      "1 Soaring Growth Stock That Could Rise Another 53%, According to Wall Street\n",
      "Ask a Pro: \"Should I Convert My IRA to a Roth After Age 60?\"\n",
      "Insiders Pour Millions Into These 2 Buy-Rated Stocks; Here’s Why You Might Want to Follow Their Lead\n",
      "Is Iovance a Buy After Its First Regulatory Win?\n",
      "This Biotech Stock Has 47% Upside, According to 1 Wall Street Analyst\n",
      "The Zacks Analyst Blog Highlights Moderna, RAPT Therapeutics, Iovance, Sarepta Therapeutics and Regeneron\n",
      "Searching for income?\n",
      "Iovance Biotherapeutics to Host Fourth Quarter and Full-Year 2023 Financial Results Conference Call and Webcast on Wednesday, February 28, 2024\n",
      "13 Best Short Squeeze Stocks To Buy Now\n",
      "Independent Director of Iovance Biotherapeutics Picks Up 22% More Stock\n",
      "Iovance Biotherapeutics Stock Rockets 30% Higher\n",
      "Is Retiring With a $500k+ Portfolio Realistic?\n",
      "Why Iovance Biotherapeutics Stock Is Skyrocketing Today\n",
      "Iovance Biotherapeutics, Inc. Announces Pricing of $211 Million Underwritten Offering of Common Stock\n",
      "Iovance (IOVA) Stock Rises on FDA Nod for Melanoma Drug Amtagvi\n",
      "UPDATE 3-US FDA grants accelerated approval for Iovance's skin cancer cell therapy\n",
      "Iovance Biotherapeutics to Host Conference Call and Webcast on Friday, February 16, 2024\n",
      "Iovance’s AMTAGVI™ (lifileucel) Receives U.S. FDA Accelerated Approval for Advanced Melanoma\n",
      "3 Opportunities for Iovance Biotherapeutics Stock, and 1 Risk\n",
      "Is Iovance Biotherapeutics a Buy Before This Key FDA Decision?\n",
      "Dexcom G7®: Easy to apply, easy to set up, and easy to use\n",
      "A Bull Market Is Here: 2 Top Growth Stocks to Buy Hand Over Fist\n",
      "What's Next for Iovance Biotherapeutics Stock?\n",
      "Iovance (IOVA) Surges More Than 150% in 3 Months: Here's Why\n",
      "Zacks.com featured highlights Universal Stainless & Alloy, Lakeland, NGL Energy and Iovance\n",
      "Texas Launches New Policy For Cars Used Less Than 50...\n",
      "4 Best Breakout Stocks to Buy for Stellar Returns\n",
      "2 Growth Stocks That Could Rocket 149% to 210% Higher in 2024, According to Wall Street\n",
      "Why Iovance Biotherapeutics Stock Popped Today\n",
      "Iovance (IOVA) Falls After Clinical Update on Lung Cancer Drug\n",
      "7 Ways to Retire Comfortably With $500k\n",
      "Gold nears $2100, biotech stocks on the move: Trending tickers\n",
      "FDA Slaps Clinical Hold On Iovance Biotherapeutics' Lung Cancer Study After Patient Death\n",
      "Iovance Biotherapeutics Announces Clinical Program Update for LN-145 in Non-Small Cell Lung Cancer\n",
      "12 Most Promising Cancer Stocks According to Analysts\n",
      "A card so good, our experts signed up personally\n",
      "Better Growth Stock: Viking Therapeutics or Iovance Biotherapeutics?\n",
      "A Bull Market Is Coming: 1 Stock That Could Rocket 219% Higher in 2024, According to Wall Street\n",
      "Why Is Iovance Biotherapeutics (IOVA) Up 53% Since Last Earnings Report?\n",
      "Why Iovance Biotherapeutics Stock Is Jumping Today\n",
      "With 75% ownership, Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) boasts of strong institutional backing\n",
      "Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q3 2023 Earnings Call Transcript\n",
      "Why Iovance Biotherapeutics Stock Is Marching Higher Today\n",
      "Iovance's (IOVA) Meets Q3 Earnings, Lags Sales Estimates\n",
      "FBI and Pentagon consultant: Move your money now\n",
      "Iovance Biotherapeutics Reports Third Quarter and Year-to-Date 2023 Financial Results and Corporate Updates\n",
      "Iovance Biotherapeutics to Host Third Quarter and Year-to-Date 2023 Financial Results Conference Call and Webcast on Tuesday, November 7, 2023\n",
      "Iovance Biotherapeutics to Present Clinical and Pre-Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Therapies at Society for Tumor Immunotherapy of Cancer’s (SITC) 38th Annual Meeting\n",
      "Should You Exit Iovance Biotherapeutics (IOVA) Following the Recent Uncertainty?\n",
      "2 Cards Charging 0% Interest Until Nearly 2026\n",
      "Iovance Biotherapeutics Announces Clinical Data for Lifileucel in Advanced Mucosal Melanoma at the European Society for Medical Oncology (ESMO) Congress\n",
      "Independent Director of Iovance Biotherapeutics Wayne Rothbaum Buys 28% More Shares\n",
      "Why Iovance Biotherapeutics Stock Rocketed 13% Higher Today\n",
      "Iovance (IOVA) Up Despite FDA's Delayed Decision on Melanoma Drug\n",
      "Texas Residents With Credit Card Debt Should Read This\n",
      "U.S. Food and Drug Administration Updates Prescription Drug User Fee Act (PDUFA) Action Date for Lifileucel for the Treatment of Advanced Melanoma\n",
      "Why Shares of Iovance Biotherapeutics Dropped Thursday\n",
      "Why Is Iovance Biotherapeutics (IOVA) Down 21.2% Since Last Earnings Report?\n",
      "Iovance Biotherapeutics to Present at 2023 Wells Fargo Healthcare Conference\n",
      "7 Wealth Tips Once Your Portfolio Reaches $1 Million\n",
      "12 Best High Risk High Reward Stocks To Buy Now\n",
      "3 Up-and-Coming Biotech Stocks to Put on Your Must-Buy List\n",
      "Iovance (IOVA) Posts Narrower-Than-Expected Loss in Q2\n",
      "Iovance Biotherapeutics (IOVA) Reports Q2 Loss, Lags Revenue Estimates\n",
      "Iovance Biotherapeutics Reports Second Quarter and First Half 2023 Financial Results and Corporate Updates\n",
      "7 Healthcare Stocks to Ditch Before They Make Your Portfolio Sick\n",
      "Iovance Biotherapeutics to Present Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Therapy at IASLC 2023 World Conference on Lung Cancer\n",
      "Iovance Biotherapeutics to Host Second Quarter 2023 Financial Results Conference Call and Webcast on Tuesday, August 8, 2023\n",
      "Iovance Biotherapeutics Announces Closing of $172.5 Million Common Stock Public Offering\n",
      "Why Iovance Biotherapeutics Stock Is Dropping Tuesday\n",
      "Iovance (IOVA) Gets Positive FDA Feedback on Lung Cancer Drug\n",
      "Why These 2 Nasdaq Biotech Stocks Fell Hard Tuesday Morning\n",
      "Save big on electricity\n",
      "Iovance Biotherapeutics slips after $150 million stock offering price announced\n",
      "Iovance Biotherapeutics, Inc. Announces Pricing of Its Public Offering of $150 Million of Common Stock\n",
      "Iovance Biotherapeutics, Inc. Announces Proposed Public Offering of Common Stock\n",
      "Iovance Biotherapeutics Announces Regulatory and Clinical Updates for TIL Therapy in Advanced Non-Small Cell Lung Cancer\n",
      "Why These Billionaires Dumped Nvidia\n",
      "11 Best Medical  Stocks Under $10\n",
      "Iovance Biotherapeutics to Host Virtual Roundtable with Key Opinion Leaders to Discuss Melanoma Treatment Landscape\n",
      "Iovance (IOVA) Updates on Combo Drug in Advanced Melanoma Study\n",
      "Iovance Biotherapeutics Announces First Patient Randomized in Phase 3 TILVANCE-301 Trial in Frontline Advanced Melanoma\n",
      "Stafford: Seniors Over 60 Only Pay $100 For Brand New...\n",
      "Iovance Biotherapeutics to Present at Jefferies Global Healthcare Conference\n",
      "Why Is Iovance Biotherapeutics (IOVA) Up 7.9% Since Last Earnings Report?\n",
      "Why Shares of Iovance Biotherapeutics Jumped Tuesday\n",
      "FDA Accepts Iovance's (IOVA) BLA Filing for Melanoma Drug\n",
      "Iovance Biotherapeutics Announces U.S. Food and Drug Administration Acceptance of the Biologics License Application of Lifileucel for the Treatment of Advanced Melanoma\n",
      "A US$352m Market Cap Boost Pleasing ToIovance Biotherapeutics Insiders \\\n",
      "Billionaire Steve Cohen Snaps Up These 2 ‘Strong Buy’ Stocks — Here’s Why You Might Want to Ride His Coattails\n"
     ]
    }
   ],
   "source": [
    "for item in news:\n",
    "    print(item['title'])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "First few rows of the DataFrame:\n",
      "     ID    SPACE         TYPE        HR      HER2  \\\n",
      "0  a cs  MED ONC     Adjuvant  POSITIVE  POSITIVE   \n",
      "1     2  MED ONC     Adjuvant  NEGATIVE  POSITIVE   \n",
      "2     3  MED ONC  Neoadjuvant  POSITIVE  NEGATIVE   \n",
      "3     4  MED ONC  Neoadjuvant  POSITIVE  POSITIVE   \n",
      "4     5  MED ONC  Neoadjuvant  NEGATIVE  POSITIVE   \n",
      "\n",
      "                                         Eligibility  \\\n",
      "0  * Stage I/II with nonpCR OR stage III (pCR or ...   \n",
      "1  * Stage I/II with nonpCR OR stage III (pCR or ...   \n",
      "2  * 1ry 20mm or more (T2 N0 and higher) by exam ...   \n",
      "3  * 1ry 20mm or more (T2 N0 and higher) by exam ...   \n",
      "4  * 1ry 20mm or more (T2 N0 and higher) by exam ...   \n",
      "\n",
      "                                         TNM Staging  \n",
      "0  T1 N0 M0, T2 N0 M0, T3 N0 M0, T1 N1 M0, T2 N1 ...  \n",
      "1  T1 N0 M0, T2 N0 M0, T3 N0 M0, T1 N1 M0, T2 N1 ...  \n",
      "2           T2 N0, T2 N1, T2 N2, T3 N0, T3 N1, T3 N2  \n",
      "3           T2 N0, T2 N1, T2 N2, T3 N0, T3 N1, T3 N2  \n",
      "4           T2 N0, T2 N1, T2 N2, T3 N0, T3 N1, T3 N2  \n",
      "\n",
      "Unique values in 'HR' column:\n",
      "['POSITIVE' 'NEGATIVE']\n",
      "\n",
      "Unique values in 'HER2' column:\n",
      "['POSITIVE' 'NEGATIVE']\n",
      "\n",
      "Unique values in 'SPACE' column:\n",
      "['MED ONC']\n",
      "\n",
      "No matching clinical trials found.\n"
     ]
    }
   ],
   "source": [
    "import pandas as pd\n",
    "\n",
    "# Sample JSON output\n",
    "json_output = {\n",
    "    \"T Staging\": \"T1b\",\n",
    "    \"N Staging\": \"cN0\",\n",
    "    \"ER Status\": \"POSITIVE\",\n",
    "    \"HER2 Presence\": \"NEGATIVE\",\n",
    "    \"Metastasis Status\": \"Metastasis is present\",\n",
    "    \"space\": \"Metastatic\"\n",
    "}\n",
    "\n",
    "# Load the clinical trials data\n",
    "file_path = '/Users/ahmed-elbakri/Downloads/Python/Ops Analytics/Clinical Trials/bcm.trial.data - Sheet1.csv'\n",
    "df = pd.read_csv(file_path)\n",
    "\n",
    "# Print first few rows of the DataFrame\n",
    "print(\"First few rows of the DataFrame:\")\n",
    "print(df.head())\n",
    "\n",
    "# Print unique values in relevant columns\n",
    "print(\"\\nUnique values in 'HR' column:\")\n",
    "print(df['HR'].unique())\n",
    "\n",
    "print(\"\\nUnique values in 'HER2' column:\")\n",
    "print(df['HER2'].unique())\n",
    "\n",
    "print(\"\\nUnique values in 'SPACE' column:\")\n",
    "print(df['SPACE'].unique())\n",
    "\n",
    "# Apply the filters\n",
    "filtered_df = df[\n",
    "    (df['HR'] == json_output['ER Status']) &\n",
    "    (df['HER2'] == json_output['HER2 Presence']) &\n",
    "    (df['SPACE'] == json_output['space'])\n",
    "]\n",
    "\n",
    "# Print the filtered DataFrame\n",
    "if not filtered_df.empty:\n",
    "    print(\"\\nFiltered DataFrame:\")\n",
    "    print(filtered_df)\n",
    "else:\n",
    "    print(\"\\nNo matching clinical trials found.\")\n"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.9.6"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
